Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use

ABSTRACT

Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer&#39;s disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.

CROSS-REFERENCE TO RELATED APPLICATIONS/INCORPORATION BY REFERENCESTATEMENT

The present application claims the benefit under 35 U.S.C. 119(e) ofU.S. Provisional Application Ser. No. 61/643,001, filed May 4, 2012, andU.S. Provisional Application Ser. No. 61/793,183, filed Mar. 15, 2013.The entire contents of each of the above-referenced applications arehereby expressly incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under Contract NumberW81XWH-081-0588 awarded by the Department of Defense (DOD) and ContractNumber HL072995 awarded by the National Institutes of Health (NIH). Thegovernment has certain rights in the invention.

BACKGROUND

α₂-Antiplasmin (α₂AP) is a glycoprotein in blood plasma that rapidly andspecifically inhibits the enzyme, plasmin, which digests blood clots,whether presenting early as intravascular platelet-fibrin deposits or aspartially or completely occlusive thrombi. Similarly, plasmin and α₂APactivities are important to the development and survival of fibrin asoccurs in inflammation, wound healing and virtually all forms of cancerand its metastases. Human a₂-antiplasmin (α₂AP), also known asα₂-plasmin inhibitor, is the main inhibitor of plasmin. Plasmin plays acritical role in fibrin proteolysis and tissue remodeling. The inventorsdiscovered antiplasmin-cleaving enzyme (APCE) in human plasma and showedthat it is a soluble isoform or derivative of fibroblast activationprotein-alpha (FAP). Like APCE, FAP is also a prolyl-specific enzymethat exhibits both endopeptidase and dipeptidyl peptidase activities.

FAP significantly over-expresses in >90% of epithelial-derived cancers[1-3]. FAP is produced transiently by activated stromal fibroblastsduring embryogenesis [4] and wound healing [3], but other than anoccasional normal fibroblast or pancreatic islet α-cell, it is notexpressed by normal adult tissues or benign tumors [2, 3, 5]. FAP isprominent on the membranes of proliferating fibroblasts in diseaseswhere fibrous tissue growth is a conspicuous feature, such as primarypulmonary fibrosis [6]; chronic hepatitis [7]; certain bone-associatedmalignancies [8, 9]; and the arthritides [10]. Selected parenchymatouscancer cells may also occasionally express FAP [11].

While a biologic substrate for the proteinase activity of FAP has notbeen definitively established, results indicate that FAP helps digestextracellular matrix (ECM) components as tissue is remodeled toaccommodate cancer expansion [2, 16, 17]. Paradoxically, activatedfibroblasts not only digest ECM, but also synthesize ECM components ofthe stromal scaffolding that support cell division and motility duringneoplastic growth [18]. FAP has been considered a potential target inthe diagnosis and therapy of cancer, with inhibition of FAP proteinaseactivity posed as possibly therapeutically useful [19, 20]. Santos etal. [21] have shown that genetic deletion or pharmacologic inhibition ofFAP by glutamyl-proline boronic acid (Glu-boroPro) decreased stromalgrowth in mouse models of lung and colon cancer. However, Glu-boroProhas an exceptionally short plasma half-life before cyclizing and losinginhibitory activity [22]. Moreover, it also inhibits dipeptidylpeptidase IV (DPPIV), which is important in plasma glucose regulationand immune function [23]. Hence, despite inhibiting FAP and suppressingtumor growth, Glu-boroPro is not likely to be therapeutically useful incancer [24].

The measurement of cellular FAP activity and inhibition is confounded byanother prolyl endopeptidase: namely, Prolyl Oligopeptidase (POP) whichis elevated in many cancers [25]. POP is a prolyl-specific serineproteinases, which cleaves peptides of less than about 30 amino acids inlength. The enzyme is present in most tissues, but is noted to be moreabundant in selected organs, e.g., brain and kidney. Recently POP hasbeen indicated as making secondary cleavages of thymosin-β4 to yield thederivative peptide, acetyl-serine-asparagine-lysine-proline, whichappears to be a potent stimulator of angiogenesis [26]. Both FAP and POPactivities are commonly measured using non-specific substrates such asZ-Gly-Pro-AMC or succinyl-Gly-Pro-AMC, neither of which distinguishesbetween the two activities [27]. Consequently, total prolyl-specificendopeptidase activity, which is often attributed to FAP alone, may alsoinclude POP activity. This complicates interpretations about the effectsof inhibiting either enzyme on cancer growth. Pre-clinical studies havesuggested other promising applications of POP inhibition for managingmemory, learning disorders and depression, but development of relativelybenign, highly effective POP inhibitors for in vivo testing have beenelusive. The results, newly described herein, indicate that POP isexpressed in significant amounts by a variety of cancer cells grown inculture.

Certain compounds which specifically inhibit either one or both of FAPand POP and therefore can be used to treat various conditions whichinvolve these proteins are desirable. Thus, the presently disclosed andclaimed inventive concept(s) is directed to, but not limited to,substrates and inhibitors of FAP and/or POP, and to methods of using FAPand/or POP inhibitors for treating conditions such as but not limitedto, cancers, neural disorders, and angiogenesis, and to screeningmethods for identifying such inhibitors, that overcome the disadvantagesand defects of the prior art.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a characterization of FAP and POP in fibroblasts. Panel A.Confocal images of permeabilized WI-38 and VA-13 fibroblasts grown onplastic slides and labeled with mouse anti-FAP mAb F19 followed byanti-mouse-AlexaFluor 568 (red) and the DNA stain DAPI (green). Panel B.FAP and POP activities of fibroblasts grown on plastic wells as measuredby cleavage of a fluorescent substrate designated as “C95”(acetyl-Arg-AEEA-Gly-Pro-AMC), and using a POP specific inhibitorcompound designated as “J94” (acetyl-Lys-Leu-Arg-(L)boroPro) to separatethe two activities. One FAP unit=Δ fluorescence/min on cleavage of C95by one ng APCE. Panel C. Immunostains of cell lysates from fibroblastcultures using mouse anti-FAP mAb 6D2. One ng APCE served as a positivecontrol while intracellular contents of α-tubulin (50 kDa) and actin (43kDa) were used for standardizing the amount of cell lysate proteinapplied in each lane. Panel D. Immunostains of cell lysates and membraneand cytosol fractions from WI-38 fibroblast cultures using mouseanti-FAP mAb 6D2. One ng APCE served as a positive control. Panel E.Immunostains of cell lysates from fibroblast cultures using goatanti-POP. One ng of POP served as a positive control, while α-tubulin(50 kDa) and actin (43 kDa) were used for standardizing loads. Panel F.Immunostains of cell lysates and membrane and cytosol fractions fromW138 fibroblast cultures using goat anti-POP. One ng of POP served as apositive control.

FIG. 2 shows the amino acid sequence of FAP (SEQ ID NO:1) andcorresponding tryptic FAP peptides isolated from four human cell types.Protein was purified by immunoprecipitation and SDS-polyacrylamide gelelectrophoresis followed by sequence determination by LC/MS/MS.Correspondence to FAP protein is indicated: Human mesenchymal stem cells(—) 51% (coverage FAP sequence); WI-38 fibroblasts (▪ ▪ ▪ ▪), 42%;MDA-MB436 cancer cells (◯ ◯ ◯ ◯), 41%; and HMVEC-d endothelial cellsdeprived of hydrocortisone (

), 6.4%. In each case, the FAP-containing region of the gel was locatedby reference to a 100 kDa protein standard band in an adjacent lane.

FIG. 3 shows the dose-response inhibition of FAP activity on WI-38fibroblast surfaces by a FAP inhibitor compound designated as “M83”(acetyl-Arg-AEEA-(D)Ala-(L)boroPro). WI-38 fibroblasts were grown onplastic, washed once with HBSS, after which the M83 inhibitor 10 μM inHBSS was added at zero time to one set, and buffer only to the otherfour sets. The fluorescent substrate C95 was added to all sets of wellsand Δ fluorescence/min, reflecting cleavage of C95 over time, wasallowed to proceed for two hours when 10 μM, 1 μM or 100 nM of the M83inhibitor was added to each of three sets of wells. As shown, eachinhibitor concentration instantly, and essentially totally, inhibitedthe proteolytic activity of FAP on the cell surface.

FIG. 4 is a characterization of FAP and POP in normal breast and breastcancer cells. Panel A. Confocal images of permeabilized MCF-12A (normalbreast cells), MDA-MB436 or HCC1419 (breast cancer cells) grown on glassslides and labeled with mAb F19 to FAP followed by anti-mouse-AlexaFluor568 (red) and DAPI (green). Panel B. FAP and POP activities on surfacesof normal and breast cancer cells grown on plastic wells as measured bycleavage of fluorescent substrate C95, and using the POP specificinhibitor J94 to separate the two activities. One FAP unit=Δfluorescence/min on cleavage of C95 by one ng APCE. Panel C.Immunostains of cell lysates from normal and breast cancer cellcultures, using mAb 6D2 to FAP. APCE 1 ng was used as a positivecontrol, while intracellular contents of α-tubulin (50 kDa) and actin(43 kDa) were used for standardizing the amount of cell lysate proteinapplied in each lane. Panel D. Immunostains of cell lysates from normaland breast cancer cell cultures using goat anti-POP. POP 1 ng was usedas a positive control, while α-tubulin (50 kDa) and actin (43 kDa)served as load controls.

FIG. 5 is a characterization of FAP and POP in microvascular endothelialcells. Panel A. Confocal images of permeabilized HMVEC-d grown on glassslides and labeled with mAb F19 to FAP followed by anti-mouse-AlexaFluor568 (red) and DAPI (green). Panel B. FAP and POP activities ofendothelial cells grown on plastic wells measured by exactly the samemethods described in FIGS. 1 and 4. Panel C. Immunostaining performed asdescribed in FIGS. 1 and 4. Panel D. Immunostaining for POP performed asdescribed in FIGS. 1 and 4.

FIG. 6 shows FAP and POP activities in microvascular endothelial cells.Panel A. HMVEC-d cells plated on plastic wells allowed to settle for onehour, then inhibitors and substrates were added and fluorescence wasmeasured over time for 18 hours. Panel B. HMVEC-d cells plated onMatrigel™ (BD Biosciences, San Jose, Calif.), allowed to settle for onehour to initiate tubule formation, and assayed for FAP and POPactivities as in Panel A. Note that POP activity is detectable from thestart in both assay conditions, but FAP activity only appears in theMatrigel™ assay at about four hours after tubule formation. Each pointrepresents 15 readings over three separate experiments.

FIG. 7 shows FAP activity and FAP protein levels in stressed cells.WI-38 fibroblasts, MCF-12A normal breast cells, and HMVEC-d endothelialcells were grown in the presence of hydrocortisone (hyc) as customarilypresent in growth media, or in its absence. Cells were grown from 7 to14 days as specified before assessing FAP activity and FAP proteinlevels. Panel A. FAP activity was measured as previously described. FAPactivity in the absence of hydrocortisone was set at 100%, with thelevel of FAP activity in the presence of hydrocortisone expressed as arelative percent. Panel B. Immunostains of cell lysates from fibroblast,normal breast and endothelial cell cultures, using mAb 6D2 to FAP. APCE1 ng is used as a positive control; α-tubulin (50 kDa) and actin (43kDa) were used to standardize cell lysate protein amounts applied toeach electrophoretic lane. MCF12A normal breast cells were grown in theabsence of hydrocortisone, (−)hyc, for 7 days, followed by repletion ofthe normal media (+) hyc content, as supplied by Lonza, for 7 days,labeled (−)hyc/(+)hyc, prior to assessing both FAP activity and FAPprotein concentration.

FIG. 8 shows the identification and characterization of FAP and POP inhuman mesenchymal stem cells (MSC). Panel A. Confocal image ofpermeabilized MSCs grown on glass slides and labeled with mAb F19 to FAPfollowed by anti-mouse-AlexaFluor 568 (red) and DAPI (green). Panel B.FAP and POP activities found on mesenchymal stem cell surfaces grown inplastic wells were measured exactly the same as described in FIGS. 1 and4. Panel C. Immunostaining was performed as described in FIGS. 1 and 4.Panel D. Immunostaining for FAP in cell lysates and membrane andcytosolic fractions of mesenchymal stem cells was performed as describedin FIG. 1. Panel E. Immunostaining for POP was performed as described inFIGS. 1 and 4. Panel F. Immunostaining for POP in cell lysates andmembrane and cytosolic fractions of mesenchymal stem cells was performedas described in FIG. 1.

FIG. 9 is a graph showing the inhibition of lung cancer xenografts innude mice by compound M83 over a period of 28 days.

FIGS. 10A and B are micrographs which demonstrate that application of 50μm of compound J94 inhibited formation of capillary-like tubes inMatrigel™.

FIG. 11 is a graph showing the inhibitory effects of M83 and J94 ongrowth of colon cancer tumors.

DETAILED DESCRIPTION

Before explaining the at least one non-limiting embodiment of theinventive concept(s) disclosed herein in detail, it is to be understoodthat the presently disclosed and claimed inventive concept(s) is notlimited in its application to the details of examples, experiments,exemplary data, and/or methods or steps as set forth in the followingdescription, or illustrated in the drawings. The presently disclosed andclaimed inventive concept(s) is capable of other embodiments or of beingpracticed or carried out in various ways. As such, the language usedherein is intended to be given the broadest possible scope and meaning;and the embodiments are meant to be exemplary—not exhaustive. Also, itis to be understood that the phraseology and terminology employed hereinis for the purpose of description and should not be regarded aslimiting.

In the following detailed description of embodiments of the presentlydisclosed and claimed inventive concept(s), numerous specific detailsare set forth in order to provide a more thorough understanding of theinventive concept(s). However, it will be apparent to one of ordinaryskill in the art that the inventive concept(s) within the disclosure maybe practiced without these specific details. In other instances,well-known features have not been described in detail to avoidunnecessarily complicating the present disclosure.

Unless otherwise defined herein, scientific and technical terms used inconnection with the presently disclosed and claimed inventive concept(s)shall have the meanings that are commonly understood by those ofordinary skill in the art. Further, unless otherwise required bycontext, singular terms shall include pluralities and plural terms shallinclude the singular. Generally, nomenclatures utilized in connectionwith, and techniques of, cell and tissue culture, molecular biology, andprotein and oligo- or polynucleotide chemistry and hybridizationdescribed herein are those well known and commonly used in the art.Standard techniques are used for recombinant DNA, oligonucleotidesynthesis, and tissue culture and transformation (e.g., electroporation,lipofection). Enzymatic reactions and purification techniques areperformed according to manufacturer's specifications or as commonlyaccomplished in the art or as described herein. The foregoing techniquesand procedures are generally performed according to conventional methodswell known in the art and as described in various general and morespecific references that are cited and discussed throughout the presentspecification. See e.g., Sambrook et al. Molecular Cloning: A LaboratoryManual (2nd ed., Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y. (1989) and Coligan et al. Current Protocols in Immunology(Current Protocols, Wiley Interscience (1994)), which are incorporatedherein by reference. The nomenclatures utilized in connection with, andthe laboratory procedures and techniques of, analytical chemistry,synthetic organic chemistry, and medicinal and pharmaceutical chemistrydescribed herein are those well known and commonly used in the art.Standard techniques are used for chemical syntheses, chemical analyses,pharmaceutical preparation, formulation, and delivery, and treatment ofpatients.

All patents, published patent applications, and non-patent publicationsmentioned in the specification are indicative of the level of skill ofthose skilled in the art to which this presently disclosed and claimedinventive concept(s) pertains. All patents, published patentapplications, and non-patent publications referenced in any portion ofthis application are herein expressly incorporated by reference in theirentirety to the same extent as if each individual patent or publicationwas specifically and individually indicated to be incorporated byreference. In particular, the present application contains subjectmatter which is related to U.S. Ser. No. 12/969,161, filed Dec. 15,2010; 61/286,558, filed Dec. 15, 2009; Ser. No. 11/811,002, filed Jun.6, 2007; 60/811,568, filed Jun. 7, 2006; and 60/836,365, filed Aug. 8,2006. The entire contents of each of these applications are herebyexpressly incorporated herein by reference in its entirety. Also, U.S.Ser. Nos. 10/774,242; 11/810,997; 11/986,058; and 60/445,774 are herebyexpressly incorporated herein by reference in their entireties.

All of the compositions and/or methods disclosed and claimed herein canbe made and executed without undue experimentation in light of thepresent disclosure. While the compositions and methods of the inventiveconcept(s) have been described in terms of particular embodiments, itwill be apparent to those of skill in the art that variations may beapplied to the compositions and/or methods and in the steps or in thesequence of steps of the method described herein without departing fromthe concept, spirit and scope of the presently disclosed and claimedinventive concept(s). All such similar substitutes and modificationsapparent to those skilled in the art are deemed to be within the spirit,scope and concept of the inventive concept(s) as defined by the appendedclaims.

In order that the presently disclosed and claimed inventive concept(s)may be more readily understood, certain term are first defined.Additional definitions are set forth throughout the detaileddescription. Unless defined otherwise, all technical and scientificterms used herein have the same meanings as commonly understood by oneskilled in the art to which the presently disclosed and claimedinventive concept(s) pertains (e.g., amino acids may be referred to bytheir commonly used abbreviations).

APCE is Antiplasmin-Cleaving Enzyme. FAP is Fibroblast ActivationProtein-alpha. POP is Prolyl Oligopeptidase. DPPIV is Dipeptidylpeptidase IV. α₂AP is α₂-Antiplasmin. AEEA is2-(2-(2-aminoethoxy)ethoxy)acetic acid, also referred to herein as8-amino-3,6-dioxaoctanoic acid. AMC is 7-amido-4-methylcoumarin.L-boroPro is L-boronyl proline. M83 isacetyl-Arg-AEEA-(D)Ala-(L)boroPro. C95 is acetyl-Arg-AEEA-Gly-Pro-AMC.J94 is acetyl-Lys-Leu-Arg-(L)boroPro. L96 is acetyl-Lys-Leu-Arg-Pro-AMC.Abz is aminobenzoyl. Ac is acetyl. Bz is benzoyl. Z isbenzyloxycarbonyl. Boc is t-Butyloxycarbonyl. Fa is Furylacryloyl.MeOSuc is methoxysuccinyl. Pyr is pyroglutamate. AFC is7-amino-trifluoromethylcoumarin. OEt is ethyl ester. OMe is methyl ester(OMe). 2NA is 2-Naphthylamide (2NA). p-NA is p-Nitroanilide. ONp isp-Nitrophenyl ester. SBzI is Thiobenzyl ester. “Tic” refers to 1,2,3,4tetrahydro isoquinoline-3-carboxylic acid. HCC, HCC1419 breast cancercells; HMVEC-d, human microvascular endothelial cells from dermis;MCF12A, normal breast cells; MDA, MDA-MB436 breast cancer cells; MSC,mesenchymal stem cells; VA-13, WI-38 VA-13 2RA SV-40 viral transformedfibroblast cells; WI-38, fibroblast cells.

The use of the word “a” or “an” when used in conjunction with the term“comprising” in the claims and/or the specification may mean “one,” butit is also consistent with the meaning of “one or more,” “at least one,”and “one or more than one.” The singular forms “a,” “an,” and “the”include plural referents unless the context clearly indicates otherwise.Thus, for example, reference to “a compound” may refer to 1 or more, 2or more, 3 or more, 4 or more or greater numbers of compounds. The term“plurality” refers to “two or more.” The use of the term “or” in theclaims is used to mean “and/or” unless explicitly indicated to refer toalternatives only or the alternatives are mutually exclusive, althoughthe disclosure supports a definition that refers to only alternativesand “and/or.” Throughout this application, the term “about” is used toindicate that a value includes the inherent variation of error for thedevice, the method being employed to determine the value, or thevariation that exists among the study subjects. For example but not byway of limitation, when the term “about” is utilized, the designatedvalue may vary by ±20% or ±10%, or ±5%, or ±1%, or ±0.1% from thespecified value, as such variations are appropriate to perform thedisclosed methods and as understood by persons having ordinary skill inthe art. The use of the term “at least one” will be understood toinclude one as well as any quantity more than one, including but notlimited to, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term “atleast one” may extend up to 100 or 1000 or more, depending on the termto which it is attached; in addition, the quantities of 100/1000 are notto be considered limiting, as higher limits may also producesatisfactory results. In addition, the use of the term “at least one ofX, Y and Z” will be understood to include X alone, Y alone, and Z alone,as well as any combination of X, Y and Z. The use of ordinal numberterminology (i.e., “first”, “second”, “third”, “fourth”, etc.) is solelyfor the purpose of differentiating between two or more items and is notmeant to imply any sequence or order or importance to one item overanother or any order of addition, for example.

As used in this specification and claim(s), the terms “comprising” (andany form of comprising, such as “comprise” and “comprises”), “having”(and any form of having, such as “have” and “has”), “including” (and anyform of including, such as “includes” and “include”) or “containing”(and any form of containing, such as “contains” and “contain”) areinclusive or open-ended and do not exclude additional, unrecitedelements or method steps.

The term “or combinations thereof” as used herein refers to allpermutations and combinations of the listed items preceding the term.For example, “A, B, C, or combinations thereof” is intended to includeat least one of: A, B, C, AB, AC, BC, or ABC, and if order is importantin a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.Continuing with this example, expressly included are combinations thatcontain repeats of one or more item or term, such as BB, AAA, MB, BBC,AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan willunderstand that typically there is no limit on the number of items orterms in any combination, unless otherwise apparent from the context.

As used herein, the term “substantially” means that the subsequentlydescribed event or circumstance completely occurs or that thesubsequently described event or circumstance occurs to a great extent ordegree. For example, the term “substantially” means that thesubsequently described event or circumstance occurs at least 90% of thetime, or at least 95% of the time, or at least 98% of the time.

As used herein, “pharmaceutically acceptable” refers to those propertiesand/or substances, which are acceptable to the patient from apharmacological/toxicological point of view including bioavailabilityand patient acceptance or to the manufacturing chemist from aphysical-chemical point of view regarding composition, formulation,stability and isolatability. The phrase “pharmaceutically acceptable” isemployed herein to refer to those compounds, materials, compositions,and/or dosage forms which are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of human beingsand animals without excessive toxicity, irritation, allergic response,or other problem or complication, commensurate with a reasonablebenefit/risk ratio. The phrase “pharmaceutically-acceptable carrier” asused herein means a pharmaceutically-acceptable material, composition,or vehicle, such as a liquid or solid filler, diluent, excipient, orsolvent encapsulating material, involved in carrying or transporting thesubject compound from one organ, or portion of the body, to anotherorgan, or portion of the body. Each carrier must be “acceptable” in thesense of being compatible with the other ingredients of the formulationand not injurious to the patient.

As used herein, a “therapeutically effective amount” the inhibitor orchemotherapeutic agent of the presently disclosed and claimed inventiveconcept(s) refers to an amount of a compound that is effective, uponsingle- or multiple-dose administration to the subject, e.g., a patient,at enhancing the inhibition of the growth or proliferation, or inducingthe killing, of hyperproliferative cells, e.g., cancer cells by achemotherapeutic compound or by radiation treatment. The term, forexample, “therapeutically effective amount” refers to an amount of aninhibitory compound of the presently disclosed and claimed inventiveconcept(s) that is administered, e.g., coadministered, (i.e.,sequentially or concomitantly) with one or more cytotoxic agents suchthat the inhibitory compound and the cytotoxic agent, are effective,upon single- or multiple-dose administration to the subject, e.g., apatient, at inhibiting the growth or proliferation, or inducing thekilling, of hyperproliferative or angiogenic cells. Such growthinhibition or killing can be reflected as a prolongation of the survivalof the subject, e.g., a patient beyond that expected in the absence ofsuch treatment, or any improvement in the prognosis of the subjectrelative to the absence of such treatment. As used herein, the term“carcinomas” refers to lesions that are cancerous. As used herein, theterm “neoplasm” refers to both precancerous and cancerous lesions. Asused herein, the terms “inhibit” or “inhibiting,” mean decreasing FAP,POP, or APCE activity, or tumor cell growth rate or other targetedactivity from the rate that would occur without treatment of theinhibitor compound and/or causing tumor mass to decrease. Inhibitingalso includes causing a complete regression of the tumor. Thus thecompounds of the presently disclosed and claimed inventive concept(s)can be either cytostatic or cytotoxic to the tumor cells, when usedalone or in combination with other therapies.

As used herein, the terms “cytotoxic agent”, “chemotherapeutic agent”,“anticancer agent”, and “antitumor agent” are used interchangeablyherein and refer to agents that have the property of inhibiting thegrowth or proliferation (e.g., a cytostatic agent), or inducing thekilling, of hyperproliferative cells. As used herein,“chemosensitization” and “chemosensitizing effect” are usedinterchangeably and refer to the enhancement of radiation orchemotherapy efficacy by the compound. “Chemosensitizer” refers to theagent that enhances the efficacy of another agent, such as the cytotoxicagent or radiation.

The term “a drug or compound for overcoming a resistance to ananticancer drug or an anticancer-drug-resistance overcoming drug” or “apharmaceutical composition for overcoming a resistance to an anticancerdrug or an anticancer-drug-resistance overcomingpharmaceutical-composition” refers to a drug which has no carcinostaticactivity itself but has a function of reducing a resistance of cancercells to an anticancer drug. In other words, it means a drug having afunction for increasing sensitivity to an anticancer drug of cancercells having an acquired resistance to the anticancer drug. In thiscase, the increase of the sensitivity means not only to increase aneffect of an anticancer drug to anticancer-drug resistant cells in ahigher level than that to anticancer-drug sensitive cells but also toincrease the effect of the anticancer drug to the anticancer-drugresistant cells in approximately the same level as that to theanticancer-drug sensitive cells. Further, another term equivalent to“overcoming a resistance” may include “restraining or inhibiting aresistance”, “releasing resistance”, “releasing tolerance” or“increasing or enhancing a sensitivity”.

The term “administrating together with” in the presently disclosed andclaimed inventive concept(s) means administering two kinds of drugssimultaneously, continuously or at intervals. The two kinds of drugs maybe administered as a mixture or as separate drugs. When administering asseparate drugs, each administering route may be or may be not the same.As defined herein, treating cancer (i.e., with an anticancer therapy) ina patient includes achieving, partially or substantially, one or more ofthe following: arresting the growth or spread of a cancer, reducing theextent of a cancer (e.g., reducing size of a tumor or reducing thenumber of affected sites). Inhibiting the growth rate of a cancer, andameliorating or improving a clinical symptom or indicator associatedwith a cancer (such as tissue or serum components). The term “treatment”as used herein is also intended to encompass prophylaxis, therapy andcure.

Also, where used herein, the terms “heterocycle” or “heterocyclic” referto ring structures, particularly 4, 5, 6, or 7-membered ring structures,and more particularly 5- to 6-membered rings, whose ring structuresinclude one to four heteroatoms such as nitrogen, sulfur, or oxygen.Heterocyclic groups include, but are not limited to, thiophene, furan,pyran, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine,pyrazine, pyrimidine, and pyridazine. The heterocyclic ring can besubstituted at one or more positions with such substituents as, forexample, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl,hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate,phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl,ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromaticmoiety, CF₃, CN, or the like. Where used herein, the term “carbocycle”or “carbocyclic” refers to an aromatic or non-aromatic ring in whicheach atom of the ring is carbon and may particularly comprise 4, 5, 6 or7 carbons per ring, such as 5 or 6 carbons per ring.

The term “stalk” or “stalk portion” as used herein will be understood torefer to portions of the compounds disclosed herein, such as but notlimited to, Formulas I-IV, that are missing the Cyc groups thereof.

Additionally, the proline analogs and derivatives or other amino acidsof the peptidomimetic compounds of the presently disclosed and claimedinventive concept(s) may exist in particular geometric or stereoisomericforms. The presently disclosed and claimed inventive concept(s) includesall such compounds, including cis- and trans-isomers, R- andS-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemicmixtures thereof, and other mixtures thereof, as falling within thescope of the presently disclosed and claimed inventive concept(s).Additional asymmetric carbon atoms may be present in a substituent suchas, but not limited to, an alkyl group. All such isomers, as well asmixtures thereof, are intended to be included in the presently disclosedand claimed inventive concept(s).

Turning now to the presently disclosed and claimed inventive concept(s),inhibitors of prolyl oligopeptidase (POP) and fibroblast activationprotein-alpha (FAP) are provided, as are substrates of APCE, FAP, orPOP. The presently disclosed and claimed inventive concept(s) alsoincludes, but is not limited to, methods of using such inhibitors totreat, inhibit, and/or ameliorate conditions and/or diseases involvingFAP and/or POP, such as, but not limited to, epithelial-derived cancers,angiogenesis (such as angiogenesis which occurs during formation oftumors or in diabetes), Alzheimer's disease, atherosclerosis, andthrombus disorders and conditions involving abnormal cell proliferation,as well as other cancers and disorders identified herein. Substrates ofAPCE, FAP, and POP may also be used, for example, in screening methodsfor identifying inhibitors of FAP and POP.

Thus, the presently disclosed and claimed inventive concept(s) isdirected to (but not limited to) methods and compounds for treatingconditions characterized by abnormal cell proliferation, angiogenesis,and/or neural disorders, including, but not limited to, cancer andmetastasis, and Alzheimer's disease, by using the inhibitors of thepresent disclosure to inhibit the enzymatic activity of FAP and POP invivo. In one embodiment, the presently disclosed and claimed inventiveconcept(s) provides a method for treating a subject having a conditioncharacterized by abnormal mammalian cell proliferation and/orangiogenesis. In the method, an agent is administered to a subject inneed of such treatment in an amount effective to inhibit cellproliferation and/or angiogenesis. The agent is, or comprises, acompound having at least one of Formula I and Formula II as describedherein.

The inventors discovered the circulating antiplasmin-cleaving enzyme(APCE) and showed it to be either a derivative of fibroblast activationprotein (FAP) or a slight variant thereof due to gene splicingdifferences [1,2]. Except for the absence of an about 26-residue aminoterminal peptide constituting the transmembrane and intracytosolicdomains, APCE is otherwise identical to FAP in molecular structure andfunction. FAP is over expressed by stromal cells in >90% ofepithelial-derived malignancies, but not by normal tissues or benigntumors, hence causing FAP to be viewed as having major potential as aunique diagnostic and therapeutic target in a wide array of humancancers.

Subsequent research indicated that POP, another member of the clade ofprolyl-specific serine proteinases, had proteolytic activity whichoverlapped that of FAP when conventionally available syntheticsubstrates such as Z-Gly-Pro-AMC were used for FAP activitymeasurements. Although the principal inhibitor of FAP manifested bothhigh selectivity and sensitivity, it also inhibited POP, and this hasbeen a consistent problem in trying to separate and quantitate theactivity of each of these enzymes. Very effective and specificinhibitors of POP have thus been designed and synthesized, as describedherein. It has also been discovered that the POP inhibitor very rapidlyand effectively blocked capillary-like tube formation by human dermalendothelial cells. Thus, in one aspect of the presently disclosed andclaimed inventive concept(s), the POP inhibitors described herein can beused as anti-angiogenic agents and as effective, high affinity,sensitive inhibitors of POP in certain mammalian diseases, particularlywhere therapeutic effectiveness has been limited due to problems ofinhibitor solubility and/or inhibition of other enzymes where suchinhibition was undesirable and carried potential for adversepharmacologic outcomes.

Further, it has been discovered that POP is extensively expressed byactivated fibroblasts that characteristically participate in thedevelopment of scaffolding over which cancer cells grow as the tumorexpands. One embodiment of the presently disclosed and claimed inventiveconcept(s) is a pseudo-peptide, acetyl-Lys(K)-Leu(L)-Arg(R), which formsa stalk of a very specific, sensitive fluorescent substrate for the POPenzyme, namely acetyl-KLRP-AMC (designated herein as L96), which hasbeen shown to be cleaved by POP with a K_(m) of 30±3 μM andk_(cat)=2.4±0.1 s⁻¹. Neither DPPIV nor APCE/FAP cleaved this substrate.The substrate can be used to assess POP activity from a variety ofsources including, but not limited to, human plasma, tissue, and culturemedia. In another embodiment, the acetyl-Lys(K)-Leu(L)-Arg(R) peptide isused as a stalk of another pseudo-peptide, acetyl-KLR-(L)-boroPro, andalternate versions thereof as represented by Formula II, which proved tobe a very highly sensitive, selective POP inhibitor (K_(I)<<100 nM), anduseful for separating the activities of POP and ACE/FAP. Using standardtissue culture methods for growing blood vessel capillaries in vitro, itis also demonstrated that POP is also expressed by human endothelialcells as they became confluent and progress to capillary-like tubeformation. It has also been demonstrated that application of 50 μM POPinhibitor (J94) abrogated the genesis of capillary-like tubes (FIG. 10).Hence one of the potent effects of the inhibitor described here is thatit disrupts angiogenesis by instantaneously inhibiting POP activity.Given the obligatory need of microcirculation to enable tissue growth,the inhibition of POP by the inhibitor indicates its ability to abrogateundesirable tissue expansion, i.e., malignant growth, by blocking thedevelopment of a requisite microcirculation.

To date, many of the POP inhibitors designed and invented by others havenot been used clinically for inhibiting angiogenesis. An importantadvantage of the novel inhibitors described herein is the high degree ofsolubility manifested under aqueous conditions, which is a requirementfor use in tissues where water is the overwhelming physiologic solvent,and counters the significant negative of previous inhibitors that areincompletely soluble under in vivo conditions.

In one embodiment, the presently disclosed and claimed inventiveconcept(s) is directed to the use of these POP inhibitors for thetreatment of human disorders and diseases, such as various mood, memory,and behavioral disorders, as well as learning disorders, and also forblocking angiogenesis by specifically and selectively inhibiting POP. Incertain embodiments, the presently disclosed and claimed inventiveconcept(s) is particularly directed to those human diseases whereformation of new blood vessels is essential for disease progression, asin malignancies (specifically epithelial-derived malignancies), inretinal blood vessel proliferation, in sickle cell disease, and indiabetes mellitus.

In one embodiment, inhibition of FAP or POP is defined herein as atleast 50% inhibition of activity of FAP or POP, respectively, forexample, at an inhibitor concentration of 20 μM. Examples of theinhibitors are described below, and in one embodiment comprise a boroProlinked to the stalk unit. Groups which may substitute for boroPro(boronyl proline), include, but are not limited to, other boronic acidderivatives, carbocyclic groups, heterocyclic groups, carbonitriles,carboxynitriles, or nitrilic-containing compounds, where the Arg (orother positively-charged N-terminal amino acid) may or may not beblocked with a protecting group such as, but not limited to, succinyl,acetyl, benzoyl, benzyloxycarbonyl, or other protecting group commonlyused for blocking peptides from attack by proteases.

The FAP inhibitors of the presently disclosed and claimed inventiveconcept(s) can be used in treatment of various cancers and/or otherFAP-related conditions or other conditions involving abnormal cellproliferation, as described in further detail below. With respect toFAP, inhibition of this enzyme will limit or obviate the ability ofepithelial-derived cancers to invade the surrounding extracellularmatrix, thereby limiting the cancer's spread and allowing more effectiveuse of chemotherapy or radiation therapy. Without wishing to be bound bytheory, the FAP inhibitors described herein are effective, highlyefficient inhibitors which prevent, inhibit, and/or reduce the expansionof extracellular space by digestion of FAP's substrate proteins, e.g.,type I collagen within the extracellular matrix (ECM). This will thenabrogate subsequent movement of activated fibroblasts for remodeling ECMspace with new stromal scaffolding to which malignant cells adhere formigration and mitosis. As a consequence, the neoplasm will then atrophyand undergo necrosis, or be arrested to an extent that radiation and/orchemotherapy measures, desirably at lower than standard doses, willeradicate the malignancy. Previously a number of studies of metastaticcancer indicated that Val-boroPro, a dipeptide containing a boronic acidderivative of proline (for example, as described in U.S. Pat. No.7,399,869), inhibits FAP, and as a consequence, cancer growth.Unfortunately, however, Val-boroPro also non-selectively inhibits mostprolylpeptidases such as dipeptidyl peptidases (such as DPPIV) andup-regulates cytokine and chemokine-5 activities. Several other prolylboronic acid derivatives have been developed and reported as putativeselective inhibitors for FAP, but their instability in aqueousenvironments at physiologic pH and their non-specific reactivities withother enzymes due to the electrophilic property of boronic acid hascomplicated progress in their use.

POP activity has been shown to be elevated in subjects with neurologicaldisorders such as, but not limited to, bipolar disorder, autism,schizophrenia, various stress-related disorders, memory loss, and memorydeficits (such as those characteristic of Alzheimer's disease). Withoutwishing to be bound by theory, POP appears to be involved in cognitivefunctions via the cleavage of neuropeptides. Increased levels of POP maylead to reduced levels of key neuropeptides, which may be restored byadministration of POP inhibitors. In any event, by whatever mechanismPOP has its effect, inhibition of POP can be used as a treatment ofthese diseases, disorders, and conditions (see, for example, references55-58 and U.S Published Patent Applications 2003/0096392, 2005/0020677,2007/0060550, and 2008/0269313, in regard to the use of POP inhibitorsin the treatment of such neural conditions; the entirety of each ofthese references being expressly incorporated herein by reference).

Prior to the presently disclosed and claimed inventive concept(s), therewere no effective inhibitors of FAP or POP that have sufficientspecificity to allow exploration of effects on the pathogenesis and/ortherapy of chronic diseases such as atherosclerosis or a variety ofdifferent cancers. For example, various dipeptide boronyl-prolineconstructs (e.g., “val-boroPro”) have been used in efforts to inhibitFAP, but as noted above, these constructs also inhibited several otherprolyl peptidases, some of the latter being critical for importantmetabolic functions. Moreover, the design of these amino acidboroProline inhibitors did not prevent or slow their cyclization andinactivation that occurs within a few minutes in aqueous environments.The inhibitors of the presently disclosed and claimed inventiveconcept(s) avoid these pitfalls.

Further, the presently disclosed inhibitor compounds with highspecificity for FAP and/or POP can be used in in vitro assays based oncancer cell lines to determine the role of FAP at various stages ofpathogenesis of FAP-related cancers. The exact mode of how FAP operatesin specific cancer etiologies is still under study, and an inhibitormolecule for selectively inhibiting FAP can be most useful.

FAP and POP Inhibitors

Certain embodiments of the presently disclosed and claimed inventiveconcept(s) include APCE-inhibitory, FAP-inhibitory, and/orPOP-inhibitory peptidomimetics. The peptidomimetics may have up to 28amino acids or more, as well as less than 28 amino acids. Thepeptidomimetics comprise proline analogs and derivatives thereof for useas a P₁ proline substitute, including, but not limited to, the prolineanalogs and derivatives shown in Table 1 or discussed or describedelsewhere herein. The peptidomimetics (inhibitors) particularly maycomprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, or 28 amino acids, and thepeptidomimetics may further comprise a spacer compound (which may be anamino acid) for separating certain amino acids of the compound, orcompounds which may be bound or complexed thereto, for extending theserum life of the peptide. Such spacers are discussed further below.

Inhibitors of the presently disclosed and claimed inventive concept(s)may possess a charged residue (positively-charged in the case of FAPinhibitors) at a distance corresponding to the length of two to sevenresidues upstream of the proline analog (0.3 nm-2.4 nm) and can be usedas a rapid, tightly binding and effective inhibitor of APCE, FAP, and/orPOP. Such inhibitors can be useful for the treatment of disordersrelating to FAP and POP, for example, as described elsewhere herein.

In certain embodiments, the inhibitors and/or substrates include asequence having 2, 3, 4, 5, 6, or 7 amino acids in the N-terminaldirection from the proline or proline substitute. In the case of FAPinhibitors and/or substrates, these 2, 3, 4, 5, 6, or 7 amino acidsinclude a positively-charged amino acid such as, but not limited to,α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, and histidine, and a glycine, D-alanine,D-serine, or D-threonine at the P₂ position. In the case of POPinhibitors and/or substrates, these 2, 3, 4, 5, 6, or 7 amino acidsinclude at least one positively-charged or negatively-charged aminoacid, such as but not limited to, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine,histidine, aspartic acid, or glutamic acid, and a positively-chargedamino acid at P₂, such as but not limited to, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, orhistidine. The inhibitors and/or substrates may also comprise anegatively-charged or aromatic amino acid (e.g., asn, gln, asp, glu,trp, tyr, and phe) at a position downstream (C-terminal direction) fromthe proline or proline substitute.

In one embodiment of the presently disclosed and claimed inventiveconcept(s), the inhibitor and/or substrate compounds comprise a spacer(linker or filler) group between the P₂ group and the positively-chargedamino acid (e.g., arginine) on the N-terminal side. Thepositively-charged amino acid, e.g., arg, his, or lys or other listedherein, may be in a position equivalent to P₇, P₆, P₅, or P₄. The spacer(i.e., linker or filler) between the P₂ group and the positively-chargedamino acid in one or more of the P₄, P₅, P₆ or P₇ positions may forexample comprise one or more neutral, non-charged amino acids, e.g.,glycine, alanine, leucine, isoleucine, valine, proline, methionine,tryptophan, tyrosine, threonine, serine, β-alanine, γ-amino butyricacid, epsilon amino caproic acid; or PEG_(n) (n=1-6), PPG_(n) (n=1-6),amino-PEG_(n)-carboxy group (n=1-6), including for example,8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid,and 14-amino-3,6,9,12-tetraoxatetradecanoic acid, andamino-PPG_(n)-carboxy oligomers (e.g., n=1-6). These individual spacermolecules may be the same (e.g., all glycine, alanine, etc., or othersingle amino acid or molecule) or different (e.g., more than one type ofamino acid, ethylene glycol/propylene glycol, or a hybrid aminoacid/amino-PEG_(n)-carboxy or amino-PPG_(n)-carboxy where n=1-6), andmay be in a range of 3.0-21 Å (0.3 nm-2.1 nm, or 1 to 7 amino acids) inlength. The spacer may be comprised of neutral monomers comprisingethylene glycol for example, or other similar monomer units (e.g.,propylene glycol) each having a length of about 0.3 nm, which togetherhave a length of 3.0-21 Å (0.3 nm-2.1 nm) such that the spacer placesthe positively charged amino acid (or, in the case of a POP substratean/dor inhibitor, a negatively- or positively-charged amino acid) withinabout 5-25 Å (0.5 nm-2.5 nm) of the proline or proline substitute,analog, or derivative at the P₁ position. The inhibitors optionallycomprise a blocking group on the N-terminal end for inhibiting proteasedegradation of the inhibitor.

FAP Inhibitors

In one embodiment, FAP inhibitors of the presently disclosed and claimedinventive concept(s) comprise compounds having Formula I as shown below:

B-Xaa₁-Sp-Xaa₂-Cyc  (Formula I).

In Formula I, Xaa₁ may be a positively-charged amino acid, including butnot limited to, α,β-diaminopropionic acid, α,γ-diaminobutyric acid,ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine,lysine, homolysine, β-homolysine, or histidine, and Xaa₂ is glycine,D-alanine, D-serine, or D-threonine. Alternatively, Xaa₁ may be absentsuch that the compound comprises the Formula Ia:

B-Sp-Xaa₂-Cyc  (Formula Ia).

B is a blocking (protecting) group. Examples of such protecting groupsinclude, but are not limited to, aminobenzoyl (Abz), acetyl (Ac),benzoyl (Bz), carbobenzoxy, benzyloxycarbonyl (Z), t-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, peptides comprising any combination of1-3 natural amino acids, and Succinyl (Suc). Where present, the blockinggroup B may have a molecular weight<400 Da, such as a molecular weight<300 Da. In other embodiments, B may be absent such that the compoundcomprises the Formula Ib:

Xaa₁-Sp-Xaa₂-Cyc  (Formula Ib).

Sp is a spacer molecule, which has a length in a range of 0.3 nm to 0.6nm to 0.9 nm to 1.2 nm to 1.5 nm to 1.8 nm to 2.1 nm to 2.5 nm(including any subrange therein, such as 0.3 nm to 1.5 nm). Examples ofsuch spacer molecules include, but are not limited to, γ-aminobutyricacid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid,11-amino-3,6,9-trioxaundecanoic acid,14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr,trp, tyr, met, leu, ile, val, ser, proline, a PEG_(n); PPG_(n), anaminocarboxy PEG_(n) or PPG_(n), or a combination of any of the abovewherein Sp has a length of 0.3 nm to 2.5 nm, and wherein n=1-6.

Cyc is a carbocyclic or heterocyclic ring. The carbocyclic ring maycomprise 4, 5, 6, or 7 carbon atoms, for example. The heterocyclic ringmay comprise 4, 5, 6, or 7 atoms, for example, wherein at least one atomis a heteroatom such as nitrogen or other atom as discussed elsewhereherein. Alternatively, Cyc may be absent such that the compoundcomprises the Formula Ic:

B-Xaa₁-Sp-Xaa₂  (Formula Ic).

The compound may further comprise one or more amino acids extendingupstream from the Cyc group, including, but not limited to, asparticacid, glutamic acid, glutamine, aspargine, serine, threonine, histidine,tyrosine, alanine, phenylalanine, glycine, valine, leucine, isoleucine,methionine, tyrosine, tryptophan, or any negatively-charged or aromaticamino acid. Examples of Cyc include, but are not limited to, those shownin Table 1 and desirably comprise boronyl prolines (L, D, or D/L),carbonitrile prolines, or nitrile pyrrolidines. Non-limiting examples ofvarious FAP inhibitor compounds of the presently disclosed and claimedinventive concept(s) having the structure of Formula I are shown inTable 2. These FAP inhibitors are generally also inhibitors of POP.

POP Inhibitors

In one embodiment, POP inhibitors of the presently disclosed and claimedinventive concept(s) comprise compounds having Formula II as shownbelow:

B-Xaa_(1a)-Sp-Xaa_(2a)-Cyc  (Formula II).

In this embodiment Xaa_(1a) is a negatively- or positively-charged aminoacid, including but not limited to, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine,histidine, aspartic acid, or glutamic acid. Alternatively, Xaa_(1a) maybe absent such that the compound comprises the Formula IIc:

B-Sp-Xaa_(2a)-Cyc  (Formula IIc).

Xaa_(2a) is a positively-charged amino acid, including but not limitedto, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, or histidine. Xaa_(1a) and Xaa_(2a) may be thesame when both are positively-charged.

B is a blocking (protecting) group. Examples of such protecting groupsinclude, but are not limited to, aminobenzoyl (Abz), acetyl (Ac),benzoyl (Bz), carbobenzoxy, benzyloxycarbonyl (Z), t-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, peptides comprising any combination of1-3 natural amino acids, and Succinyl (Suc). Where present, the blockinggroup B may have a molecular weight <400 Da, such as a molecular weight<300 Da. In other embodiments, B may be absent such that the compoundcomprises the Formula IIa:

Xaa_(1a)-Sp-Xaa_(2a)-Cyc  (Formula IIa).

Sp is a spacer molecule which may have a length in a range of 0.3 nm to0.6 nm to 0.9 nm to 1.2 nm to 1.5 nm to 1.8 nm to 2.1 nm to 2.5 nm(including any subrange therein, such as 0.3 nm to 1.5 nm). Examples ofsuch spacer molecules include, but are not limited to, γ-aminobutyricacid; E-aminocaproic acid; 8-amino-3,6-dioxaoctanoic acid;11-amino-3,6,9-trioxaundecanoic acid;14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid; β-alanine, glycine,alanine, threonine, tryptophan, tyrosine, methionine, leucine,isoleucine, valine, serine, or proline; PEG_(n) (wherein n=1-6); PPG_(n)(wherein n=1-6); an aminocarboxy PEG_(n) or PPG_(n) (wherein n=1-6); ora combination of any of the above, so long as Sp has a length of 0.3 nmto 2.5 nm, and. Particular versions of Sp are leucine, isoleucine,valine, and alanine.

Cyc is a carbocyclic or heterocyclic ring. The carbocyclic ring maycomprise 4, 5, 6, or 7 carbon atoms, for example. The heterocyclic ringmay comprise 4, 5, 6, or 7 atoms, for example wherein at least one atomis a heteroatom such as nitrogen or other atom as discussed elsewhereherein. The compound may further comprise one or more amino acidsextending upstream from the Cyc group, including, but not limited toaspartic acid, glutamic acid, glutamine, aspargine, serine, threonine,histidine, tyrosine, alanine, phenylalanine, glycine, valine, leucine,isoleucine, methionine, tyrosine, tryptophan, or any negatively-chargedor aromatic amino acid. Examples of Cyc include, but are not limited to,those shown in Table 1 and desirably comprise boronyl prolines (L, D, orD/L), carbonitrile prolines or nitrile pyrrolidines. Non-limitingexamples of various POP inhibitor compounds of the presently disclosedand claimed inventive concept(s) having the structure of Formula II areshown in Tables 3-5.

In a particular embodiment, the inhibitor compounds of the presentlydisclosed and claimed inventive concept(s) are non-immunogenic (i.e.,induce no antibody response) and have zero cell membrane permeability,as well as a solubility in water of at least 5 mg/ml.

The inhibitors described herein may comprise isostere bonds. For examplebut not by way of limitation, in a compound comprisingacetyl-arginyl-amino-PEG₂-carboxy-D-alanyl-L-boroproline, the carbonylof the carboxyl group of the arginine moiety may be reduced to amethylene group to form a reduced isostere bond between the residualarginine group and the amino-PEG₂-carboxy spacer group. Any of theinhibitor compounds of the presently disclosed and claimed inventiveconcept(s) may comprise such a reduced isostere bond, or may be formedwith the regular peptide bond, between the arginine (or other chargedamino acid) and the spacer group, i.e., between Xaa₁ (or Xaa_(1a)) andSp. The reduced isostere bond is effective in further reducing peptidaseactivity upon the compound.

The compound may further comprise, with, or in place of B, an N-terminaloligopeptide having 1 to 10 amino acids extending in an N-terminaldirection from Xaa₁ or Xaa_(1a) and/or a C-terminal oligopeptide having1-10 amino acids extending in a C-terminal direction from Cyc, whereinthe N-terminal oligopeptide and C-terminal oligopeptide may comprise oneor more of the 20 naturally-occurring amino acids in any combination.

In certain embodiments of a FAP inhibitor compound of the presentlydisclosed and claimed inventive concept(s), D-ala replaces gly, becauseit was observed in a surprising result that this unnatural amino acidsignificantly amplified inhibitory selectivity of the compound for FAPor APCE versus DPPIV. D-ser and D-thr may also substitute for gly. Forexample, as shown in Table 7, an inhibitor compound comprisingD-ala-L-boroPro had an APCE K_(i) of 5.7 nM and DPPIV Ki of 6130 nM,while a compound comprising gly-boroPro had an APCE K_(i) of 1.8 nM andDPPIV K_(i) of 440 nM. Unlike FAP, DPPIV is expressed by normal tissuesand is involved in normal physiologic reactions; therefore, a high K_(i)(low affinity) for DPPIV is greatly desired. The D-amino acid-containinginhibitors may inhibit APCE with a K_(i) in the low nM range (e.g., suchas <100 nM, <50 nM, <20 nM, <15 nM, or <10 nM) and do not significantlyinhibit DPPIV (e.g., >5,000 nM), unless used at unacceptable andunusually high concentrations. In a particular version of the presentlydisclosed and claimed inventive concept(s), the inhibitor compounds arehighly selective for APCE and FAP versus DPPIV. For example, the ratioof K_(i) (DPPIV): K_(i) (APCE/FAP) may be >200, such as >500, or >600,or >700, or >800, or >900, or >1,000. The K_(i) (DPPIV) may be >200 nM,such as >500 nM, >1,000 nM, >2,500 nM, >4,000 nM, >5,000 nM, >6,000nM, >7,500 nM, or >10,000 nM. The molecular weight of the inhibitorcompound of the presently disclosed and claimed inventive concept(s) maybe <1000 Da, such as <800 Da, or <600 Da. The inhibitors which arespecific for POP may have a K_(i) (POP)<100 nM while the K_(i) (FAP)is >200 nM or >500 μM. The inhibitors of POP may have a Ki (DPPIV)>200nM, such as >500 nM, >1,000 nM, >2,500 nM, >4,000 nM, >5,000 nM, >6,000nM, >7,500 nM, or >10,000 nM.

The inhibitors described herein exhibit very good to excellentselectivity and are highly water soluble; in addition, given this lengthand the lack of exposed amino-terminal amino group, the inhibitors arenot prone to cyclization with resultant loss of activity. In certainembodiments, a chemotherapeutic agent, such as described below, can belinked to the inhibitor molecule, directly via an exposed amino orcarboxy group or via a linking group. In an alternative embodiment, thepresently disclosed and claimed inventive concept(s) includes a compoundwhich comprises the “stalk” portion of the compound of Formula I, i.e.,B-Xaa₁-Sp-Xaa₂ (Formula Ic), wherein Xaa₁ is a positively-charged aminoacid, such as but not limited to, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, orhistidine (or is absent), and Xaa₂ is glycine, D-alanine, D-serine, orD-threonine. The presently disclosed and claimed inventive concept(s)also include the stalk portion of Formula II, i.e.,B-Xaa_(1a)-Sp-Xaa_(2a) (Formula IIb), wherein Xaa_(1a) is a negatively-or positively-charged amino acid, such as but not limited to,α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, histidine, aspartic acid, or glutamic acid,and Xaa₂₃ is a positively-charged amino acid, such as but not limitedto, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, or histidine (or is absent). Xaa_(1a) andXaa_(2a) may be the same when both are positively-charged. The “stalks”may be used as precursors of the inhibitor compounds, or linked to atargeting agent or delivery agent, to deliver a “warhead” (i.e., Cyc, orother compound) to FAP or POP, respectively, for example.

The presently disclosed and claimed inventive concept(s) is thusdirected to compounds comprising or otherwise based on these “stalks” asa component, and to the use of these compounds in any therapeutic,diagnostic, or assay method described, contemplated, or enabled herein.The compound may be disposed in a pharmaceutically-acceptable carrier asdescribed elsewhere herein.

FAP and POP Substrates

Embodiments of the presently disclosed and claimed inventive concept(s)include substrates for APCE, FAP, and/or POP, and particularlysubstrates which are specific for POP.

FAP Substrates

In one embodiment, the presently disclosed and claimed inventiveconcept(s) includes substrates of FAP (and APCE) having Formula III asshown below:

B-Xaa₁-Sp-Xaa₂-Pro-Rep  (Formula III).

B is a blocking (protecting) group. Examples of such protecting groupsinclude, but are not limited to, aminobenzoyl (Abz), acetyl (Ac),benzoyl (Bz), carbobenzoxy, benzyloxycarbonyl (Z), t-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, peptides comprising any combination of1-3 natural amino acids, and Succinyl (Suc). Where present, the blockinggroup B may have a molecular weight <400 Da, such as a molecular weight<300 Da. In other embodiments, B may be absent such that the compoundcomprises the Formula IIIa:

Xaa₁-Sp-Xaa₂-Pro-Rep  (Formula IIIa).

In Formula III, Xaa₁ is a positively-charged amino acid such as, but notlimited to, α,β-diaminopropionic acid, α,γ-diaminobutyric acid,ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine,lysine, homolysine, β-homolysine, or histidine. Xaa₂ is glycine,D-alanine, D-serine, or D-threonine.

Sp is a spacer molecule comprising one or more of γ-aminobutyric acid;ε-aminocaproic acid; 8-amino-3,6-dioxaoctanoic acid;11-amino-3,6,9-trioxaundecanoic acid;14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid; (3-alanine; alanine,threonine, tryptophan, tyrosine, methionine, leucine, isoleucine,valine, serine, proline; PEG_(n) (n=1-6); PPG_(n) (n=1-6); aminocarboxyPEG_(n) (n=1-6); aminocarboxy PPG_(n) (n=1-6); or a combination of anyof the above, so long as Sp has a length in a range of 0.3 nm to 0.6 nmto 0.9 nm to 1.2 nm to 1.5 nm to 1.8 nm to 2.1 nm to 2.5 nm (includingany subrange therein, such as 0.3 nm to 1.5 nm).

Pro is proline or a proline analog which can form a P₁—P₁′ bond which iscleavable by FAP. Rep may be absent, or is a reporter group such as, butnot limited to, at least one of 7-amido-4-methylcoumarin (AMC),7-amino-trifluoromethylcoumarin (AFC), ethyl ester (OEt), methyl ester(OMe), 2-Naphthylamide (2NA), p-Nitroanilide (p-NA), p-Nitrophenyl ester(ONp), or Thiobenzyl ester (SBzI). The substrate may further comprisepeptide(s) (n=1-10) extending from the N-terminal amino acid and/or fromthe C-terminal amino acid thereof. The compounds of Formula IIIgenerally are also substrates of POP.

POP Substrates

In another embodiment, the presently disclosed and claimed inventiveconcept(s) includes substrates of POP having Formula IV as shown below:

B-Xaa_(1a)-Sp-Xaa_(2a)-Pro-Rep  (Formula IV).

B is a blocking (protecting) group. Examples of such protecting groupsinclude, but are not limited to, aminobenzoyl (Abz), acetyl (Ac),benzoyl (Bz), carbobenzoxy, benzyloxycarbonyl (Z), t-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, peptides comprising any combination of1-3 natural amino acids, and Succinyl (Suc). Where present, the blockinggroup B may have a molecular weight <400 Da, such as <300 Da. In otherembodiments, B may be absent such that the compound comprises theFormula IVa:

Xaa_(1a)-Sp-Xaa_(2a)-Pro-Rep  (Formula IV).

In Formula IV, Xaa_(1a) is a negatively- or positively-charged aminoacid, such as but not limited to, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine,histidine, aspartic acid, or glutamic acid.

Xaa_(2a) is a positively-charged amino acid, such as but not limited to,α,β-diaminopropionic acid; α,γ-diaminobutyric acid; ornithine;β-homoornithine; arginine; (3-homoarginine; homoarginine; lysine;homolysine; β-homolysine; or histidine. Xaa_(1a) and Xaa_(2a) may be thesame when both are positively-charged.

Sp is a spacer molecule comprising one or more of γ-aminobutyric acid;ε-aminocaproic acid; 8-amino-3,6-dioxaoctanoic acid;11-amino-3,6,9-trioxaundecanoic acid;14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid; (3-alanine; alanine,threonine, tryptophan, tyrosine, methionine, leucine, isoleucine,valine, serine, proline; PEG_(n) (n=1-6); PPG_(n) (n=1-6); aminocarboxyPEG_(n) (n=1-6); aminocarboxy PPG_(n) (n=1-6); or a combination of anyof the above, so long as Sp has a length in a range of 0.3 nm to 0.6 nmto 0.9 nm to 1.2 nm to 1.5 nm to 1.8 nm to 2.1 nm to 2.5 nm (includingany subrange therein, such as 0.3 nm to 1.5 nm).

Pro is proline or a proline analog which can form a P₁—P₁′ bond which iscleavable by POP. Rep may be absent, or is a reporter group such as, butnot limited to, at least one of 7-amido-4-methylcoumarin (AMC),7-amino-trifluoromethylcoumarin (AFC), ethyl ester (OEt), methyl ester(OMe), 2-Naphthylamide (2NA), p-Nitroanilide (p-NA), p-Nitrophenyl ester(ONp), or Thiobenzyl ester (SBzI). The substrate may further comprisepeptides (n=1-10) extending from the N-terminal amino acid and/or fromthe C-terminal amino acid.

Screening for APCE, FAP and POP Inhibitors

Certain embodiments of the presently disclosed and claimed inventiveconcept(s) also include methods of screening for inhibitors of APCE,FAP, and/or POP. In the method, at least one of an APCE, FAP, or POPenzyme substrate such as is contemplated herein is provided; thesubstrate may particularly comprise a reporter group. A quantity of atleast one of APCE, FAP, and POP if provided, and the enzyme is exposedto an inhibitor candidate to form a test mixture. The test mixture iscombined with the substrate, and the fluorescence emission from the testmixture is measured to identify when the activity of the enzyme isinhibited by the enzyme inhibitor candidate. Any cleavable substrate ofAPCE, FAP, and/or POP which produces an observable signal (fluorescenceor other signal), such as discussed elsewhere herein, may be used. Inone embodiment, the presently disclosed and claimed inventive concept(s)is directed to a method of screening for inhibitors of POP. In themethod, a substrate compound of Formula IV which is cleavable by POP,and which has signaling activity when cleaved by the POP, is obtainedalong with quantity of POP. The POP is then exposed to a POP inhibitorcandidate to form a test mixture, and the test mixture is combined withthe substrate compound. The signal emitted from the testmixture/substrate compound mixture is measured to identify a POPinhibitor which inhibits the activity of the POP.

In one particular embodiment, the presently disclosed and claimedinventive concept(s) is directed to a compound (and to a compositioncontaining the compound) having the formula:

B-Xaa_(1a)-Sp-Xaa₂₃-Cyc  (Formula II).

B is defined as a protecting group or is absent. Xaa_(1a) is apositively-charged or negatively-charged amino-acid, or is absent. Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm.Xaa₂₃ is a positively-charged amino acid. Cyc is a carbocyclic orheterocyclic compound.

Xaa_(1a) may be, for example, α,β-diaminopropionic acid,α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine,histidine, aspartic acid or glutamic acid. Xaa₂₃ may be, for example,α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, or histidine. Sp may be selected from thegroup consisting of, for example, γ-aminobutyric acid; ε-aminocaproicacid; 8-amino-3,6-dioxaoctanoic acid; 11-amino-3,6,9-trioxaundecanoicacid; 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid; β-alanine; glycine;alanine; threonine, tryptophan; tyrosine; methionine; leucine;isoleucine; valine; serine; proline; ethylene glycol; PEG_(n) (whereinn=1-6); propylene glycol; PPG_(n) (wherein n=1-6); amino-PEG_(n)-carboxy(wherein n=1-6); amino-PPG_(n)-carboxy (wherein n=1-6); and combinationsthereof. B may be, for example, at least one of aminobenzoyl (Abz),acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z), τ-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, a 1-3 mer peptide, and Succinyl (Suc).

Cyc may be, for example, a 4, 5, 6, or 7-member carbon carbocycle. Cycmay be, for example, a 4, 5, 6, or 7-member carbon heterocycle, and maycomprise a nitrogen heteroatom. Cyc may comprise, for example, aboronylproline, proline carbonitrile, nitrile pyrrolidone, orcyanopyrrolidine. Sp may be selected from the group consisting of, forexample, ethylene glycol, PEG_(n) (wherein n=1-6), propylene glycol,8-amino-3,6-dioxaoctanoic acid, PPG_(n) (wherein n=1-6)),amino-PEG_(n)-carboxy group (wherein n=1-6), an amino-PPG_(n)-carboxygroup (wherein n=1-6), and combinations thereof. The compound maycomprise an isostere bond between Xaa_(1a) and Sp. Xaa_(1a) maycomprise, for example, a methylene group in substitution for thecarbonyl group adjacent Sp. Sp may have a length in a range of 0.6 nm to1.75 nm. Sp may be, for example, leucine, isoleucine, valine, oralanine. The compound may further comprise a 1-10mer peptide oroligopeptide extending from Cyc in the C-terminal direction.

In one embodiment, the compound is capable of binding to the active siteof POP at a K_(i)<100 nM, <50 nM, or <20 nM, for example, and capable ofbinding to DPPIV at a Ki>500 nM, or >1000 nM or greater and/or has a Ki(DPPIV):Ki (POP) ratio >500. In one embodiment B is an acetyl orpyrazine; Xaa_(1a) is lysine; Xaa_(2a) is arginine; and Cyc isL-boroproline. In one embodiment the compound is combined with apharmaceutically-acceptable carrier or vehicle to form a pharmaceuticalcomposition.

In another particular embodiment of the presently disclosed and claimedinventive concept(s), a pharmaceutical composition is provided thatincludes any of the compounds described herein disposed within orotherwise combined with a pharmaceutically-acceptable carrier orvehicle. In one embodiment, the compound is the compound of Formula IIas described herein above. In particular embodiments, Xaa_(1a) of thecompound is lysine, and the Sp of the compound is leucine, isoleucine,valine, or alanine.

Yet another particular embodiment of the presently disclosed and claimedinventive concept(s) is directed to a method of inhibiting activity ofprolyl oligopeptidase (POP) in a POP-expressing cell or tissue,comprising administering to the POP-expressing cell or tissue any of thecompounds described herein. In one embodiment, the compound is thecompound of Formula II as described herein. The POP-expressing cells ortissues to which the compound is administered may be cancer cells and/oractivated fibroblast cells. The compound may be administered to cellsand/or tissues in vitro or in vivo. For example, the compound may beadministered to a patient, such as but not limited to, a mammalianpatient. In one embodiment of the method, formation ofacetyl-ser-asp-lys-pro is inhibited upon administration of the compoundto the cells or tissues.

Another particular embodiment of the presently disclosed and claimedinventive concept(s) is directed to a method of inhibiting angiogenesisin a tissue. In the method, a pharmaceutically acceptable amount of anyof the compounds described herein is administered to a tissue exhibitingangiogenesis and/or having the potential to exhibit angiogenesis,thereby inhibiting angiogenesis in the tissue. In one embodiment, thecompound is the compound of Formula II as described herein above. Thetissue exhibiting angiogenesis and/or having the potential to exhibitangiogenesis to which the compound is administered may comprise cancercells and/or activated fibroblast cells. The compound may beadministered to cells and/or tissues in vitro or in vivo. For example,the compound may be administered to a patient, such as but not limitedto, a mammalian patient. In one embodiment of the method, formation ofacetyl-ser-asp-lys-pro is inhibited upon administration of the compoundto the cells or tissues.

Yet another particular embodiment of the presently disclosed and claimedinventive concept(s) is directed to a method of treating cancer in asubject. In the method, a therapeutically-effective amount of any of thecompounds described herein is administered to a subject in need of suchtherapy. In one embodiment, the compound is the compound of Formula IIas described herein above.

Another particular embodiment of the presently disclosed and claimedinventive concept(s) is directed to a compound (and to a compositioncontaining the compound) having the formula:

B—Xaa_(1a)-Sp-Xaa_(2a)  (Formula IIb).

B is defined as a protecting group or is absent. Xaa_(1a) is apositively-charged or negatively-charged amino-acid, or is absent. Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm.Xaa_(2a) is a positively-charged amino acid.

The presently disclosed and claimed inventive concept(s) is furtherdirected to a method of inhibiting activity of prolyl oligopeptidase(POP) in a subject suffering from a disorder for which inhibition of POPprovides a therapeutically-effective benefit. In the method, any of thePOP inhibitors described herein is administered to a subject in need ofsuch therapy.

In one embodiment, the therapeutically-effective benefit is theinhibition of angiogenesis. In one embodiment, the compound is thecompound of Formula II or Formula IIb as described herein above.

Certain embodiments of the presently disclosed and claimed inventiveconcept(s) include FAP and POP inhibitor compounds described hereinwhich are conjugated to carrier compounds which are able to pass throughthe cell membrane, including, but not limited to, protein transductiondomains (PTDs). PTDs are positively charged peptides or peptide-likemolecules that permeate cell membrane lipid bilayers. Typically PTDscontain several arginine residues and can be used to deliver otheragents, such as peptides, proteins, oligonucleotides or small moleculesthrough a cell membrane and into the cytosol. One PTD is a highlyefficient molecular transporter formed by synthesizing an oligomer ofarginines alternating with EACAs. PTDs are well-known in the art.Examples of PTDs which may be used herein are shown, for example, inU.S. Pat. Nos. 7,166,692; 7,217,539; 7,053,200; 6,835,810; 6,645,501;and Published U.S. Patent Applications 2002/0009491; 2003/0032593;2003/0162719; 2006/0159719; 2006/0293234; and 2007/0105775, each ofwhich is expressly incorporated herein in its entirety by reference.

Similarly, based on the results showing that the inhibitors likewiseinhibit FAP with high sensitivity and specificity, the inhibitors can beused to selectively inhibit the proteolytic activity of FAP on cellsurfaces of fibroblasts and cancer cells towards collagen within theextracellular matrix, and without impacting other prolyl-specificproteinases (e.g., DPPIV) for which it has no specificity thus enablinganalysis of various characteristics of the sample with otherprolyl-specific proteinases present while FAP is inhibited. Further, thehigh aqueous solubility of the particular inhibitors (>500 μg/ml)indicates they will not permeabilize the universal highly lipophilic,hydrophobic nature of cell membranes.

Utility

Further to, and in addition to the utilities already describedhereinabove, in one embodiment, a subject may be treated with a compounddescribed herein in a manner and in an amount so as to treat any of theconditions, diseases or disorders described herein. For example, thecompounds can be used to inhibit proliferation of a primary tumor, or toinhibit metastatic spread or growth while minimizing the potential forsystemic toxicity. In certain embodiments, the abnormal mammalian cellproliferation is manifested as a tumor. Some conditions intended to betreated by the present methods using the present compounds includebenign (i.e., non-cancerous), pre-malignant and malignant (i.e.,cancerous) tumors especially those characterized by angiogenesis. Insome embodiments, the condition characterized by abnormal mammalian cellproliferation is further characterized by the presence of reactivestromal fibroblasts. Inhibitors of POP described herein are intended toinhibit angiogenesis, particularly angiogenesis which is related to suchmalignancies. Inhibitors of POP and FAP described herein may also beused to treat conditions which exhibit excessive or undesirable stromalgrowth such as idiopathic pulmonary fibrosis, rheumatoid arthritis, andperitoneal and pleural adhesions. Effective treatment is defined in atleast one embodiment as resulting in reduced tumor growth and/or tumorshrinkage, defined, for example, as a reduction in tumor volume of atleast a 10%, or at least 25%, or at least 50% after a predeterminedcourse of treatment.

In other embodiments, the abnormal mammalian cell proliferation treatedwith the presently described inhibitors is a carcinoma, a sarcoma, or amelanoma or others described elsewhere herein. More particularly, thecondition may be, but is not limited to, a breast cancer, colorectalcancer, ovarian cancer, prostate cancer, pancreatic cancer, kidneycancer, lung cancer, melanoma, or fibrosarcoma, or bone and connectivetissue sarcomas, including, but not limited to, osteosarcoma andfibrosarcoma. The abnormal mammalian cell proliferation may beepithelial cell-derived, meaning that it is epithelial cells which areabnormally proliferating. Some conditions characterized by abnormalmammalian epithelial cell proliferation include adenomas of epithelialtissues such as the breast, colon, pancreas, lung, and prostate, as wellas malignant tumors identified above. According to other embodiments ofthe presently disclosed and claimed inventive concept(s), a method isprovided for treating a subject having a metastasis of epithelialorigin.

According to some embodiments of the presently disclosed and claimedinventive concept(s), the inhibitor (agent) is administered locally. Insome embodiments, the agent is targeted to a tumor. This can be achievedby the particular mode of administration. For example, certain moreeasily accessible tumors such as breast or prostate tumors may betargeted by direct needle injection to the site of the lesion. Lungtumors may be targeted, for example, by the use of inhalation as a routeof administration.

In some embodiments, the agents may be administered in a systemicmanner, via administration routes such as, but not limited to, oral,intravenous, intramuscular and intraperitoneal administration. Systemicadministration routes may be desired, for example, if the subject hasmetastatic lesions. In other embodiments, the agent is administered in asustained release formulation.

In administering the present compounds to subjects, dosing amounts,dosing schedules, routes of administration and the like may be selectedso as to affect the other known activities of these compounds. Forexample, amounts, dosing schedules and routes of administration can beselected as described herein, whereby therapeutically effective levelsfor inhibiting proliferation are provided, yet are provided at levelswhich do not affect other proteins (e.g., enzymes necessary for healthyfunction such as DPPIV) in the subject. In some embodiments of thepresently disclosed and claimed inventive concept(s), a method isprovided in which the inhibitor is administered in combination withsurgery (before, during, or after) to remove an abnormal proliferativecell mass.

In another aspect, the FAP and/or POP inhibitors as described herein maybe used in treatment for inhibiting angiogenesis in a subject having acondition characterized by abnormal mammalian cell proliferation, suchas a cancer, comprising administering to a subject in need of suchtreatment, an agent in an amount effective to inhibit angiogenesis in anabnormal proliferative cell mass, wherein the agent is an inhibitor asdescribed herein.

In one embodiment, an inhibitor having Formula I or II, or a combinationthereof, is provided along with at least one other anti-cancer compound(i.e., an anti-cancer compound other than a compound having Formula I orFormula II or as otherwise contemplated herein), and a pharmaceuticallyacceptable carrier. In another aspect, a pharmaceutical preparation isprovided which comprises a compound having Formula I or Formula II, or acombination thereof, at least one other anti-angiogenic compound (i.e.,an anti-angiogenic compound other than a compound of Formula I orFormula II, or as otherwise contemplated herein), and a pharmaceuticallyacceptable carrier.

In other embodiments, anti-cancer cocktails containing an inhibitorcompound of the presently disclosed and claimed inventive concept(s) andother anti-proliferative compounds and/or other anti-angiogeniccompounds as described herein are also provided. In still otherembodiments, compounds having the Formula I or Formula II, orcombinations thereof, are used in the preparation of a medicament fortreating subjects having conditions characterized by abnormal mammaliancell proliferation.

In still other embodiments, the inhibitory compound may be targeted to acell mass (e.g., a tumor) through the use of a targeting compoundspecific for a particular tissue or tumor type. In some embodiments, theinhibitors may be targeted to primary or in some instances, secondary(i.e., metastatic) lesions through the use of targeting compounds whichpreferentially recognize a cell surface marker.

As described herein, the inhibitors and substrates of the presentlydisclosed and claimed inventive concept(s) comprise peptides orpeptidomimetics which may include non-amino acid residues such assaccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines,derivatives or structural analogs of the above, or combinations thereofand the like. In particular, as described herein, it is possible tosubstitute non-naturally occurring amino acids as described herein forthe “P₁” proline residue. In one embodiment, the P₁ group is an analogof proline in which the carboxylate group (COOH) is replaced with aboronyl group (BOH₂). Alternative compounds of the presently disclosedand claimed inventive concept(s) have an analogous structure in whichthe boronyl group is replaced by, for example, a nitrile, acarbonitrile, carboxynitrile, a phosphonate or a fluoroalkylketone,alphaketos, N-peptiolyl-β-(acylhydroxylamines), azapeptides, azetidines,fluoroolefins dipeptide isoesteres, peptidyl (alpha-aminoalkyl)phosphonate esters, aminoacyl pyrrolidine-2-nitriles and4-cyanothiazolidides, or other structures for example as shown in Table1.

As noted herein, certain embodiments of the presently disclosed andclaimed inventive concept(s) include methods for treating a subjecthaving a condition characterized by an abnormal cell proliferation orother conditions described herein. As used herein, the term subject isintended to refer to a mammal including, but not limited to, humans,apes, monkeys, other nonhuman primates, dogs, cats, sheep, llamas,goats, horses, cattle, zoo animals, pigs, and rodents. As used herein,the terms subject and patient are used interchangeably. An abnormalmammalian cell proliferation disorder or condition, as used herein,refers to a localized region of cells (e.g., a tumor) which exhibit anabnormal (e.g., increased) rate of division as compared to their normaltissue counterparts.

In one aspect, as noted, the presently disclosed and claimed inventiveconcept(s) includes methods for treating a subject having a conditioncharacterized by an abnormal epithelial cell proliferation. Epithelialcells are cells occurring in one or more layers which cover the entiresurface of the body and which line most of the hollow structures of thebody, excluding the blood vessels, lymph vessels, and the heart interiorwhich are lined with endothelium, and the chest and abdominal cavitieswhich are lined with mesothelium. Examples of such epithelial cellsinclude, but are not limited to, cells of the anterius corneae, anteriorepithelium of cornea, Barrett's epithelium, capsular epithelium,ciliated epithelium, columnar epithelium, corneal epithelium, cubicalepithelium, cuboidal epithelium, epithelium eductus semicircularis,enamel epithelium, false epithelium, germinal epithelium, gingivalepithelium, glandular epithelium, glomerular epithelium, laminatedepithelium, epithelium of lens, epithelium lentis, mesenchymalepithelium, olfactory epithelium, pavement epithelium, pigmentaryepithelium, pigmented epithelium, protective epithelium,pseudostratified epithelium, pyramidal epithelium, respiratoryepithelium, rod epithelium, seminiferous epithelium, sense epithelium,sensory epithelium, simple epithelium, squamous epithelium, stratifiedepithelium, subcapsular epithelium, sulcular epithelium, tessellatedepithelium, and transitional epithelium.

One category of conditions characterized by abnormal epithelial cellproliferation is proliferative dermatologic disorders. These include,but are not limited to, conditions such as keloids, seborrheickeratosis, papilloma virus infection (e.g., producing verruca vulbaris,verruca plantaris, verruca plana, condylomata, etc.) and eczema. Anepithelial precancerous lesion is a skin lesion which has a propensityto develop into a cancerous condition. Epithelial precancerous skinlesions also arise from other proliferative skin disorders such ashemangiomas, keloids, eczema, and papilloma virus infections producingverruca vulbaris, verruca plantaris and verruca planar. The symptoms ofthe epithelial precancerous lesions include skin-colored or red-brownmacule or papule with dry adherent scales. Actinic keratosis is the mostcommon epithelial precancerous lesion among fair skinned individuals. Itis usually present as lesions on the skin which may or may not bevisually detectable. The size and shape of the lesions varies. This is aphotosensitive disorder and may be aggravated by exposure to sunlight.Bowenoid actinic keratosis is another form of an epithelial precancerouslesion. In some cases, the lesions may develop into an invasive form ofsquamous cell carcinoma and may pose a significant threat of metastasis.Other types of epithelial precancerous lesions include, but are notlimited to, hypertrophic actinic keratosis, arsenical keratosis,hydrocarbon keratosis, thermal keratosis, radiation keratosis, viralkeratosis, Bowen's disease, erythroplaquia of queyrat, oralerythroplaquia, leukoplakia, and intraepidermal epithelialoma.

As noted above, another category of conditions characterized by abnormalepithelial cell proliferation is tumors of epithelial origin. Epithelialtumors are known to those of ordinary skill in the art and include, butare not limited to, benign and premalignant epithelial tumors, such asbreast fibroadenoma and colon adenoma, and malignant epithelial tumors.Malignant epithelial tumors include primary tumors, also referred to ascarcinomas, and secondary tumors, also referred to as metastases ofepithelial origin. Carcinomas intended for treatment with the methods ofthe presently disclosed and claimed inventive concept(s) include, butare not limited to, acinar carcinoma, acinous carcinoma, alveolaradenocarcinoma (also called adenocystic carcinoma, adenomyoepithelioma,cribriform carcinoma and cylindroma), carcinoma adenomatosum,adenocarcinoma, carcinoma of adrenal cortex, alveolar carcinoma,alveolar cell carcinoma (also called bronchiolar carcinoma, alveolarcell tumor and pulmonary adenomatosis), basal cell carcinoma, carcinomabasocellulare (also called basaloma, or basiloma, and hair matrixcarcinoma), basaloid carcinoma, basosquamous cell carcinoma, breastcarcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma,bronchogenic carcinoma, cerebriform carcinoma, cholangiocellularcarcinoma (also called cholangioma and cholangiocarcinoma), chorioniccarcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma,cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum,cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma,carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epibulbarcarcinoma, epidermoid carcinoma, carcinoma epitheliale adenoides,carcinoma exulcere, carcinoma fibrosum, gelatiniform carcinoma,gelatinous carcinoma, giant cell carcinoma, gigantocellulare, glandularcarcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoidcarcinoma, hepatocellular carcinoma (also called hepatoma, malignanthepatoma and hepatocarcinoma), Hurthle cell carcinoma, hyalinecarcinoma, hypernephroid carcinoma, infantile embryonal carcinoma,carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma,Krompecher's carcinoma, Kulchitzky-cell carcinoma, lenticular carcinoma,carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma,carcinoma mastitoides, carcinoma medullare, medullary carcinoma,carcinoma melanodes, melanotic carcinoma, mucinous carcinoma, carcinomamuciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinomamucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngealcarcinoma, carcinoma nigrum, oat cell carcinoma, carcinoma ossificans,osteoid carcinoma, ovarian carcinoma, papillary carcinoma, periportalcarcinoma, preinvasive carcinoma, prostate carcinoma, renal cellcarcinoma of kidney (also called adenocarcinoma of kidney andhypemephoroid carcinoma), reserve cell carcinoma, carcinomasarcomatodes, scheinderian carcinoma, scirrhous carcinoma, carcinomascroti, signet-ring cell carcinoma, carcinoma simplex, small-cellcarcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cellcarcinoma, carcinoma spongiosum, squarnous carcinoma, squamous cellcarcinoma, string carcinoma, carcinoma telangiectaticum, carcinomatelangiectodes, transitional cell carcinoma, carcinoma tuberosum,tuberous carcinoma, verrucous carcinoma, carcinoma vilosum. In certainembodiments, the methods of the inventive concept(s) are used to treatsubjects having cancer in at least one or more of the breast, cervix,ovary, prostate, lung, colon, rectum, pancreas, stomach and kidney.

Other conditions characterized by an abnormal mammalian cellproliferation to be treated by the methods described herein include, butare not limited to, sarcomas. Sarcomas are rare mesenchymal neoplasmsthat arise in bone and soft tissues. Different types of sarcomas arerecognized and these include: liposarcomas (including myxoidliposarcomas and pleiomorphic liposarcomas), leiomyosarcomas,rhabdomyosarcomas, malignant peripheral nerve sheath tumors (also calledmalignant schwannomas, neurofibrosarcomas, or neurogenic sarcomas),Ewing's tumors (including Ewing's sarcoma of bone, extraskeletal Ewing'ssarcoma, and primitive neuroectodermal tumor), synovial sarcoma,angiosarcomas, hemangiosarcomas, lymphangiosarcomas, Kaposi's sarcoma,hemangioendothelioma, fibrosarcoma, desmoid tumor (also calledaggressive fibromatosis), dermatofibrosarcoma protuberans, malignantfibrous histiocytoma, hemangiopericytoma, malignant mesenchymoma,alveolar soft-part sarcoma, epithelioid sarcoma, clear cell sarcoma,desmoplastic small cell tumor, gastrointestinal stromal tumor (alsoknown as GI stromal sarcoma), osteosarcoma (also known as osteogenicsarcoma)-skeletal and extraskeletal, and chondrosarcoma.

The methods of the presently disclosed and claimed inventive concept(s)also include the treatment of subjects with melanoma. Melanomas aretumors arising from the melanocytic system of the skin and other organs.Examples of melanoma include lentigo maligna melanoma, superficialspreading melanoma, nodular melanoma, and acral lentiginous melanoma.

Conditions characterized by an abnormal mammalian cell proliferation asnoted are cancers including, but not limited to, biliary tract cancer,endometrial cancer, esophageal cancer, gastric cancer, pancreaticcancer, intraepithelial neoplasms, including Bowen's disease and Paget'sdisease, liver cancer, oral cancer, including squamous cell carcinoma,sarcomas, including fibrosarcoma and osteosarcoma, skin cancer,including melanoma, Kaposi's sarcoma, testicular cancer, includinggerminal tumors (seminoma, non-seminoma (teratomas, choriocarcinomas)),stromal tumors and germ cell tumors, thyroid cancer, including thyroidadenocarcinoma and medullar carcinoma, and renal cancer includingadenocarcinoma and Wilms tumor.

Further, certain embodiments of the presently disclosed and claimedinventive concept(s) include a method of treating a subject having anabnormal proliferation originating in bone, muscle or connective tissue.Exemplary conditions intended for treatment by the present methodsinclude primary tumors (i.e., sarcomas) of bone and connective tissue.The methods also include treatment of subjects with metastatic tumors,for example metastatic tumors of epithelial origin. Carcinomas maymetastasize to bone, as has been observed with breast cancer, and liver,as is sometimes the case with colon cancer. The methods of the presentlydisclosed and claimed inventive concept(s) are intended to treatmetastatic tumors regardless of the site of the metastasis and/or thesite of the primary tumor.

The presently disclosed and claimed inventive concept(s) includesmethods for inhibiting POP and/or FAP in a subject having a pathologywhich involves angiogenesis. Angiogenesis is defined as the formation ofnew blood vessels. These disorders include conditions characterized byabnormal mammalian cell proliferation, such as cancerous conditionswherein overexpression of FAP and/or POP associated with the tumorsstimulates angiogenesis and rapid tumor growth, as well as non-cancerconditions including diabetes, diabetic retinopathy, neovascularglaucoma and psoriasis. Thus, in particular embodiments, the presentmethods are aimed using the disclosed FAP and/or POP inhibitors toinhibit tumor and/or non-tumor angiogenesis. Tumor angiogenesis refersto the formation of new blood vessels in the vicinity or within a tumormass. Solid tumor cancers require angiogenesis particularly for oxygenand nutrient supply. It has been previously shown that inhibition ofangiogenesis in solid tumor can cause tumor regression in animal models.Thus in one aspect, the presently disclosed and claimed inventiveconcept(s) relates to methods for inhibiting angiogenesis by inhibitingthe proliferation, migration or activation of endothelial cells andfibroblasts, wherein this angiogenesis is unrelated to wound healing inresponse to injury, infection or inflammation.

Thus, the present methods are intended for the treatment of diseases andprocesses that involve or are mediated by angiogenesis including, butnot limited to, hemangioma, solid tumors, tumor metastasis, benigntumors, for example hemangiomas, acoustic neuromas, neurofibromas andtrachomas, Osler-Webber Syndrome, telangiectasia, myocardialangiogenesis, angiofibroma, plaque neovascularization, coronarycollaterals, ischemic limb angiogenesis, corneal diseases, rubiosis,neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia,diabetic neovascularization, macular degeneration, keloids, ovulation,menstruation, placentation, and any cancer involving angiogenesis.

The compositions and methods of the presently disclosed and claimedinventive concept(s) in certain instances may be useful for replacingexisting surgical procedures or drug therapies, although in mostinstances the methods are useful in improving the efficacy of existingtherapies for treating such conditions. Accordingly combination therapymay be used to treat the subjects. For example, the inhibitors may beadministered to a subject in combination with another anti-proliferative(e.g., an anti-cancer) therapy. Suitable anti-cancer therapies include,but are not limited to, surgical procedures to remove the tumor mass,chemotherapy or localization radiation. The other anti-proliferativetherapy may be administered before, concurrent with, or after treatmentwith the inhibitors of the presently disclosed and claimed inventiveconcept(s). There may also be a delay of several hours, days and in someinstances weeks between the administration of the different treatments,such that the inhibitor may be administered before or after the othertreatment. As an example, the inhibitor may be administered incombination with surgery to remove an abnormal proliferative cell mass.As used herein, “in combination with surgery” means that the agent maybe administered prior to, during or after the surgical procedure.

The subjects treated with the presently disclosed FAP and/or POPinhibitors may be treated in combination with other non-surgicalanti-proliferative (e.g., anti-cancer) drug therapy. In one embodiment,the inhibitor may be administered in combination with an anti-cancercompound such as a cytostatic compound. A cytostatic compound is acompound (e.g., a nucleic acid, or a protein) that suppresses cellgrowth and/or proliferation. In some embodiments, the cytostaticcompound is directed towards the malignant cells of a tumor. In yetother embodiments, the cytostatic compound is one which inhibits thegrowth and/or proliferation of vascular smooth muscle cells orfibroblasts.

The presently disclosed and claimed inventive concept(s) in oneembodiment is directed to a method of treating cancer comprisingadministering to a patient in need thereof a cancer treatment comprisingradiation and/or an effective amount of a chemotherapeutic composition,and administering at least one compound of the presently disclosed andclaimed inventive concept(s), with pharmaceutical acceptable additives,diluents, carriers and excipients, and pharmaceutically acceptable saltsthereof.

The presently disclosed and claimed inventive concept(s) also providesthe use of compositions which comprise of one or more of the compoundsof the presently disclosed and claimed inventive concept(s), theirderivatives, metabolites, analogues and/or mimic molecules withpharmaceutical acceptable additives, diluents, carriers and excipientsand pharmaceutically acceptable salts thereof, for the manufacture of amedicament for a cancerous condition. As noted elsewhere herein, thepharmaceutical formulations may be administered in combination (beforeor simultaneously) with other therapeutic treatments, such as radiationtreatment or chemotherapeutic drugs.

The presently disclosed and claimed inventive concept(s) is exemplifiedin terms of in vitro and in vivo activity against various neoplasticcell lines. The test cell lines employed in the in vitro assays are wellrecognized and accepted as models for anti-tumor activity in animals.The term animals as used herein includes, but is not limited to, mice,rats, domesticated animals such as but is not limited to, cats, dogs,and other animals but is not limited to, cattle, sheep, pigs, horses,and primates such as but not limited to, monkeys, humans and moregenerally mammals.

In one aspect, certain embodiments of the presently disclosed andclaimed inventive concept(s) feature the use of an inhibitory compoundof the presently disclosed and claimed inventive concept(s) as achemosensitizer, in combination with at least one other chemotherapeuticagent or radiation dosage. In a particular embodiment, the compound isco-administered with the chemotherapeutic agent, to a subject. In aparticular embodiment, the compound is co-administered with repeateddosages of the same, or a different chemotherapeutic agent, to asubject. In a particular embodiment, the inhibitory compound of thepresently disclosed and claimed inventive concept(s) enhances theefficacy of the chemotherapeutic agent, e.g., a cytotoxic agent orradiation dosage, relative to the effect of the cytotoxic agent orradiation dosage in the absence of the compound. The inhibitory compoundmay be used in combination therapy with conventional cancerchemotherapeutics or treatments. Conventional treatment regimens fortumors include radiation, antitumor agents, interferons, interleukins,tumor necrosis factors, or a combination of two or more of these agents,as well as other chemotherapeutic (cytotoxic) agents described herein.

Suitable anti-proliferative drugs or cytostatic compounds to be used incombination with the presently disclosed and claimed inhibitors includeanti-cancer drugs. Numerous anti-cancer drugs which may be used are wellknown and include, but are not limited to: Acivicin; Aclarubicin;Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin; Altretamine;Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine;Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa;Azotomycin; Batimastat; Benzodepa; Bicalutamide; BisantreneHydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate;Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone;Caracemide; Carbetimer; Carboplatin; Carmustine; CarubicinHydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin;Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine;Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine;Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel;Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; DroloxifeneCitrate; Dromostanolone Propionate; Duazomycin; Edatrexate; EflornithineHydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine;Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride;Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide;Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine;Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil;Fluorocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; GemcitabineHydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide;Ilmofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1;Interferon Alfa-n3; Interferon Beta-I a; Interferon Gamma-I b;Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole;Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium;Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine;Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate;Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium;Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin;Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride;Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran;Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate;Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride;Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine;Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride;Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride;Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; SpirogermaniumHydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin;Sulofenur; Talisomycin; Taxol; Taxotere; Tecogalan Sodium; Tegafur;Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone;Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin;Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; TrestoloneAcetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate;Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide;Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine;Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate;Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate;Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; and ZorubicinHydrochloride.

Other anti-cancer drugs include, but are not limited to: 20-epi-1,25dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; acylfulvene;adecypenol; adozelesin; ALL-TK antagonists; ambamustine; amidox;amifostine; aminolevulinic acid; amrubicin; anagrelide; andrographolide;angiogenesis inhibitors; antagonist D; antagonist G; antarelix;anti-dorsalizing morphogenetic protein-1; antiestrogen; antineoplaston;antisense oligonucleotides; aphidicolin glycinate; apoptosis genemodulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA;arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1;axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatinIII derivatives; balanol; batimastat; BCR/ABL antagonists;benzochlorins; benzoylstaurosporine; beta lactam derivatives;beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor;bisaziridinylspermine; bisnafide; bistratene A; breflate; budotitane;buthionine sulfoximine; calcipotriol; calphostin C; camptothecinderivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole;carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor;casein kinase inhibitors (ICOS); castanospermine; cecropin B;cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost;cis-porphyrin; clomifene analogues; clotrimazole; collismycin A;collismycin B; combretastatin A4; combretastatin analogue; conagenin;crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives;curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabineocfosfate; cytolytic factor; cytostatin; dacliximab; dehydrodidemnin B;deslorelin; dexifosfamide; dexrazoxane; dexverapamil; didemnin B; didox;diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin;diphenyl spiromustine; docosanol; dolasetron; doxifluridine; dronabinol;duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab;eflornithine; elemene; emitefur; epirubicin; epristeride; estramustineanalogue; estrogen agonists; estrogen antagonists; etanidazole;etoposide phosphate; exemestane; filgrastim; finasteride; flavopiridol;flezelastine; fluasterone; fludarabine; fluorodaunorunicinhydrochloride; forfenimex; formestane; fotemustine; gadoliniumtexaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinaseinhibitors; glutathione inhibitors; hepsulfam; heregulin; hexamethylenebisacetamide; hypericin; ibandronic acid; idoxifene; idramantone;ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulantpeptides; insulin-like growth factor-I receptor inhibitor; interferonagonists; interferons; interleukins; iobenguane; iododoxorubicin;ipomeanol, 4-; irinotecan; iroplact; irsogladine; isobengazole;isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F;lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinansulfate; leptolstatin; leukemia inhibiting factor; leukocyte alphainterferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole;liarozole; linear polyamine analogue; lipophilic disaccharide peptide;lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine;lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides;maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysininhibitors; matrix metalloproteinase inhibitors; merbarone; meterelin;methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine;mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol;mitomycin analogues; mitonafide; mitotoxin fibroblast growthfactor-saporin; mofarotene; molgramostim; monoclonal antibody, humanchorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wallsk; mopidamol; multiple drug resistance gene inhibitor; multiple tumorsuppressor 1-based therapy; mustard anti cancer compound; mycaperoxideB; mycobacterial cell wall extract; myriaporone; N-acetyldinaline;N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine;napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronicacid; neutral endopeptidase; nilutamide; nisamycin; nitric oxidemodulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine;octreotide; okicenone; oligonucleotides; onapristone; ondansetron;ondansetron; oracin; oral cytokine inducer; osaterone; oxaliplatin;oxaunomycin; paclitaxel analogues; paclitaxel derivatives; palauamine;palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin;pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium;pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol;phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil;pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetinB; plasminogen activator inhibitor; platinum complex; platinumcompounds; platinum-triamine complex; porfimer sodium; porfiromycin;propyl bis-acridone; prostaglandin J2; proteasome inhibitors; proteinA-based immune modulator; protein kinase C inhibitor; protein kinase Cinhibitors, microalgal; protein tyrosine phosphatase inhibitors; purinenucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists;raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors;ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re186 etidronate; rhizoxin; ribozymes; RII retinamide; rohitukine;romurtide; roquinimex; rubiginone B1; ruboxyl; saintopin; SarCNU;sarcophytol A; sargramostim; Sdi 1 mimetics; senescence derivedinhibitor 1; sense oligonucleotides; signal transduction inhibitors;signal transduction modulators; single chain antigen binding protein;sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate;solverol; somatomedin binding protein; sonermin; sparfosic acid;spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine;stem cell inhibitor; stem-cell division inhibitors; stipiamide;stromelysin inhibitors; sulfinosine; superactive vasoactive intestinalpeptide antagonist; suradista; suramin; swainsonine; syntheticglycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine;tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomeraseinhibitors; temozolomide; tetrachlorodecaoxide; tetrazomine;thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietinmimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan;thyroid stimulating hormone; tin ethyl etiopurpurin; titanocenedichloride; topsentin; toremifene; totipotent stem cell factor;translation inhibitors; tretinoin; triacetyluridine; triciribine;tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBCinhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor;urokinase receptor antagonists; variolin B; vector system, erythrocytegene therapy; velaresol; veramine; verdins; vinorelbine; vinxaltine;vitaxin; zanoterone; zilascorb; and zinostatin stimalamer.

Anti-cancer supplementary potentiating compounds include, but are notlimited to: Tricyclic anti-depressant drugs (e.g., imipramine,desipramine, amitryptyline, clomipramine, trimipramine, doxepin,nortriptyline, protriptyline, amoxapine and maprotiline); non-tricyclicanti-depressant drugs (e.g., sertraline, trazodone and citalopram); Ca²⁺antagonists (e.g., verapamil, nifedipine, nitrendipine and caroverine);Calmodulin inhibitors (e.g., prenylamine, trifluoroperazine andclomipramine); Amphotericin B; Triparanol analogues (e.g., tamoxifen);antiarrhythmic drugs (e.g., quinidine); antihypertensive drugs (e.g.,reserpine); Thiol depleters (e.g., buthionine and sulfoximine) andmultiple drug resistance reducing compounds such as Cremaphor EL.

Other compounds which are useful in combination therapy for the purposesof the presently disclosed and claimed inventive concept(s) include, butare not limited to, the antiproliferation compound PiritreximIsethionate; the antiprostatic hypertrophy compound Sitogluside; thebenign prostatic hyperplasia therapy compound Tamsulosin Hydrochloride;the prostate growth inhibitor Pentomone; radioactive compounds such asFibrinogen I 125, Fludeoxyglucose F 18, Fluorodopa F 18, Insulin I 125,Insulin I 131, lobenguane I 123, Iodipamide Sodium I 131, IodoantipyrineI 131, Iodocholesterol I 131, Iodohippurate Sodium I 123, IodohippurateSodium I 125, Iodohippurate Sodium I 131, Iodopyracet I 125, IodopyracetI 131, Iofetamine Hydrochloride I 123, Iomethin I 125, Iomethin I 131,Iothalamate Sodium I125, Iothalamate Sodium I 131, Iotyrosine I 131,Liothyronine I 125, Liothyronine I 131, Merisoprol Acetate Hg 197,Merisoprol Acetate Hg 203, Merisoprol Hg 197, Selenomethionine Se 75,Technetium Tc 99m Antimony Trisulfide Colloid, Technetium Tc 99mBicisate, Technetium Tc 99m Disofenin, Technetium Tc 99m Etidronate,Technetium Tc 99m Exametazine, Technetium Tc 99m Furifosmin, TechnetiumTc 99m Gluceptate, Technetium Tc 99m Lidofenin, Technetium Tc 99mMebrofenin, Technetium Tc 99m Medronate, Technetium Tc 99m MedronateDisodium, Technetium Tc 99m Mertiatide, Technetium Tc 99m Oxidronate,Technetium Tc 99m Pentetate, Technetium Tc 99m Pentetate CalciumTrisodium, Technetium Tc 99m Sestamibi, Technetium Tc 99m Siboroxime,Technetium Tc 99m Succimer, Technetium Tc 99m Sulfur Colloid, TechnetiumTc 99m Teboroxime, Technetium Tc 99m Tetrofosmin, Technetium Tc 99mTiatide, Thyroxine 1125, Thyroxine 1131, Tolpovidone 1131, Triolein 1125and Triolein 1131.

According to the methods of the presently disclosed and claimedinventive concept(s), the inhibitors of FAP and/or POP may beadministered prior to, concurrent with, or following the otheranti-cancer compounds described herein (or others not listed). Theadministration schedule may involve administering the different agentsin an alternating fashion. In other embodiments, the inhibitor may bedelivered before and during, or during and after, or before and aftertreatment with other therapies. In some cases, the inhibitor isadministered more than 24 hours before the administration of the otheranti-proliferative treatment. In other embodiments, more than oneanti-proliferative therapy may be administered to a subject. Forexample, the subject may receive the present inhibitors, in combinationwith both surgery and at least one other anti-proliferative compound.Alternatively, the inhibitor may be administered in combination withmore than one anti-cancer drug.

Other compounds useful in combination therapies with the inhibitorcompounds of the presently disclosed and claimed inventive concept(s)include, but are not limited to, anti-angiogenic compounds such asangiostatin, endostatin, fumagillin, non-glucocorticoid steroids andheparin or heparin fragments and antibodies to one or more angiogenicpeptides such as α-FGF, β-FGF, VEGF, IL-8 and GM-CSF. These latteranti-angiogenic compounds may be administered along with the inhibitorcompounds of the presently disclosed and claimed inventive concept(s)for the purpose of inhibiting proliferation or inhibiting angiogenesisin all of the aforementioned conditions as described herein. In certainembodiments, the inhibitors may be administered in combination with ananti-angiogenic compound and at least one of the anti-proliferativetherapies described above including surgery or anti-proliferative drugtherapy.

In yet other examples, the inhibitors according to the presentlydisclosed and claimed inventive concept(s) can be used to treat CNSmaladies such as strokes, tumors, ischemia, Parkinson's disease, memorydeficits, memory loss, eating disorders, senile dementia, hearing loss,vision loss, migraines, depression, brain injury, bipolar disorder,spinal cord injury, Alzheimer's disease, and amyotrophic lateralsclerosis (which has a CNS component) and can be used to improvelearning and memory function.

The inhibitor compounds of the presently disclosed and claimed inventiveconcept(s) are administered in therapeutically effective amounts. Aneffective amount is a dosage of the inhibitor sufficient to provide atherapeutically or medically desirable result or effect in the subjectto which the compound is administered. The effective amount will varywith the particular condition being treated, the age and physicalcondition of the subject being treated, the severity of the condition,the duration of the treatment, the nature of the concurrent orcombination therapy (if any), the specific route of administration andlike factors within the knowledge and expertise of the healthpractitioner. For example, in connection with methods directed towardstreating subjects having a condition characterized by abnormal cellproliferation, an effective amount to inhibit proliferation would be anamount sufficient to reduce or halt altogether the abnormal cellproliferation so as to slow or halt the development of or theprogression of a cell mass such as, for example, a tumor. As used in theembodiments, “inhibit” embraces all of the foregoing. In otherembodiments, a therapeutically effective amount will be an amountnecessary to extend the dormancy of micrometastases or to stabilize anyresidual primary tumor cells following surgical or drug therapy.

Generally, a therapeutically effective amount will vary with thesubject's age, condition, and sex, as well as the nature and extent ofthe disease in the subject, all of which can be determined by one ofordinary skill in the art. The dosage may be adjusted by the individualphysician or veterinarian, particularly in the event of anycomplication. A therapeutically effective amount is typically, but notlimited to, an amount in a range from 0.1 μg/kg to about 2000 mg/kg, orfrom 1.0 μg/kg to about 1000 mg/kg, or from about 0.1 mg/kg to about 500mg/kg, or from about 1.0 mg/kg to about 100 mg/kg, in one or more doseadministrations daily, for one or more days. If desired, the effectivedaily dose of the active compound may be administered as two, three,four, five, six or more sub-doses for example administered separately atappropriate intervals throughout the day, optionally, in unit dosageforms. In some embodiments, the inhibitors are administered for morethan 7 days, more than 10 days, more than 14 days and more than 20 days.In still other embodiments, the inhibitor is administered over a periodof weeks, or months. In still other embodiments, the inhibitor isdelivered on alternate days. For example, the agent is delivered everytwo days, or every three days, or every four days, or every five days,or every six days, or every week, or every month.

The inhibitor compounds of the presently disclosed and claimed inventiveconcept(s) can also be administered in prophylactically effectiveamounts, particularly in subjects diagnosed with benign or pre-malignanttumors or conditions likely to present pathogenic angiogenesis, such asdiabetes. In these instances, the inhibitors are administered in anamount effective to prevent the development of an abnormal mammaliancell proliferative mass or to prevent angiogenesis in the solid tumormass, depending on the embodiment. The inhibitors may also beadministered in an amount effective to prevent metastasis of cells froma tumor to other tissues in the body. In these latter embodiments, thepresently disclosed and claimed inventive concept(s) includes methods ofpreventing the metastatic spread of a primary tumor or angiogenesisrelated to pathogenic conditions.

According to another aspect of the presently disclosed and claimedinventive concept(s), a kit is provided. The kit is a package whichhouses a container which contains an inhibitor of the presentlydisclosed and claimed inventive concept(s) and also includesinstructions for administering the inhibitor to a subject having acondition characterized by an abnormal mammalian cell proliferation orother condition described herein. The kit may optionally also containone or more other anti-proliferative compounds or one or moreanti-angiogenic compounds for use in combination therapies as describedherein.

The compounds of the presently disclosed and claimed inventiveconcept(s) may be administered alone or in combination with theabove-described drug therapies by a variety of administration routesavailable. The particular mode selected will depend, of course, upon thecompound selected, the condition being treated, the severity of thecondition, whether the treatment is therapeutic or prophylactic, and thedosage required for efficacy. The methods of the presently disclosed andclaimed inventive concept(s), generally speaking, may be practiced usingany mode of administration that is medically acceptable, meaning anymode that produces effective levels of the active compounds withoutcausing clinically unacceptable adverse effects. The administration may,for example, be oral, intraperitoneal, intra-cavity such as rectal orvaginal, transdermal, topical, nasal, inhalation, mucosal, interdermal,or parenteral routes. The term “parenteral” includes subcutaneous,intravenous, intramuscular, or infusion.

Intravenous or intramuscular routes may not particularly suitable forlong term therapy and prophylaxis. In certain embodiments, however, itmay be appropriate to administer the compound in a continuous infusionevery several days, or once a week, or every several weeks, or once amonth. Intravenous or intramuscular routes may be desired in emergencysituations. Oral administration may be used for prophylactic treatmentbecause of the convenience to the patient as well as the dosingschedule. Likewise, sustained release devices as described herein may beuseful in certain embodiments for prophylactic or post surgerytreatment, for example.

When using the compounds of the presently disclosed and claimedinventive concept(s) in subjects in whom the primary site of abnormalproliferation is well delineated and easily accessible, directadministration to the site may be desired, provided the tumor has notalready metastasized. For example, administration by inhalation for lungtumors or by suppositories in the treatment of cervical, ovarian orrectal tumors may be desired. Likewise, melanoma, for example, may betreated with the compound via topical administration in and around thearea of the lesion. In still other embodiments aimed at the treatment ofsubjects with breast, lung, pancreatic, or prostate cancer, for example,the compounds may be delivered by injection directly into the tissuewith, for example, a biopsy needle and syringe.

Systemic administration may be desired in some instances such as, forexample, if the subject is known to have or is suspected of havingmetastases. In this way, all tumor sites, whether primary or secondary,may receive the compound. Systemic delivery may be accomplished throughfor example, oral or parenteral administration. Inhalation may be usedin either systemic or local delivery, as described herein.

Compositions of the compound for parenteral administration particularlyinclude, but are not limited to, sterile aqueous or non-aqueoussolutions, suspensions, and emulsions. Examples of non-aqueous solventsare propylene glycol, polyethylene glycol, vegetable oils such as oliveoil, and injectable organic esters such as ethyl oleate. Aqueouscarriers include water, alcoholic/aqueous solutions, emulsions orsuspensions, including saline and buffered media. Parenteral vehiclesinclude, for example, sodium chloride solution, Ringer's dextrose,dextrose and sodium chloride, lactated Ringer's or fixed oils.Intravenous vehicles include fluid and nutrient replenishers,electrolyte replenishers (such as those based on Ringer's dextrose), andthe like. Preservatives and other additives may also be present such as,for example, antimicrobials, anti-oxidants, chelating compounds, andinert gases and the like. The pharmaceutical compositions mayconveniently be presented in unit dosage form and may be prepared by anyof the methods well-known in the art of pharmacy.

Compositions suitable for oral administration may particularly comprisediscrete units, such as capsules, tablets, lozenges, each containing apredetermined amount of the inhibitor. Other compositions includesuspensions in aqueous liquids or non-aqueous liquids such as a syrup,elixir, or an emulsion. In yet other embodiments, the particular vehicleis a biocompatible microparticle or implant that is suitable forimplantation into the mammalian recipient.

In other embodiments of the methods and compounds of the presentlydisclosed and claimed inventive concept(s), the compound is targeted toa site of abnormal cell proliferation, such as, a tumor, through the useof a targeting compound specific for a particular tissue or tumor type.The compounds of the presently disclosed and claimed inventiveconcept(s) may be targeted to primary or in some instances, secondary(i.e., metastatic) lesions through the use of targeting compounds whichpreferentially recognize a cell surface marker. The targeting compoundmay be directly conjugated to the compounds of the presently disclosedand claimed inventive concept(s) via a covalent linkage. The compoundmay be indirectly conjugated to a targeting compound via a linker.Alternatively, the targeting compound may be conjugated or associatedwith an intermediary compound such as, for example, a liposome withinwhich the inhibitor is encapsulated. Liposomes are artificial membranevessels which are useful as a delivery vector in vivo or in vitro. Ithas been shown that large unilamellar vessels (LUV), which range in sizefrom 0.2-4.0 μm can encapsulate large macromolecules. Liposomes may betargeted to a particular tissue, such as the vascular cell wall, bycoupling the liposome to a specific ligand such as a monoclonalantibody, sugar, glycolipid, or protein. In still other embodiments, thetargeting compound may be loosely associated with the compounds of thepresently disclosed and claimed inventive concept(s), such as within amicroparticle comprising a polymer, the compound of the presentlydisclosed and claimed inventive concept(s) and the targeting compound.

Targeting compounds useful according to the methods of the presentlydisclosed and claimed inventive concept(s) are those which direct thecompound to a site of abnormal proliferation such as a tumor site. Thetargeting compound of choice will depend upon the nature of the tumor orthe tissue origin of the metastasis. In some instances it may bedesirable to target the compound to the tissue in which the tumor islocated. For example, the compounds can be delivered to breastepithelium by using a targeting compound specific for breast tissue. Inparticular embodiments, the target is specific for malignant breastepithelium. Examples of compounds which may localize to malignant breastepithelium include, but are not limited to, estrogen and progesterone,epithelial growth factor (EGF) and HER-2/neu ligand, among others. TheHER-2/neu ligand may also be used to target compounds to ovariancancers. Ovarian cancers are also known to express EGFR and c-fms, andthus could be targeted through the use of ligands for either receptor.In the case of c-fms which is also expressed by macrophages andmonocytes, targeted delivery to an ovarian cancer may require acombination of local administration such as a vaginal suppository aswell as a targeting compound. Prostate cancers can be targeted usingcompounds such as peptides (e.g., antibodies or antibody fragments)which bind to prostate specific antigen (PSA) or prostate specificmembrane antigen (PSMA). Other markers which may be used for targetingof the agent to specific tissues include, for example, in liver: HGF,insulin-like growth factor I, II, insulin, OV-6, HEA-125, hyaluronicacid, collagen, N-terminal propeptide of collagen type III,mannose/N-acetylglucosamine, asialoglycoprotein, tissue plasminogenactivator, low density lipoprotein, carcinoembryonic antigen; in kidneycells: angiotensin II, vasopressin, antibodies to CD44v6; inkeratinocytes and skin fibroblasts: KGF, very low density lipoprotein,RGD-containing peptides, collagen, laminin; in melanocytes: kit ligand;in gut: cobalamin-intrinsic factor, heat stable enterotoxin of E. Coli;in breast epithelium: heregulin, prolactin, transferrin, cadherin-11.Other markers specific to particular tissues are available and would beknown to one of ordinary skill in the art.

In still other embodiments, the compounds of the presently disclosed andclaimed inventive concept(s) may be targeted to fibroblastsspecifically, via ligands or binding partners for fibroblast specificmarkers. Examples of these markers include, but are not limited tofibroblast growth factors (FGF) and platelet derived growth factor(PDGF). In some embodiments, it is desirable to target the compound toFAP specifically through the use of binding peptides for FAP which donot interfere with inhibition by the compound of the presently disclosedand claimed inventive concept(s).

Other embodiments of the presently disclosed and claimed inventiveconcept(s) include pharmaceutically acceptable compositions whichcomprise a therapeutically-effective amount of one or more of thecompounds described herein, formulated together with one or morepharmaceutically acceptable carriers (additives) and/or diluents. Asdescribed in detail below, the pharmaceutically acceptable compositionsmay be specially formulated for administration in solid or liquid form,including, but not limited to, those adapted for the following: (1) oraladministration, for example, aqueous or non-aqueous solutions orsuspensions, tablets, e.g., those targeted for buccal, sublingual, andsystemic absorption, boluses, powders, granules, pastes for applicationto the tongue; (2) parenteral administration, for example, bysubcutaneous, intramuscular, intravenous or epidural injection as, forexample, a sterile solution or suspension, or sustained-releaseformulation; (3) topical application, for example, as a cream, ointment,or a controlled-release patch or spray applied to the skin; (4)intravaginally or intrarectally, for example, as a cream or foam; (5)sublingually; (6) ocularly; (7) transdermally; or (8) nasally.

Some examples of materials which can serve aspharmaceutically-acceptable carriers include, but are not limited to:(1) sugars, such as lactose, glucose and sucrose; (2) starches, such ascorn starch and potato starch; (3) cellulose, and its derivatives, suchas sodium carboxymethyl cellulose, ethyl cellulose and celluloseacetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8)excipients, such as cocoa butter and suppository waxes; (9) oils, suchas peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil,corn oil and soybean oil; (10) glycols, such as propylene glycol; (11)polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol;(12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14)buffering agents, such as magnesium hydroxide and aluminum hydroxide;(15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18)Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21)polyesters, polycarbonates and/or polyanhydrides; and (22) othernon-toxic compatible substances employed in pharmaceutical formulations.

As set forth above, in certain embodiments, the compounds of thepresently disclosed and claimed inventive concept(s) contain a basicfunctional group, such as amino or alkylamino, and are, thus, capable offorming pharmaceutically-acceptable salts withpharmaceutically-acceptable acids. The term “pharmaceutically-acceptablesalts” in this respect, refers to the relatively non-toxic, inorganicand organic acid addition salts of the compounds. These salts can beprepared in situ in the administration vehicle or the dosage formmanufacturing process, or by separately reacting a purified compound ofthe presently disclosed and claimed inventive concept(s) in its freebase form with a suitable organic or inorganic acid, and isolating thesalt thus formed during subsequent purification. Representative saltsinclude, but are not limited to, the hydrobromide, hydrochloride,sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate,palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate,citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate,glucoheptonate, lactobionate, and laurylsulphonate salts and the like.

The pharmaceutically acceptable salts of the compounds of the presentlydisclosed and claimed inventive concept(s) include, but are not limitedto, the conventional nontoxic salts or quaternary ammonium salts of thecompounds, e.g., from non-toxic organic or inorganic acids. For example,such conventional nontoxic salts include those derived from inorganicacids such as hydrochloride, hydrobromic, sulfuric, sulfamic,phosphoric, nitric, and the like; and the salts prepared from organicacids such as acetic, propionic, succinic, glycolic, stearic, lactic,malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic,phenylacetic, glutamic, benzoic, salicyclic, sulfanilic,2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanedisulfonic, oxalic, isothionic, and the like.

In other cases, the compounds of the presently disclosed and claimedinventive concept(s) may contain one or more acidic functional groupsand, thus, are capable of forming pharmaceutically-acceptable salts withpharmaceutically-acceptable bases. The term “pharmaceutically-acceptablesalts” in these instances refers to the relatively non-toxic, inorganicand organic base addition salts of compounds of the presently disclosedand claimed inventive concept(s). These salts can likewise be preparedin situ in the administration vehicle or the dosage form manufacturingprocess, or by separately reacting the purified compound in its freeacid form with a suitable base, such as the hydroxide, carbonate orbicarbonate of a pharmaceutically-acceptable metal cation, with ammonia,or with a pharmaceutically-acceptable organic primary, secondary ortertiary amine. Representative alkali or alkaline earth salts include,but are not limited to, the lithium, sodium, potassium, calcium,magnesium, and aluminum salts and the like. Representative organicamines useful for the formation of base addition salts include, but arenot limited to, ethylamine, diethylamine, ethylenediamine, ethanolamine,diethanolamine, piperazine and the like.

Wetting agents, emulsifiers and lubricants, including, but not limitedto, sodium lauryl sulfate and magnesium stearate, as well as coloringagents, release agents, coating agents, sweetening, flavoring andperfuming agents, preservatives and antioxidants can also be present inthe compositions. Examples of pharmaceutically-acceptable antioxidantsinclude, but are not limited to: (1) water soluble antioxidants, such asascorbic acid, cysteine hydrochloride, sodium bisulfate, sodiummetabisulfite, sodium sulfite and the like; (2) oil-solubleantioxidants, such as ascorbyl palmitate, butylated hydroxyanisole(BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate,alpha-tocopherol, and the like; and (3) metal chelating agents, such ascitric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaricacid, phosphoric acid, and the like.

As noted above, formulations of the compounds of the presently disclosedand claimed inventive concept(s) include those suitable for oral, nasal,topical (including buccal and sublingual), rectal, vaginal and/orparenteral administration. The formulations may conveniently bepresented in unit dosage form and may be prepared by any methods wellknown in the art of pharmacy. The amount of active ingredient which canbe combined with a carrier material to produce a single dosage form willvary depending upon the host being treated, the particular mode ofadministration. The amount of active ingredient which can be combinedwith a carrier material to produce a single dosage form will generallybe that amount of the compound which produces a therapeutic effect.Generally, out of one hundred percent, this amount will range from about1 percent to about ninety-nine percent of active ingredient, such asfrom about 5 percent to about 70 percent, or from about 10 percent toabout 30 percent.

In certain embodiments, a formulation of the compounds of the presentlydisclosed and claimed inventive concept(s) comprises an excipientselected from the group consisting of cyclodextrins, liposomes, micelleforming agents, e.g., bile acids, and polymeric carriers, e.g.,polyesters and polyanhydrides.

Methods of preparing these formulations or compositions may include thestep of bringing into association a compound of the presently disclosedand claimed inventive concept(s) with the carrier and, optionally, oneor more accessory ingredients. In general, the formulations are preparedby uniformly and intimately bringing into association a compound of thepresently disclosed and claimed inventive concept(s) with liquidcarriers, or finely divided solid carriers, or both, and then, ifnecessary, shaping the product.

Formulations of the compounds of the presently disclosed and claimedinventive concept(s) suitable for oral administration may be, but arenot limited to, the form of capsules, cachets, pills, tablets, lozenges(using a flavored basis, usually sucrose and acacia or tragacanth),powders, granules, or as a solution or a suspension in an aqueous ornon-aqueous liquid, or as an oil-in-water or water-in-oil liquidemulsion, or as an elixir or syrup, or as pastilles (using an inertbase, such as gelatin and glycerin, or sucrose and acacia) and/or asmouth washes and the like, each containing a predetermined amount of acompound of the presently disclosed and claimed inventive concept(s) asan active ingredient. A compound of the presently disclosed and claimedinventive concept(s) may also be administered as a bolus, or paste.

In solid dosage forms of the compounds of the presently disclosedinventive concept(s) for oral administration (capsules, tablets, pills,powders, granules and the like), the compound or compounds are mixedwith one or more pharmaceutically-acceptable carriers, including, butnot limited to, sodium citrate or dicalcium phosphate, and/or any of thefollowing: (1) fillers or extenders, such as starches, lactose, sucrose,glucose, mannitol, and/or silicic acid; (2) binders, such as, forexample, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol;(4) disintegrating agents, such as agar-agar, calcium carbonate, potatoor tapioca starch, alginic acid, certain silicates, and sodiumcarbonate; (5) solution retarding agents, such as paraffin; (6)absorption accelerators, such as quaternary ammonium compounds; (7)wetting agents, such as, for example, cetyl alcohol, glycerolmonostearate, and non-ionic surfactants; (8) absorbents, such as kaolinand bentonite clay; (9) lubricants, such a talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof; and (10) coloring agents. In the case of capsules,tablets and pills, the pharmaceutical compositions may also comprisebuffering agents. Solid compositions of a similar type may also beemployed as fillers in soft and hard-shelled gelatin capsules using suchexcipients as lactose or milk sugars, as well as high molecular weightpolyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one ormore accessory ingredients. Compressed tablets may be prepared usingbinder (for example, gelatin or hydroxypropylmethyl cellulose),lubricant, inert diluent, preservative, disintegrant (for example,sodium starch glycolate or cross-linked sodium carboxymethyl cellulose),surface-active or dispersing agent. Molded tablets may be made bymolding in a suitable machine a mixture of the powdered compoundmoistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceuticalcompositions of the presently disclosed and claimed inventiveconcept(s), such as dragees, capsules, pills and granules, mayoptionally be scored or prepared with coatings and shells, such asenteric coatings and other coatings well known in thepharmaceutical-formulating art. They may also be formulated so as toprovide slow or controlled release of the compound or compounds thereinusing, for example, hydroxypropylmethyl cellulose in varying proportionsto provide the desired release profile, other polymer matrices,liposomes and/or microspheres. They may be formulated for rapid release,e.g., freeze-dried. They may be sterilized by, for example, filtrationthrough a bacteria-retaining filter, or by incorporating sterilizingagents in the form of sterile solid compositions which can be dissolvedin sterile water, or some other sterile injectable medium immediatelybefore use. These compositions may also optionally contain opacifyingagents and may be of a composition that they release the activeingredient(s) only, or preferentially, in a certain portion of thegastrointestinal tract, optionally, in a delayed manner. Examples ofembedding compositions which can be used include polymeric substancesand waxes. The active ingredient can also be in micro-encapsulated form,if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration of the compounds of thepresently disclosed and claimed inventive concept(s) include, but arenot limited to, pharmaceutically acceptable emulsions, microemulsions,solutions, suspensions, syrups and elixirs. In addition to the activeingredient, the liquid dosage forms may contain inert diluents commonlyused in the art, such as, for example, water or other solvents,solubilizing agents and emulsifiers, such as ethyl alcohol, isopropylalcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzylbenzoate, propylene glycol, 1,3-butylene glycol, oils (in particular,cottonseed, groundnut, corn, germ, olive, castor and sesame oils),glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acidesters of sorbitan, and mixtures thereof. Besides inert diluents, theoral compositions can also include adjuvants such as wetting agents,emulsifying and suspending agents, sweetening, flavoring, coloring,perfuming and preservative agents. Suspensions, in addition to theactive compounds, may contain suspending agents as, for example,ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitanesters, microcrystalline cellulose, aluminum metahydroxide, bentonite,agar-agar and tragacanth, and mixtures thereof.

Formulations of the compounds of the pharmaceutical compositions of thepresently disclosed and claimed inventive concept(s) for rectal orvaginal administration may be presented as a suppository, which may beprepared by mixing one or more compounds of the presently disclosed andclaimed inventive concept(s) with one or more suitable nonirritatingexcipients or carriers comprising, for example, cocoa butter,polyethylene glycol, a suppository wax or a salicylate, and which issolid at room temperature, but liquid at body temperature and,therefore, will melt in the rectum or vaginal cavity and release theactive compound.

Formulations of the presently disclosed and claimed inventive concept(s)which are suitable for vaginal administration also include, but are notlimited to, tampons, creams, gels, pastes, foams or spray formulationscontaining such carriers as are known in the art to be appropriate.Dosage forms for the topical or transdermal administration of a compoundof the presently disclosed and claimed inventive concept(s) include, butare not limited to, powders, sprays, ointments, pastes, creams, lotions,gels, solutions, patches and inhalants. The active compound may be mixedunder sterile conditions with a pharmaceutically-acceptable carrier, andwith any preservatives, buffers, or propellants which may be required.The ointments, pastes, creams and gels may contain, for example, inaddition to an active compound of the presently disclosed and claimedinventive concept(s), excipients, such as animal and vegetable fats,oils, waxes, paraffins, starch, tragacanth, cellulose derivatives,polyethylene glycols, silicones, bentonites, silicic acid, talc and zincoxide, or mixtures thereof. Powders and sprays can contain, for example,in addition to a compound of the presently disclosed and claimedinventive concept(s), excipients such as lactose, talc, silicic acid,aluminum hydroxide, calcium silicates and polyamide powder, or mixturesof these substances. Sprays can additionally contain customarypropellants, such as chlorofluorohydrocarbons and volatile unsubstitutedhydrocarbons, such as butane and propane.

Transdermal patches have the added advantage of providing controlleddelivery of a compound of the presently disclosed and claimed inventiveconcept(s) to the body. Such dosage forms can be made by dissolving ordispersing the compound in the proper medium. Absorption enhancers canalso be used to increase the flux of the compound across the skin. Therate of such flux can be controlled by either providing a ratecontrolling membrane or dispersing the compound in a polymer matrix orgel. Ophthalmic formulations, eye ointments, powders, solutions and thelike, are also contemplated as being within the scope of the presentlydisclosed and claimed inventive concept(s).

Pharmaceutical compositions of the compounds of the presently disclosedand claimed inventive concept(s) suitable for parenteral administrationcomprise one or more compounds of the presently disclosed and claimedinventive concept(s) in combination with one or morepharmaceutically-acceptable sterile isotonic aqueous or nonaqueoussolutions, dispersions, suspensions or emulsions, or sterile powderswhich may be reconstituted into sterile injectable solutions ordispersions just prior to use, which may contain sugars, alcohols,antioxidants, buffers, bacteriostats, solutes which render theformulation isotonic with the blood of the intended recipient orsuspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may beemployed in the pharmaceutical compositions of the presently disclosedand claimed inventive concept(s) include, but are not limited to, water,ethanol, polyols (such as glycerol, propylene glycol, polyethyleneglycol, and the like), and suitable mixtures thereof, vegetable oils,such as olive oil, and injectable organic esters, such as ethyl oleate.Proper fluidity can be maintained, for example, by the use of coatingmaterials, such as lecithin, by the maintenance of the required particlesize in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofthe action of microorganisms upon the subject compounds may be ensuredby the inclusion of various antibacterial and antifungal agents, forexample, paraben, chlorobutanol, phenol sorbic acid, and the like. Itmay also be desirable to include isotonic agents, such as sugars, sodiumchloride, and the like into the compositions. In addition, prolongedabsorption of the injectable pharmaceutical form may be brought about bythe inclusion of agents which delay absorption such as aluminummonostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirableto slow the absorption of the drug from subcutaneous or intramuscularinjection. This may be accomplished by the use of a liquid suspension ofcrystalline or amorphous material having poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally-administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Injectable depot forms are made by forming microencapsule matrices ofthe subject compounds in biodegradable polymers such aspolylactide-polyglycolide. Depending on the ratio of drug to polymer,and the nature of the particular polymer employed, the rate of drugrelease can be controlled. Examples of other biodegradable polymersinclude poly(orthoesters) and poly(anhydrides). Depot injectableformulations are also prepared by entrapping the drug in liposomes ormicroemulsions which are compatible with body tissue.

When the compounds of the presently disclosed and claimed inventiveconcept(s) are administered as pharmaceuticals, to human or animalsubjects, they are generally given as a pharmaceutical compositioncontaining, for example, 0.01% to 99.5% (such as 0.5 to 90%) of thecompound (with or without other compounds given adjunctively incombination with a pharmaceutically acceptable carrier).

The preparations of the presently disclosed and claimed inventiveconcept(s) may be given, for example, orally, parenterally, topically,or rectally as explained above. They are of course given in formssuitable for each administration route. For example, they areadministered in tablets or capsule form, by injection, inhalation, eyelotion, ointment, suppository, by injection, infusion or inhalation,topical by lotion or ointment, and rectal by suppositories. The phrases“parenteral administration” and “administered parenterally” as usedherein means modes of administration other than enteral and topicaladministration, usually by injection, and includes, but is not limitedto, intravenous, intramuscular, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subeuticular, intraarticulare, subcapsular,subarachnoid, intraspinal and intrasternal injection and infusion. Thephrases “systemic administration,” “administered systemically,”“peripheral administration” and “administered peripherally” as usedherein mean the administration of a compound, drug or other materialother than directly into the central nervous system, such that it entersthe patient's system and, thus, is subject to metabolism and other likeprocesses, for example, subcutaneous administration.

Regardless of the route of administration selected, the compounds of thepresently disclosed and claimed inventive concept(s), which may be usedin a suitable hydrated form, and/or the pharmaceutical compositions ofthe presently disclosed and claimed inventive concept(s), are formulatedinto pharmaceutically-acceptable dosage forms by conventional methodsknown to those of skill in the art. Actual dosage levels of the activeingredients in the pharmaceutical compositions of the presentlydisclosed and claimed inventive concept(s) may be varied so as to obtainan amount of the active ingredient which is effective to achieve thedesired therapeutic response for a particular patient, composition, andmode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factorsincluding the activity of the particular compound of the presentlydisclosed and claimed inventive concept(s) employed, or the ester, saltor amide thereof, the route of administration, the time ofadministration, the rate of excretion or metabolism of the particularcompound being employed, the duration of the treatment, other drugs,compounds and/or materials used in combination with the particularcompound employed, the age, sex, weight, condition, general health andprior medical history of the patient being treated, and like factorswell known in the medical arts. A physician or veterinarian havingordinary skill in the art can readily determine and prescribe theeffective amount of the pharmaceutical composition required. Forexample, the physician or veterinarian could start doses of thecompounds of the presently disclosed and claimed inventive concept(s)employed in the pharmaceutical composition at levels lower than thatrequired in order to achieve the desired therapeutic effect andgradually increase the dosage until the desired effect is achieved.While it is possible for compounds of the presently disclosed andclaimed inventive concept(s) to be administered alone, it may be desiredto administer the compound as a pharmaceutical formulation(composition).

As noted, particular amounts and modes of administration are able to bedetermined by one skilled in the art. One skilled in the art ofpreparing formulations can readily select the proper form and mode ofadministration depending upon the particular characteristics of thecompound selected, the disease state to be treated, the stage of thedisease, and other relevant circumstances using formulation technologyknown in the art, described, for example, in Remington's PharmaceuticalSciences, latest edition, Mack Publishing Co.

Pharmaceutical compositions can be manufactured utilizing techniquesknown in the art. Typically the therapeutically effective amount of thecompound will be admixed with a pharmaceutically acceptable carrier asdescribed elsewhere herein. In one embodiment, the half-life of thecompounds described herein can be extended by their being conjugated toother molecules such as polymers using methods known in the art to formdrug-polymer conjugates. For example, the molecules can be bound tomolecules of inert polymers known in the art, such as a molecule ofpolyethylene glycol (PEG) in a method known as “PEGylation”. Pegylationcan therefore extend the in vivo lifetime and thus therapeuticeffectiveness of the molecule.

PEG molecules can be modified by functional groups, for example as shownin Harris et al., “Pegylation, A Novel Process for ModifyingPhararmacokinetics”, Clin Pharmacokinet, 2001:40(7); 539-551, and theamino terminal end of the molecule, or cysteine residue if present, orother linking amino acid therein can be linked thereto, wherein the PEGmolecule can carry one or a plurality of one or more types of molecules.

By “polyethylene glycol” or “PEG” is meant a polyalkylene glycolcompound or a derivative thereof, with or without coupling agents orderviatization with coupling or activating moeities (e.g., with thiol,triflate, tresylate, azirdine, oxirane, or particularly with a maleimidemoiety). Compounds such as maleimido monomethoxy PEG are exemplary oractivated PEG compounds of the inventive concept(s). Other polyalkyleneglycol compounds, such as polypropylene glycol, may be used in thepresently disclosed and claimed inventive concept(s). Other appropriatepolymer conjugates include, but are not limited to, non-polypeptidepolymers, charged or neutral polymers of the following types: dextran,colominic acids or other carbohydrate based polymers, biotinderiviatives and dendrimers, for example. The term PEG is also meant toinclude other polymers of the class polyalkylene oxides.

The PEG can be linked to any N-terminal amino acid of the moleculedescribed herein and/or can be linked to an amino acid residuedownstream of the N-terminal amino acid, such as lysine, histidine,tryptophan, aspartic acid, glutamic acid, and cysteine, for example orother such amino acids known to those of skill in the art. The PEGcarrier moiety attached to the peptide may range in molecular weightfrom about 200 to 20,000 MW. Particularly, the PEG moiety may be fromabout 1,000 to 8,000 MW, such as from about 3,250 to 5,000 MW, or about5,000 MW. The actual number of PEG molecules covalently bound permolecule of the inventive concept(s) may vary widely depending upon thedesired stability (i.e. serum half-life). Molecules contemplated hereincan be linked to PEG molecules using techniques shown, for example (butnot limited to), in U.S. Pat. Nos., 4,179,337; 5,382,657; 5,972,885;6,177,087; 6,165,509; 5,766,897; and 6,217,869; the specifications anddrawings each of which are hereby expressly incorporated herein byreference.

Alternatively, it is possible to entrap the molecules in microcapsulesprepared, for example, by coacervation techniques or by interfacialpolymerization (for example, hydroxymethylcellulose orgelatine-microcapsules and poly-(methylmethacylate) microcapsules,respectively), in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles, andnanocapsules), or in macroemulsions. Such techniques are disclosed inthe latest edition of Remington's Pharmaceutical Sciences.

U.S. Pat. No. 4,789,734 describes methods for encapsulating biochemicalsin liposomes and is hereby expressly incorporated by reference herein.Essentially, the material is dissolved in an aqueous solution, theappropriate phospholipids and lipids added, along with surfactants ifrequired, and the material dialyzed or sonicated, as necessary. A reviewof known methods is by G. Gregoriadis, Chapter 14. “Liposomes”, DrugCarriers in Biology and Medicine, pp. 287-341 (Academic Press, 1979).Microspheres formed of polymers or proteins are well known to thoseskilled in the art, and can be tailored for passage through thegastrointestinal tract directly into the blood stream. Alternatively,the agents can be incorporated and the microspheres, or composite ofmicrospheres, implanted for slow release over a period of time, rangingfrom days to months. See, for example, U.S. Pat. Nos. 4,906,474;4,925,673; and 3,625,214 which are incorporated by reference herein.

When the composition of the presently disclosed and claimed inventiveconcept(s) is to be used as an injectable material, it can be formulatedinto a conventional injectable carrier. Suitable carriers includebiocompatible and pharmaceutically acceptable phosphate buffered salinesolutions, which may be isotonic.

For reconstitution of a lyophilized product in accordance with thepresently disclosed and claimed inventive concept(s), one may employ asterile diluent, which may contain materials generally recognized forapproximating physiological conditions and/or as required bygovernmental regulation. In this respect, the sterile diluent maycontain a buffering agent to obtain a physiologically acceptable pH,such as sodium chloride, saline, phosphate-buffered saline, and/or othersubstances which are physiologically acceptable and/or safe for use. Ingeneral, the material for intravenous injection in humans should conformto regulations established by the Food and Drug Administration, whichare available to those in the field. The pharmaceutical composition mayalso be in the form of an aqueous solution containing many of the samesubstances as described above for the reconstitution of a lyophilizedproduct.

The compounds of the presently disclosed and claimed inventiveconcept(s) can also be administered as a pharmaceutically acceptableacid- or base-addition salt, formed by reaction with inorganic acidssuch as, but not limited to, hydrochloric acid, hydrobromic acid,perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, andphosphoric acid, and organic acids such as formic acid, acetic acid,propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid,malonic acid, succinic acid, maleic acid, and fumaric acid, or byreaction with an inorganic base such as sodium hydroxide, ammoniumhydroxide, potassium hydroxide, and organic bases such as mono-, di-,trialkyl and aryl amines and substituted ethanolamines.

EXAMPLES

While the presently disclosed and claimed inventive concept(s) will nowbe described in connection with certain embodiments in the followingexamples so that aspects thereof may be more fully understood andappreciated, it is not intended to limit the inventive concept(s) tothese particular examples. On the contrary, it is intended to cover allalternatives, modifications and equivalents as may be included withinthe scope of the presently disclosed and claimed inventive concept(s) asdefined herein and in the appended claims. Thus, the following examples,which include particular embodiments will serve to illustrate thepractice of the presently disclosed and claimed inventive concept(s), itbeing understood that the particulars shown are by way of example andfor purposes of illustrative discussion of particular embodiments of thepresently disclosed and claimed inventive concept(s) only and arepresented in the cause of providing what is believed to be the mostuseful and readily understood description of compounds, methods of use,and formulation procedures as well as of the principles and conceptualaspects of the presently disclosed and claimed inventive concept(s).

Experimental

The following describes various experimental procedures used tosynthesize examples of substrates and inhibitors and furtherexperimentation based on these substrates and inhibitors.

Materials and Methods

Cell Culture:

Fibroblasts, WI-38 and WI-38 VA13 2RA (VA-13); breast cancer cells,MDA-MB436 (MDA) and HCC1419 (HCC); and normal breast cells, MCF-12A,were all purchased from American Type Culture Collection (ATCC). Humandermal microvascular endothelial cells (HMVEC-d) and mesenchymal stemcells (MSC) were purchased from Lonza. All cells were authenticated bythe companies and used within six months of purchase or recovery fromcryopreservation. WI-38 and VA-13 were grown in MEM (Mediatech Inc.)supplemented with 10% FCS (fetal calf serum, Gibco), 2 mM GlutaMAX-1(Gibco) and 1 mM sodium pyruvate (Gibco). MDA and HCC were grown in DMEM(Mediatech Inc.) supplemented with 10% FCS. MCF-12A and HMVEC-d weregrown in EGM2-MV (Lonza) with all provided supplements, unless otherwisespecified. MSC were grown in MSCGM (Lonza).

Monoclonal Antibody Production:

Human antiplasmin-cleaving enzyme (APCE) was purified as previouslydescribed [28] and used as the antigen for monoclonal antibody (mAb)production. The hybridoma cells were produced at the Hybridoma Centerfor Agricultural and Biological Sciences at Oklahoma State University.After initial screening against pure APCE by direct ELISA, the positivecells were cloned three times by limited dilution. Selected antibodieswere produced in serum free media (SFM, Gibco) in roller bottles, thenpurified using MEP Hypercel (Pall) chromatography and isotyped using thePierce Rapid Isotyping kit (Thermo Scientific). Out of 24 mAbsidentified, mAb 6D2, an IgG1κ antibody, which recognized both APCE andFAP by ELISA and Western blotting with the greatest sensitivity, wasused in these studies. Mouse F19 mAb to FAP was produced and purifiedfrom cultures of hybridoma cells purchased from ATCC, and used forconfocal imaging and immunoprecipitation (IP).

Immunostaining:

Selected normal or neoplastic cells were grown to confluency in 10 cmtissue culture dishes, rinsed in phosphate buffered saline (PBS) andlysed on the plate in 1 ml of 2× Laemmli denaturing sample buffer withDTT for whole cell lysate. Membrane and cytosolic fractions wereprepared from confluent tissue culture dishes using the Mem-PER kit(Pierce) per manufacturer instructions. Whole cell lysates wereelectrophoresed under reducing conditions on 4-12% Bis-tris SDS-PAGEgels (Invitrogen) and transferred to nitrocellulose for Westernblotting. After blocking with 3% bovine serum albumin (BSA)/TBS-Tween(TBST), blots were incubated with a combination of 0.5 μg/ml mAb 6D2,0.1 μg/ml anti-α tubulin (Sigma #6199) and 0.1 μg/ml anti-actin (Abcam2Q1055) all in 1% BSA/TBST, and then washed and incubated with 1:50,000goat anti-mouse-HRP (Thermo-Fisher). Blots for POP were blocked with 3%BSA/TBST, then incubated with a combination of 0.1 μg/ml goat anti-POP(R & D Systems #AF4308), 0.1 μg/ml anti-α tubulin (Sigma #6199) and 0.1μg/ml anti-actin (Abcam 2Q1055) in 1.5% BSA/0.5M NaCl/TBST. Afterwashing in the same buffer, blots were incubated with 1:18,000 rabbitanti-goat-HRP (R & D Systems #HAF017) in 1.5% BSA/0.5M NaCl/TBST.ECL-Plus (Thermo-Fisher) was added and blots were visualized on RPI blueradiographic film (Amersham).

Confocal analysis of FAP protein in cells was accomplished first bygrowing cells to confluence on four-well glass chamber slides (Lab-Tek).The cells were fixed with 0.75% paraformaldehyde, blocked with 1%BSA/PBS, and then incubated with mouse F19 mAb 2 μg/ml or isotypecontrol antibody, MOPC 21(Sigma), 2 μg/ml in 0.1% BSA/PBS, with 0.1%saponin. After washing, the slides were incubated with goatanti-mouse-Alexa Fluor 568 (Invitrogen) at 1:2000 in 0.1% BSA/PBS andthen mounted with Prolong Gold/DAPI (Molecular Probes). Cells werevisualized using a Leica TCS NT Microscope fitted with a 40× PlanFluotar 1.0 NA oil immersion objective. Images were analyzed using LeicaTCS and Volocity software.

Protein Characterization:

Cells of each type were grown to confluence in 10 cm tissue culturedishes, rinsed in PBS and then lysed in 1 ml ice-cold IP buffercontaining 1% Triton/150 mM NaCl/10 mM Tris, pH 7.5/1 mM EDTA/1 mMEGTA/0.5% NP-40/10% sucrose with Complete Ultra protease inhibitorcocktail (Roche) added. Whole cell lysates were centrifuged to removedetergent-insoluble proteins. Five μg/ml of mAb F19 were added andallowed to bind overnight at 4° C. Then 25 μl of 75% slurry of Protein Gbeads (Amersham) in TBS were added and incubated for 1 hour at 4° C.Protein G beads were spun down, washed three times with IP buffer,resuspended in loading buffer and boiled for five minutes, after whichthe beads were removed by centrifugation and a portion of thesupernatant was electrophoresed under reducing conditions on 4-12%Bis-tris SDS-PAGE gels. To confirm the presence of FAP, the regions ofeach lane corresponding to the molecular weight of FAP were excised andthe proteins within each gel slice were reduced withTris[2-carboxyethyl]phosphine, then alkylated with iodoacetamide, anddigested with trypsin as described by the In-gel Tryptic Digestion Kitprotocol (Thermo-Fisher). Each trypsin digest sample was analyzed byhigh performance liquid chromatography-tandem mass spectrometry(LC/MS/MS) on a nanoscale Dionex UltiMate 3000 HPLC equipped with anAcclaim PepMap C18 column (75 μm internal diameter×15 cm length with 3μm particles) connected to an AB-Sciex QSTAR Elite mass spectrometer.The peptide molecular weights and MS/MS fragment ion spectra observedfor each peptide were used to query an NCBI comprehensive non-identicalhuman protein database (updated Jan. 31, 2011) loaded on an in-houseMASCOT database server (version 2.3).

Inhibitors and Substrates:

The pseudo-peptide inhibitor, M83 (acetyl-Arg-AEEA-(D)Ala-(L)boroPro),has dual FAP (K_(i)=5.7 nM) and POP (K_(i)=7.4 nM) inhibition. Thespecific POP inhibitor, J94 (acetyl-Lys-Leu-Arg-(L)boroPro (K_(i)<100nM)); and the substrate, C95 (acetyl-Arg-AEEA-Gly-Pro-AMC), weredesigned, synthesized and characterized by us as previously reported[27]. All are soluble in aqueous buffers. The inhibitors (J94 and M83)were dissolved in Hanks Balanced Salt Solution (HBSS; Gibco) at 1 mM andstored at −20° C. The substrate (C95) was dissolved in HBSS at 2.5 mMand stored at 4° C. FAP and POP at equimolar concentrations cleaved C95substrate at equivalent rates (data not shown). Tic-Pro-AFC, aprolyl-specific fluorescent substrate, was supplied by Vantia(Southampton, England).

APCE (^(˜)4 μg), DPPIV (^(˜)2 μg) or POP (^(˜)2 μg) was incubated in 25mM sodium phosphate buffer, pH 7.5, containing 1.0 mM EDTA and 2%methanol in a total volume of 200 μl for 20 min at 22° C. UsingTic-Pro-AFC (10-300 μM for APCE, 5-200 μM for DPPIV, and 40-800 μM forPOP), fluorescence was monitored with time at excitation/emissionwavelengths of 400/508 nm, using a black-sided 96-well plate in aBIO-TEK FL600 fluorescence plate reader. For accurate assessment ofkinetic parameters, saturating concentrations of substrate were used.For standard curves, dilutions of AFC(7-amino-4-trifluoromethylcoumarin) were prepared in the same assaybuffer and corresponding fluorescence was measured. The substrate infive different concentrations (20, 40, 60, 80 & 160 μM) was mixed withfour different concentrations of inhibitors around the preliminaryapparent (app) K_(i) values.

Whole Cell Activity Assays:

Cells were cultured in normal growth media unless otherwise stated. Forcells grown in media with selected components either withheld or added,and depending on each experimental design as indicated in the Resultssection, growth times were chosen from 7 to 14 days in specific mediabefore plating for activity assays. For activity assays, cells wereplated into 96-well black-sided, clear bottom tissue culture plates(Costar) at densities selected for achieving confluency in three days asindicated in the Results section or each such experiment. Cell densitiesvaried with cell type and the selected growth media; the number of cellsnecessary for plating was estimated from pilot experiments. After threedays growth, cultures were washed with HBSS. The wash solution wasreplaced with 188 μl fresh buffer (HBSS) and either buffer or two μl ofM83 or J94 inhibitor (10 μM final) was added. Ten μl of fluorescentsubstrate, C95 were added to give a final concentration of 125 μM, andfluorescence was measured with time at 360/460 nm excitation/emissionwavelengths using an FL600 microplate fluorescence reader (Bio-tekInstruments). Fluorescence units were converted to FAP units/100,000cells by using a conversion factor determined from an APCE standardcurve of prolyl-specific endopeptidase activity, such that 1 FAP unit isequivalent to the fluorescence produced by 1 ng of APCE/min. Since FAPand POP cleave the C95 substrate at an equivalent rate, both FAP and POPactivities are expressed as FAP units in all figures.

For tube formation assays, Matrigel™ (BD Biosciences, San Jose, Calif.)80 μl was added to black-sided, clear bottom 96-well plates as above andallowed to gel at 37° C. for 30 minutes. Then 15,000 HMVEC-d in EC mediawithout serum were added and allowed to settle for 1 hour. Eitherbuffer, the M83 inhibitor or the J94 inhibitor (10 μM final) was addedand the assay then started by adding the dual FAP/POP fluorescent C95substrate. The reader was maintained at 37° C. and fluorescence wasmeasured with time for 18 hours.

Results

FAP/APCE and POP are prolyl-specific serine endopeptidases, with theproteolytic activity of POP generally restricted to peptides having lessthan about 30 residues [31]. FAP appears to be membrane-inserted and POPmembrane-associated [32, 33], while APCE circulates in blood, possiblyas a shed soluble derivative or splice-variant of FAP [12]. Non-specificsingle amino acid and dipeptide prolyl boronic acid compounds ormutations of the serine active-site in FAP inhibit FAP proteolyticactivity on cancer associated fibroblasts and diminishes cancer growth[17, 21]. POP, commonly expressed by neoplasms [7, 25, 33-35], manifestsoverlapping proteolytic activity with FAP/APCE when measured as usualwith non-specific fluorescent peptide substrates such as Z-Gly-Pro-AMCor succinyl-Gly-Pro-AMC [27]. Efforts to use inhibitors to separate thetwo enzymatic activities have likewise been compromised by significantinhibition of both FAP and POP [27]. The problem of measuring FAP andPOP activities separately in biologic or pathologic scenarios whereeither may play a critical role, had received scant attention prior tothe present work.

Characterization of Tic-Pro-AFC as substrate: A new substrate,Tic-Pro-AFC, was used for assessing APCE/FAP, DPPIV and POP, eachbelonging to the same clade of prolyl-specific serine proteinases andeach with activity towards unique substrates. The typical syntheticsubstrate for APCE/FAP or POP is benzyloxycarbonyl (Z)-GP-AMC for whicheach enzyme exhibits a catalytic efficiency (k_(cat)/K_(m)) of 6.7×10³and 9.5×10⁵ M⁻¹s⁻¹, respectively. Z-GP-AMC is not cleaved by DPPIV;however, the latter does cleave GP-AMC (k_(cat)/K_(m)=3.2×10⁴ M¹s⁻¹).GP-AMC is a poor substrate for APCE/FAP (k_(cat)/K_(m)=1.1×10³ M⁻¹s⁻¹)and is not cleaved by POP. Based on K_(i), K_(m) and k_(cat) values inTables 6 and 7, Tic-Pro-AFC was readily cleaved by each enzyme, withk_(cat)/K_(m) for APCE/FAP being slightly higher than POP and slightlylower than DPPIV. Importantly, k_(cat)/K_(m) values were in keeping withthose determined using Gly-Pro-AMC or Z-Gly-Pro-AMC as substrates;however, Tic-Pro-AFC proved more sensitive and gave more reproducibleresults. Thus, Tic-Pro-AFC was chosen as the substrate for comparing thepotency and selectivity of the inhibitors towards APCE/FAP, DPPIV, orPOP.

In FIG. 1A, confocal microscopy of immunostained saponin-permeabilizedWI-38 fibroblasts shows abundant FAP, most of which appearsmembrane-associated. As reported, FAP was absent in SV-40 transformedVA-13 fibroblasts [5]. FIG. 1B shows results for FAP and POP activityassays, using highly selective, specific substrates and inhibitorsdesigned and synthesized in the inventors lab [27]. Overlying media wasfirst removed from each cell culture after which cells were washed withphysiologic buffer and overlaid with fresh buffer. FAP or POP inhibitorwas added, and each culture assayed with time for both FAP and POPactivity. By using the specific substrate C95, which is cleaved only byFAP or POP, and the high affinity POP inhibitor J94 which has strictspecificity for POP, but none towards FAP, it was possible to measureeach enzyme's activity [27]. For each cell type, total prolyl-specificendopeptidase activity on intact cell membranes was determined using C95substrate, which is cleaved at equal rates by FAP or POP; on parallelcultures J94 inhibitor was added to block solely that activity due toPOP, thereby defining the remaining endopeptidase activity as uniquelyattributable to membrane-associated FAP (FIGS. 1B, 3, 4B, 5B, 6 & 8B).As expected, the dipeptidase, DPPIV, neither cleaved C95 substrate norwas it inhibited by M83 or J94. The previous studies showed that APCEand FAP have essentially identical activities [12], thereby allowing theuse of an APCE standard curve to determine moles of active FAP on thecell surface and hence, the number of FAP proteinase molecules/cell.Therefore, knowing the FAP activity and number of WI-38 fibroblasts in aconfluent well, each cell was estimated to have ^(˜)117,000 FAPmolecules on its membrane surface. FIG. 1C demonstrates FAP by Westernblot and FIG. 1D indicates that the majority of FAP ismembrane-associated, with a lesser amount in the cytosol, which agreeswith our confocal results. FIG. 1E shows POP by Western blot in bothWI-38 and VA-13 fibroblasts, although the activity assay did not detectany surface accessible POP activity in VA-13 cells. The majority of POPis cytosolic with a significant fraction being membrane-associated,which agrees with our assay results of cell surface POP activity (FIG.1F).

Neither FAP nor POP activity was found in media that had been in contactwith cells for three days, indicating that neither enzyme was shed orreleased (data not shown). When fresh buffer was again placed over thecells, both FAP and POP activities were found to be unchanged andimmediately detectable, thereby supporting the membrane location of bothenzymes. As can be seen in FIG. 1B, WI-38 fibroblasts yielded higher FAPthan POP activity. In FIG. 1C, immunoblot analyses of lysates derivedfrom a specified number of cells of each cell type, using the cellularcontent of α-tubulin (50 kDa) and actin (43 kDa) as protein loadcontrols, showed relative FAP levels in accord with those estimated byconfocal microscopy of corresponding immunostained cells or byendopeptidase activity measurements. As shown in FIG. 2, amino acidsequence determinations for tryptic peptides of the isolated putativeFAP protein band from each cell type ensured that the ^(˜)100 kDa bandfrom WI-38 fibroblasts was indeed FAP.

FIG. 3 illustrates the effectiveness and rapidity of FAP and POPinhibition by the pseudo-peptide inhibitor construct, M83. CulturedW-138 cells were exposed to the inhibitor at either the beginning of theassay, or after incubation for two hours with the substrate C95 that iscleaved by FAP or POP. After an increasing fluorescent signal indicatedthe accrual of significant proteolytic activity, the addition of evennanomolar concentrations of inhibitor M83 instantly abolishedendopeptidase activity as evidenced by lack of further fluorescenceincrease.

As shown in FIG. 4, three methods of assessment, namely: confocalmicroscopy, Western blotting, and endopeptidase activity, indicated thatnormal human MCF-12A breast cells or human breast carcinoma MDA-MB 436cells contained far less FAP protein and FAP activity than observed forWI-38 activated fibroblasts (FIG. 1). While POP activity for MCF-12Acells and WI-38 fibroblasts was similar, human MDA-MB436 breast cancercells had about five times that amount. Human HCC1419 breast cancercells possessed about the same amount of POP activity as MCF-12A normalbreast cells; however, HCC1419 cancer cells contained neither FAPprotein nor FAP activity. Without wishing to be bound by theory,over-expression of POP in neoplasms has not been explained, but recentresults of Myohanen et al. [36] suggest that POP is responsible for asecond-step proteolytic cleavage in the autoregulation of thymosin-β4that yields the derivative tetrapeptide, acetyl-SDKP, which is known tobe a potent stimulator of angiogenesis.

In FIG. 5A, confocal microscopy of cultured normal human dermalmicrovascular endothelial cells (HMVEC-d) on plastic demonstrated thatcell-associated FAP was only occasionally encountered (panel A shows afield containing a rare positive cell). Western blotting of HMVEC-dlysates lacked a band consistent with FAP protein (FIG. 5C). Likewise,HMVEC-d were devoid of FAP activity, but HMVEC-d cultures did containconsiderable POP activity, and as shown in FIG. 6B, when grown onMatrigel™ and allowed to form tubules over an 18-hr period, significantamounts of both FAP and POP activities were expressed and easilydetectable. POP expression began just before capillary-like tubulesstarted forming and continued as the complexity of the tubule networkincreased. Interestingly, detectable FAP expression as reflected byproteolytic activity began about 3-4 hours after tubule formation hadclearly begun (i.e., 8 hours from plating HMVEC-d) and then continued toincrease during the subsequent 18-hr. period of growth. These findingsindicate the involvement of POP in the initiation and propagation ofvessel formation, with the timing of FAP expression synchronized withECM invasion by the forming capillary-type tubules. While FAP mRNA isup-regulated coincident with capillary formation [38], the observationthat proteolytically active FAP protein becomes easily detectable andincreases progressively with tubulogenesis has not been reportedpreviously.

As shown in FIG. 7, when HMVEC-d and other selected cell types werestressed by removing hydrocortisone (hyc) from growth media, FAP becamesubstantially over expressed as detected by Western blots of celllysates and corresponding increases in FAP proteolytic activity.Identification of the over-expressed protein as FAP was validated byamino acid sequence determination as shown in FIG. 2. In FIG. 7A, thegreatest over expression of FAP in response to omission ofhydrocortisone in growth media was seen with MCF-12A normal breastcells. When hydrocortisone (hyc) was restored to concentrations used forgrowth of normal cells in culture, over expression of FAP by MCF-12Acells was totally reversed (FIG. 7B, compare MCF-12A (−) hyc and MCF-12A(−)hyc/(+)hyc). In contrast, removal of various growth factors (VEGF,bFGF, EGF, IGF) from growth media had no apparent effect, even after 42days of culture.

Cancerous mesenchymal stem cells may be the best target in the searchfor a broadly applicable common denominator or “pan-tumor” approach fortreating a large number of cancers [40, 41]. The inventors are aware ofonly one report showing FAP to be associated with mesenchymal stem cellmembranes as evidenced by immunoselection of mesenchymal stem cells fromhuman cryopreserved bone marrow with a FAP monoclonal antibody [42].This prompted us to question whether mesenchymal stem cells, as theputative precursor to activated stromal fibroblasts [43], also expressedproteolytically active, membrane-bound FAP, and if so, how much relativeto the activated fibroblast, and could it be readily inhibited? Confocalmicroscopy of permeabilized human mesenchymal cells in FIG. 8A showsmost of the immunostained FAP in the cytosol, with relatively less intheir membranes, which is opposite to what was observed for WI-38fibroblasts. Western immunoblots of mesenchymal cell lysates (FIG. 8C)confirmed the large amount of FAP present and did identify POP proteinas well (FIG. 8E). LC/MS/MS analysis of tryptic peptides from digestionof the ^(˜)100 kDa band in lysates of mesenchymal stem cells establishedthe protein band as a subunit of homodimeric FAP (FIG. 2). Whenmesenchymal membrane and cytosolic fractions were separated andsubjected to Western blotting, it was clear that FAP is abundant onmembranes and is in the cytosol to a lesser extent (FIG. 8D). Incontrast, the majority of POP is in the cytosol, with a lesser amountfound in the membrane (FIG. 8F). Mesenchymal cells and fibroblasts hadabout the same amount of FAP and POP activity, which might be expectedgiven that mesenchymal cells are believed precursors of fibroblast.Assuming mesenchymal stem cell and fibroblast membranes are impermeableto C95 substrate because of the latter's positive charge and lack ofhydrophobicity, cytosolic FAP activity in live cells would not likelycontribute to measurement of membrane activity.

FIG. 9 shows the inhibition of lung cancer xenografts in nude mice bycompound M83. Mice were given a 50 μl injection into each hind legconsisting of human lung adenocarcinoma epithelial cells (2×10⁶ cells)suspended in Matrigel™. After ten days the tumors had grown to anestimated 40 mm³, so M83 treatment was initiated (day 0 in graph). Forthe M83 treatment group, mice were given a daily intraperitonealinjection of 26.5 micrograms of M83 dissolved in 20 microliters ofsterile saline. The mice of the control group were given anintraperitoneal injection of 20 microliters of sterile saline. After tendays, tumors in the control group began to grow rapidly, while tumors inmice treated with M83 failed to progress and by day 28 of treatment theaverage tumor volume was no greater than on day zero. In addition, oneof the six tumors in the M83 treatment group had completely disappeared.The treatment groups consisted of three mice each with two tumors permouse. FIGS. 10A and B are micrographs which demonstrate thatapplication of 50 μm of compound J94 inhibited formation ofcapillary-like tubes in Matrigel™.

FIG. 11 depicts results which show that J94 inhibitor is effective inHCT116 human colon cancer xenografts in immunodeficient mice treatedwith J94 or M83. Clearly during the 28-day treatment period, J94diminished cancer growth by ^(˜)75%, while M83 was slightly moreeffective than this. Although not shown here, microscopy of control andtreated tumor specimens by Immunohistocytochemistry confirmed thepresence of FAP and POP; demonstrated thicker bundles of collagensurrounding residual tumor; widespread areas of tumor cell apoptosiswithin treated tumors; strong suggestions of diminished capillaryvascularity within treated tumors; and lastly, raised the question ofwhether tumor cell autophagy might also have occurred. In every occasionof J94 or M83 treatment, xenografted human tumors, be they colon canceror lung cancer, showed strikingly decreased rates of growth.

FAP is considered to be a potent diagnostic or therapeutic targetbecause it is (i) over-expressed by activated stromal fibroblasts inepithelial-derived human malignancies [19-21] and (ii) absent in normaladult tissues and benign tumors [19-21]. Santos et al. [21] showed thattargeted gene disruption or pharmacologic inhibition of FAP proteinaseactivity slowed or halted tumor growth in mouse models of endogenouslung cancer and human colon cancer. In both tumor scenarios, cancer cellproliferation decreased, collagen increased, and myofibroblast contentand blood vessel density decreased, prompting the suggestion thattargeting fibroblasts within the tumor microenvironment might be usefultherapeutically. To date, however, studies of such relativelynon-specific putative inhibitors of FAP, e.g. Glu-boroPro orVal-boroPro, show that both also inhibit physiologically importantDPPIV. On a molar basis both are ^(˜)50% or less effective forinhibiting POP than FAP and, both undergo cyclization and haveabbreviated survivals in vivo that detract from therapeutic potential.

Recently Kraman and associates [44] reported that absence ofFAP-expressing cells in mice allowed effective vaccination strategiesfor immunological control of epithelial cell-derived cancer growth. Inthat study, direct efforts were not made to determine whether FAPproteolytic activity was necessary for immunosuppressive effects withinthe tumor environment. In accord with both proteolytic andnon-proteolytic roles for FAP in malignant growth, Huang et al. [45]have recently suggested that FAP proteolytic function is important inextracellular matrix degradation, but that other undefined properties(possibly immunologic) of FAP may promote tumor growth. While thefunction of FAP proteinase activity within malignancies has been poorlyunderstood, most efforts to assess FAP as a therapeutic target haveinvolved inhibiting its proteinase activity. Characterizing theproteolytic activity of membrane-inserted FAP has been unusuallydifficult, since a physiologic or pathologic substrate has not beendefinitively identified. Having discovered APCE and its only knownphysiologic substrate, precursor α₂-antiplasmin (α₂AP), the inventorstook advantage of APCE being essentially identical to FAP and used theamino acid sequence surrounding the scissile bond of precursor α₂AP todesign stable and highly effective water-soluble inhibitors of APCE andFAP [27]. In the process, it was discovered that a positively chargedresidue in the P6 or P7 position augmented the cleavage ratesignificantly [29, 46], and this proved useful in developing a highlyeffective FAP inhibitor, M83, and the fluorescent substrate C95 [27,29]. Both manifested high affinity and good specificity for FAP;however, these properties were also directed toward anotherprolyl-specific serine protease family member, namely, POP, which theinventors, like others [33, 47], have found associated with selectednormal and cancer cell lines.

To put the overall endopeptidase activity on cell membrane surfaces inperspective, it was reasoned that FAP and POP activities should each bequantitated. The C95 FAP and POP substrate as well as the M83 inhibitorof both FAP and POP were used in conjunction with a novel and highlyspecific J94 POP inhibitor, the latter having no effect on FAP, forestimating membrane-associated FAP or POP endopeptidase activity. POPcleaves selected peptides of <^(˜)30 residues. Most recently, as notedabove, POP has been proposed to have a significant role in angiogenesisby cleaving a short derivative peptide from the ubiquitouslytissue-distributed thymosin β4, to yield the tetrapeptide compound,acetyl-SDKP, that stimulates angiogenesis [35].

Notably, the dipeptidase proteolytic activity of eithermembrane-inserted or soluble DPPIV is directed only towardamino-terminal dipeptides, and as expected, DPPIV neither cleaved C95substrate nor was it inhibited by M83 or J94. Other prolyl dipeptidaseshave the added negative of being cytosolic or inactive and hence areunlikely to cleave extracellular substrates or to become inhibited bywater-soluble agents that must permeate the cell membrane.

The results provided herein show that activated fibroblasts, i.e., thosethat are (i) rapidly dividing, (ii) highly mobile, (iii) containα-smooth muscle actin (myofibroblasts), and (iv) manifest enhanced ECMdeposition, also have impressive amounts of FAP on their membranes withlesser amounts in the cytosol (FIGS. 1A and D). Cancer-associatedfibroblasts are activated fibroblasts that typically help form thestromal scaffolding of metastatic epithelial-derived tumormicroenvironments. Assays for FAP or POP activity in the non-serumcontaining media in which cells grew, or in buffer washes of those cellcultures, were always devoid of proteolytic activity, thereby supportingFAP and POP as membrane-associated proteins, with each in a conformationthat allows proteolytic activity to be easily and rapidly inhibited.Subtraction of the activity specifically inhibited by the POP inhibitorJ94 provided an assessment of accessible FAP proteolytic activity.Assuming equivalent recoveries of FAP from different cell types, theamount of FAP protein and FAP proteinase activity in WI-38 fibroblastsexceeded that in any other cell, except for mesenchymal stem cells.Immunoreactive FAP protein samples recovered from WI-38 fibroblasts,MDA-MB436 cancer cells, HMVEC-d deprived of hydrocortisone, ormesenchymal stem cells all had essentially identical amino acidsequences to that established for FAP. Proteolytic assays confirmed thatviral-transformed VA-13 human fibroblasts lacked bothmembrane-associated FAP and POP activities.

Small amounts of FAP and POP activity and protein in normal breastcells, about the same amount of FAP activity in MDA-MB436 humanmetastatic breast cancer cells, were demonstrated; however, the lattercells contained about 6 times the amount of POP activity compared tonormal breast cells. It seems reasonable that within hormonally-inducedcyclical tissue responses, an occasional normal breast parenchymal cellmight be induced to express a small amount of FAP and POP. HCC1419intraluminal primary breast cancer cells contained barely detectable FAPby immunostaining, and no assayable FAP proteinase activity; POPactivity was greatly reduced, but POP protein, likely intracellular, waseasily demonstrable. Within a growing HCC1419 tumor, however, this doesnot preclude the possibility that requisite stroma within the breastcancer malignancy may express FAP and POP. The basis of abundant POPactivity found on MDA-MB436 breast cancer cells (FIG. 4) remainsobscure, despite such increases having been noted before in severalother malignancies. Larrinaga et al. [33] reported POP on cell membranesof various human cancers, but usually in amounts not much different thanthose on corresponding normal cell types; however, cytosolic POP withincancers cells was regularly significantly increased beyond that incorresponding normal cells, which is in keeping with our finding forHCC1419 breast cancer cells.

Endothelial cells (HMVEC-d) grown on plastic contained a rareFAP-positive cell by immunostaining, but no FAP protein byimmunoblotting or proteinase assay. However, as confluence was achieved,significant POP activity was expressed concordantly. As expected, tubeformation did not occur on plastic despite endothelial cell confluency;however, POP expression continued unabated. FAP was not expressed duringthe 72-hr growth period (FIG. 5B). In contrast, when grown on Matrigel™,by about four hours, the HMVEC-d cells began to align progressively intubular structures and POP expression continued to increase (FIG. 6B).Shortly after tube-like capillaries began forming, FAP activity becamedemonstrable (FIG. 6B). By about 18 hours, well-defined capillary-likenetworks dominated. These results prompted the speculation thatexpression of proteolytically active FAP might be synchronized withcapillary growth to foster invasiveness of developing microvasculatureinto the ECM [37]. Aimes et al. [38] noted endothelial expression ofmRNA transcripts of several serine proteases, including FAP, inassociation with the nature of the culture substratum and progression ofangiogenesis. The finding of increasing FAP proteolytic activitydemonstrates that the increased FAP mRNA is actually translated duringtubule formation. Several studies have suggested that endothelial cellswithin the developing microvasculature of malignant tissues express FAP[8, 39, 50]. While it might be speculated that FAP's presence couldresult from growth of fibroblast-related pericytes that accompanyneovascularization, fibroblasts were never observed in HMVEC-d cultures.These results indicate that membrane-inserted proteolytically-active FAPis synthesized and expressed by endothelial cells as they participate inangiogenesis.

As shown by immunoblotting and activity assays (FIG. 7), stress causedby removal of hydrocortisone from growth media stimulated both HMVEC-dand MCF12A normal breast cells to over-express FAP, which was directlydocumented as the source of proteolytic activity by its isolation andamino acid sequence (FIG. 2). Notably, replenishment of hydrocortisonereturned MCF12A expression of FAP to levels before its removal (FIG. 7).Similarly, WI-38 activated fibroblasts which are ordinarily grown in theabsence of hydrocortisone, showed a detectable decrease in FAPexpression when hydrocortisone was added. Analogous effects withhydrocortisone have been noted before with other cells, e.g., decreasedhydrocortisone in cultures of selected normal human epithelial cells wasassociated with increased syntheses of both urokinase and tissueplasminogen activator [51]. These data suggest that cells are capable ofaltering expression of FAP if they should become stressed as might occurin a rapidly expanding metastatic tumor microenvironment.

Mesenchymal stem cells give rise to progenitor adipocytes, bone cellsand myocytes, and are also considered precursive to fibroblasts [43,52].Conceivably, activated mesenchymal stem cells could arise as aconsequence of epithelial-mesenchymal cell transformation [53] andrepresent the progenitor cell of the “tumor niche”. Some propose,however, that mesenchymal stem cells originate from bone marrow, moveinto a selected tissue and undergo malignant transformation to producecancer cells characteristic of that tissue [40,54]. Others consider thata precursive cancer stem cell might derive from a dormant multipotentcell unique to a specific tissue. The amounts of FAP we observed formesenchymal stem cells by confocal microscopy and Western blotting (FIG.8) were more than for WI-38 activated fibroblasts (FIG. 1). The multipleroles of mesenchymal cells suggest they may exist in an activated statemore frequently than do fibroblasts. This may be particularly true withrespect to mesenchymal cell involvement in malignancies and account forthe large amount of FAP we observed in these cells.

The results provided herein allow the following conclusions: (i) FAP andPOP are both expressed on the membranes of cells critical to tumor nicheformation in primary tumors or metastases, namely: cancer-associatedfibroblasts, mesenchymal stem cells, selected cancer cells, andendothelial cells as the latter participate in angiogenesis. (ii) Intheir membrane bound form, each enzyme is proteolytically active andeasily accessible for efficient inhibition by a new soluble, highaffinity, selective pseudo-peptide inhibitor that meets structuralrequirements for the respective enzyme's substrate-binding region. (iii)Endothelial cells readily express POP as they grow, and in addition,membrane-inserted proteolytically-active FAP is synthesized andexpressed as tubulogenesis occurs [38,50]. (iv) FAP and POP aretherapeutic targets for a large number of cancers and the two newinhibitors, M83 and J94, have use as therapeutics against commonlyencountered epithelial-derived cancers and their metastatic foci.

Although the presently disclosed and claimed inventive concept(s) andthe advantages thereof have been described in detail, it should beunderstood that various changes, substitutions and alterations can bemade herein without departing from the spirit and scope of the presentlydisclosed and claimed inventive concept(s) as defined in the presentdisclosure. Moreover, the scope of the present application is notintended to be limited to the particular embodiments of the processes,compositions of matter, means, methods and steps described in thespecification. As one of ordinary skill in the art will readilyappreciate from the disclosure of the presently disclosed and claimedinventive concept(s), processes, compositions of matter, means, methods,or steps, presently existing or later to be developed that performsubstantially the same function or achieve substantially the same resultas the corresponding embodiments described herein may be utilizedaccording to the presently disclosed and claimed inventive concept(s).Accordingly, the presently disclosed and claimed inventive concept(s) isintended to include within their scope all such processes, compositionsof matter, means, methods, or steps.

TABLE 1 Cyclic Amines and Proline Analogs4-hydroxypyrrolidine-2-carboxylic acid (cis and trans)3-phenylpyrrolidine-2-carboxylic acid (cis and trans)3-hydroxypyrrolidine-2-carboxylic acid (cis and trans)4-hydroxypyrrolidine-2-carboxylic acid (cis and trans)2-ethylthiazolidine-4-carboxylic acid (cis and trans)2-methylthiazolidine-4-carboxylic acid (cis and trans)2-phenylthiazolidine-4-carboxylic acid (cis and trans)5,5-dimethylthiazolidine-4-carboxylic acid thiazolidine-2-carboxylicacid (cis and trans) thiazolidine-4-carboxylic acid (cis and trans)azetidine-2-carboxylic acid (cis and trans) thiazolidine-2-carboxylicacid (cis and trans) thiazolidine-4-carboxylic acid (cis and trans)amino-L-proline methyl ester cyano-L-proline methyl ester4-cyano-L-proline 3,4-dehydro-L-proline Boronylproline4-fluoro-L-proline Nitrileproline lysyl piperidideN-(4-chlorobenzyl)4-0x0-4-(1-piperidinyl)-1,3-(s)-butane-diaminebromocyclopentyl carboxylic acid chlorocyclopentyl carboxylic acidfluorocyclopentyl carboxylic acid cis-3-methylproline cis-3-ethylprolinecis-3-isopropylproline cis-3-isopentanylproline homoprolinebenzyl-proline (2-fluoro-benzyl)-proline (3-fluoro-benzyl)-proline(4-fluoro-benzyl)-proline (2-chloro-benzyl)-proline(3-chloro-benzyl)-proline (4-chloro-benzyl)-proline(2-bromo-benzyl)-proline (3-bromo-benzyl)-proline(4-bromo-benzyl)-proline phenethyl-proline (2-methyl-benzyl)-proline(3-methyl-benzyl)-proline (4-methyl-benzyl)-proline(2-nitro-benzyl)-proline (3-nitro-benzyl)-proline(4-nitro-benzyl)-proline (1-Naphthalenylmethyl)-proline(2-Naphthalenylmethyl)-proline (2,4-dichloro-benzyl)-proline(3,4-dichloro-benzyl)-proline (3,4-difluoro-benzyl)-proline(2-trifluoromethyl-benzyl)-proline (3-trifluoromethyl-benzyl)-proline(4-trifluoromethyl-benzyl)-proline (2-cyano-benzyl)-proline(3-cyano-benzyl)-proline (4-cyano-benzyl)-proline(4-iodo-benzyl)-proline (3-Phenyl-allyl)-proline(3-Phenyl-allyl)-proline (3-Phenyl-propyl)-proline(4-tert-Butyl-benzyl)-proline Benzhydryl-proline(4-Biphenylmethyl)-proline (4-Thiazolylmethyl)-proline(3-Benzo[b]thiophenylmethyl)-proline (2-Thiophenylmethyl)-proline(5-Bromo-2-Thiophenylmethyl)-proline (3-Thiophenylmethyl)-proline(2-Furanylmethyl)-proline (2-Pyridinylmethyl)-proline(3-Pyridinylmethyl)-proline (4-Pyridinylmethyl)-proline Prolinecarbonitrile Allyl-proline Propynyl-proline4-Phenyl-pyrrolidine-3-carboxylic acid4-(2-fluoro-phenyl)-pyrrolidine-3-carboxylic acid4-(3-fluoro-phenyl)-pyrrolidine-3-carboxylic acidtrans-4-(4-fluoro-phenyl)-pyrrolidine-3-carboxylic acidtrans-4-(2-chloro-phenyl)-pyrrolidine-3-carboxylic acidtrans-4-(3-chloro-phenyl)-pyrrolidine-3-carboxylic acid4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid4-(2-bromo-phenyl)-pyrrolidine-3-carboxylic acid4-(3-bromo-phenyl)-pyrrolidine-3-carboxylic acidtrans-4-(4-bromo-phenyl)-pyrrolidine-3-carboxylic acid4-(2-methyl-phenyl)-pyrrolidine-3-carboxylic acid4-(3-methyl-phenyl)-pyrrolidine-3-carboxylic acid4-(4-methyl-phenyl)-pyrrolidine-3-carboxylic acid4-(2-nitro-phenyl)-pyrrolidine-3-carboxylic acid4-(3-nitro-phenyl)-pyrrolidine-3-carboxylic acid4-(4-nitro-phenyl)-pyrrolidine-3-carboxylic acid4-(1-naphthyl)-pyrrolidine-3-carboxylic acid4-(2-naphthyl)-pyrrolidine-3-carboxylic acid4-(2,5-dichloro-phenyl)-pyrrolidine-3-carboxylic acid4-(2,3-dichloro-phenyl)-pyrrolidine-3-carboxylic acid4-(2-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid4-(3-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid4-(4-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid4-(2-cyano-phenyl)-pyrrolidine-3-carboxylic acid4-(3-cyano-phenyl)-pyrrolidine-3-carboxylic acid4-(4-cyano-phenyl)-pyrrolidine-3-carboxylic acid4-(2-methoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(3-methoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(2-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid4-(3-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid4-(4-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid4-(2,3-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(3,4-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(3,5-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid4-(2-pyridinyl)-pyrrolidine-3-carboxylic acid4-(3-pyridinyl)-pyrrolidine-3-carboxylic acid4-(6-methoxy-3-pyridinyl)-pyrrolidine-3-carboxylic acid4-(4-pyridinyl)-pyrrolidine-3-carboxylic acid4-(2-thienyl)-pyrrolidine-3-carboxylic acid4-(3-thienyl)-pyrrolidine-3-carboxylic acid4-(2-furanyl)-pyrrolidine-3-carboxylic acid4-isopropyl-pyrrolidine-3-carboxylic acid Pyrrolidides 2-nitrilepyrrolidine Fluoropyrrolidine Bromopyrrolidine ChloropyrrolidinePyrrolidinenitriles Piperidine Pyrrolidone Azetidine pipecolic acidPiperidide 3-carboxy-1,2,3,4-tetrahydro-isoquinoline2-carboxy-2,3-dehydroindole Cyclopentyls N-substituted cyclopentylderivatives Cyclohexyls N-substituted cyclohexyl derivatives val-boroProglu-boroPro Oxazolidine and proline analogs and derivatives as definedin U.S. Pat. No. 4,428,939; 6,890,904; 4,762,821 and PublishedApplications 2003/0158114; 20050272703; and 2006/0287245.

TABLE 2 APCE/FAP Inhibitor Compounds Number Compound 1Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl- boroProline 2Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-boroProline 3Benzoyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-boroProline 4Benzyloxycarbonyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 5Succinyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-boroProline 6Acetyl-β-homoArgininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 7 Acetyl-Lysinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 8 Acetyl-β-homoLysinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 9Acetyl-Ornithinyl-(8-amino-3,6-Dioxaoctanoyl)-D- Alaninyl-boroProline 10Acetyl-Diaminopropionyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 11 Acetyl-Histidinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 12Acetyl-Argininyl-(11-amino-3,6,9-Trioxaundecanoyl)-D-Alaninyl-boroProline 13Acetyl-Argininyl-(12-amino-4,7,10-trioxadodecanoyl)-D-Alaninyl-boroProline 14 Acetyl-Argininyl-β-Alaninyl-β-Alaninyl-D-Alaninyl-boroProline 15 Acetyl-Argininyl-(6-aminohexanoyl)-D-Alaninyl-boroProline 16 Acetyl-Argininyl-(8-aminooctanoyl)-D-Alaninyl-boroProline 17 Acetyl-Argininyl-Glycinyl-Glycinyl-Glycinyl-D-Alaninyl-boroProline 18 Acetyl-Argininyl-Glycinyl-Glycinyl-Serinyl-D-Alaninyl-boroProline 19Acetyl-Argininyl-Glutaminyl-Leucinyl-Threoninyl-Serinyl-D-Alaninyl-boroProline 20Acetyl-Argininyl-Glycinyl-Glycinyl-boroProline 21Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-Serinyl-Glycinyl-boroProline 22Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- Glycinyl-boroProline 23Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Serinyl-boroProline 24Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-2-nitrilepyrrolidine 25 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-pyrrolidine-2-carbonitrile 26Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-prolinal 27Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)- D-Alaninyl-2-nitrilepiperidine 28 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-2-nitrile-4-fluoro-pyrrolidineAmino acids or amino acid derivatives or analogs may be either L- orD-form unless specified.

TABLE 3 POP Inhibitor Compounds Number Compound 1Lysyl-Leucyl-Arginyl-boroProline 2Acetyl-Lysyl-Leucyl-Arginyl-boroProline 3Benzoyl-Lysyl-Leucyl-Arginyl-boroProline 4Benzyloxycarbonyl-Lysyl-Leucyl-Arginyl-boroProline 5Succinyl-Lysyl-Leucyl-Arginyl-boroProline 6Pyrazinyl-Lysyl-Leucyl-Arginyl-boroProline 7Acetyl-β-homoLysyl-Leucyl-Arginyl-boroProline 8Acetyl-Diaminopropionyl-Leucyl-Arginyl-pyrrolidine-2- carbonitrile 9Acetyl-Ornithinyl-Leucyl-Arginyl-boroProline 10Pyrazinyl-β-homoArginyl-Leucyl-Arginyl-Prolinal 11Acetyl-Arginyl-Leucyl-Arginyl-boroProline 12Acetyl-Aspartyl-Leucyl-Arginyl-boroProline 13Acetyl-Glutamyl-Leucyl-Arginyl-2-nitrile piperdine 14Pyrazinyl-Lysyl-Isoleucyl-Arginyl-boroProline 15Acetyl-Lysyl-Valyl-Arginyl-boroProline 16Acetyl-Lysyl-Alanyl-Arginyl-boroProline 17Acetyl-Lysyl-Phenylalanyl-Arginyl-2-nitrile-4-fluoro- pyrrolidine 18Pyrazinyl-Lysyl-Threonyl-Arginyl-boroProline 19Acetyl-Lysyl-Glycyl-Arginyl-boroProline 20Acetyl-Lysyl-Leucyl-Lysyl-boroProline 21Acetyl-Lysyl-Leucyl-Diaminopropionyl-pyrrolidine-2- carbonitrile 22Pyrazinyl-Arginyl-Leucyl-Lysyl-boroProline 23Acetyl-Lysyl-(8-amino-3,6-Dioxaoctanoyl)-Arginyl- boroProline 24Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-Arginyl- boroProline 25Pyrazinyl-Argininyl-(epsilon-amino-Caproyl)-Arginyl- Prolinal 26Acetyl-Argininyl-(gamma-amino-Butyryl)-Arginyl- boroProline 27Acetyl-Lysyl-Leucyl-Arginyl-pyrrolidine-2-carbonitrile 28Acetyl-Lysyl-Leucyl-Arginyl-prolinal 29Pyrazinyl-Lysyl-Leucyl-Arginyl-2-nitrile piperidine 30Acetyl-Lysyl-Leucyl-Arginyl-2-nitrile-4-fluoro- pyrrolidine 31Acetyl-Lysyl-Leucyl-Arginyl-4-fluoro-piperidine-2- boronic acid 32Acetyl-Lysyl-Leucyl-Arginyl-4-fluoro prolinal 33Acetyl-Lysyl-Leucyl-Arginyl-4,4-difluoro-piperidine-2- boronic acid 34Acetyl-Lysyl-Leucyl-Arginyl-4,4-difluoro-pyrrolidine-2- boronic acid 35Acetyl-Lysyl-Leucyl-Arginyl-2-nitrile-4,4-difluoro- pyrrolidine 36Acetyl-Lysyl-Leucyl-Arginyl-2-nitrile-4,4-difluoro- piperidineAmino acids or amino acid derivatives or analogs may be either L- orD-form unless specified.

TABLE 4 POP Inhibitor Compounds Number Compound 1Lysyl-Leucyl-Lysyl-boroProline 2Acetyl-Lysyl-Leucyl-Homolysyl-pyrrolidine- 2-carbonitrile 3Benzoyl-Lysyl-Leucyl-Homoarginyl-boroProline 4Benzyloxycarbonyl-Lysyl-Leucyl-Histidyl- boroProline 5Succinyl-Lysyl-Leucyl-Ornithyl-Prolinal 6Pyrazinyl-Lysyl-Leucyl-Diaminobutyryl-boroProline 7Acetyl-β-homoLysyl-Leucyl-Diaminopropionyl- boroProline 8Acetyl-Diaminopropionyl-Leucyl-Homoarginyl- boroProline 9Aminobenzoyl-Ornithinyl-Leucyl-Diaminobutyryl- boroProline 10Acetyl-β-homoArginyl-Leucyl-Diaminopropionyl- 2-nitrile piperdine 11Pyrazinyl-Arginyl-Leucyl-Lysyl-boroProline 12Benzoyl-Aspartyl-Leucyl-Homolysyl-boroProline 13Acetyl-Glutamyl-Leucyl-Homoarginyl-2-nitrile- 4-fluoro-pyrrolidine 14Succinyl-Lysyl-Isoleucyl-Histidyl-boroProline 15Acetyl-Lysyl-Valyl-Ornithyl-boroProline 16Acetyl-Lysyl-Alanyl-Diaminobutyryl-pyrrolidine- 2-carbonitrile 17Aminobenzoyl-Lysyl-Phenylalanyl-Diaminopropionyl- boroProline 18Pyrazinyl-Lysyl-Threonyl-Lysyl-Prolinal 19Benzoyl-Lysyl-Glycyl-Homolysyl-boroProline 20Acetyl-Lysyl-Leucyl-Homoarginyl-boroProline 21Succinyl-Aspartyl-Leucyl-Diaminopropionyl-2-nitrile piperdine 22Acetyl-Aspartyl-Leucyl-Lysyl-boroProline 23Aminobenzoyl-Aspartyl-(8-amino-3,6-Dioxaoctanoyl)-Arginyl-2-nitrile-4-fluoro-pyrrolidine 24Acetyl-Glutamyl-(8-amino-3,6-Dioxaoctanoyl)-Arginyl- boroProline 25Benzoyl-Glutamyl-(epsilon-amino-Caproyl)-Arginyl-pyrrolidine-2-carbonitrile 26Acetyl-Glutamyl-(gamma-amino-Butyryl)-Arginyl- boroProline 27Succinyl-Glutamyl-Leucyl-Arginyl-pyrrolidine- 2-carbonitrile 28Pyrazinyl-Lysyl-Leucyl-Lysyl-prolinal 29Acetyl-Lysyl-Leucyl-Histidyl-2-nitrile piperidine 30Acetyl-Lysyl-Leucyl-Ornithyl-2-nitrile-4-fluoro- pyrrolidine 31Acetyl-Histidyl-Leucyl-Arginyl-4-fluoro-piperidine- 2-boronic acid 32Acetyl-Histidyl-Leucyl-Arginyl-4-fluoro prolinal 33Acetyl-Aspartyl-Leucyl-Arginyl-4,4-difluoro-piperidine- 2-boronic acid34 Acetyl-Ornithyl-Leucyl-Arginyl-4,4-difluoro-pyrrolidine- 2-boronicacid 35 Acetyl-Ornithyl-Leucyl-Arginyl-2-nitrile-4,4-difluoro-pyrrolidine 36 Acetyl-Glutamyl-Leucyl-Arginyl-2-nitrile-4,4-difluoro-piperidineAmino acids or amino acid derivatives or analogs may be either L- orD-form unless specified.

TABLE 5 POP Inhibitor Compounds Number Compound 1Lysyl-Leucyl-Arginyl-boroProline 2Acetyl-Aspartyl-Leucyl-Lysyl-boroProline 3Benzoyl-Lysyl-Leucyl-Homolysyl-boroProline 4Benzyloxycarbonyl-Lysyl-Leucyl-Ornithyl- pyrrolidine-2-carbonitrile 5Succinyl-Glutamyl-Leucyl-Diaminobutyryl- boroProline 6Pyrazinyl-Lysyl-Leucyl-Diaminopropionyl- boroProline 7Acetyl-β-homoLysyl-Leucyl-Lysyl-boroProline 8Aminobenzoyl-Diaminopropionyl-Leucyl- Homolysyl-Prolinal 9Acetyl-Ornithinyl-Leucyl-Arginyl-boroProline 10Benzoyl-β-homoArginyl-Leucyl-Arginyl- boroProline 11Acetyl-Aspartyl-Leucyl-Histidyl-boroProline 12Succinyl-Aspartyl-Leucyl-Arginyl-2- nitrile piperidine 13Pyrazinyl-Glutamyl-Leucyl-Arginyl-boroProline 14Aminobenzoyl-Lysyl-Isoleucyl-Arginyl-boroProline 15Acetyl-Glutamyl-Valyl-Arginyl-2-nitrile-4- fluoro-pyrrolidine 16Benzoyl-Lysyl-Alanyl-Arginyl-boroProline 17Acetyl-Lysyl-Phenylalanyl-Arginyl-pyrrolidine- 2-carbonitrile 18Succinyl-Aspartyl-Threonyl-Arginyl-boroProline 19Acetyl-Lysyl-Glycyl-Arginyl-boroProline 20Aminobenzoyl-Glutamyl-Leucyl-Lysyl-Prolinal 21Acetyl-Lysyl-Leucyl-Diaminopropionyl-boroProline 22Benzoyl-Arginyl-Leucyl-Lysyl-boroProline 23Pyrazinyl-Aspartyl-(8-amino-3,6-Dioxaoctanoyl)- Arginyl-2-nitrilepiperidine 24 Succinyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-Arginyl-boroProline 25 Aminobenzoyl-Argininyl-(epsilon-amino-Caproyl)-Arginyl-2-nitrile-4-fluoro-pyrrolidine 26Succinyl-Glutamyl-(gamma-amino-Butyryl)-Arginyl- boroProline 27Benzoyl-Lysyl-Leucyl-Arginyl-pyrrolidine-2- carbonitrile 28Aminobenzoyl-Lysyl-Leucyl-Arginyl-prolinal 29Pyrazinyl-Lysyl-Leucyl-Arginyl-2-nitrile piperidine 30Succinyl-Lysyl-Leucyl-Arginyl-2-nitrile-4-fluoro- pyrrolidine 31Benzoyl-Lysyl-Leucyl-Lysyl-4-fluoro-piperidine-2- boronic acid 32Succinyl-Lysyl-Leucyl-Lysyl-4-fluoro prolinal 33Pyrazinyl-Lysyl-Leucyl-Histidyl-4,4-difluoro- piperidine-2-boronic acid34 Aminobenzoyl-Lysyl-Leucyl-Histidyl-4,4-difluoro-pyrrolidine-2-boronic acid 35Benzoyl-Lysyl-Leucyl-Ornithyl-2-nitrile-4,4- difluoro-pyrrolidine 36Pyrazinyl-Lysyl-Leucyl-Homoarginyl-2-nitrile- 4,4-difluoro-piperidineAmino acids or amino acid derivatives or analogs may be either L- orD-form unless specified.

TABLE 6 Catalytic efficiencies of APCE/FAP, DPPIV and POP forTic-Pro-AFC Prolyl peptidase K_(m) (μM) k_(cat) (s⁻¹)k_(cat)/K_(m)(M⁻¹s⁻¹) APCE/FAP 53 ± 5 1.19 ± 0.11 2.2 × 10⁴ DPPIV 33 ± 21.49 ± 0.12 4.5 × 10⁴ POP 161 ± 12 0.76 ± 0.01 4.7 × 10³

TABLE 7 APCE/FAP, DPPIV, and POP Inhibition Constants (K_(i)) Of VariousInhibitor Compounds Selectivity Selectivity APCE/ K_(i) K_(i) FAP DPPIV(DPPIV) POP (POP) Inhibitor K_(i) K_(i) K_(i) K_(i) K_(i) Compound (nM)(nM) (APCE-FAP) (nM) (APCE/FAP) Ac-Gly-L- 20.7 314 15.2 23.3 1.1 boroProAc-Arg-peg-Gly- 3.1 1150 371 DL-boroPro Ac-Arg-Gly-Gly- 22.9 341 14.9DL-boroPro Ac-Arg-peg-D- 189 20480 108 Ala-D-boroPro Ac-Arg-peg-D- 5.76136 1076 7.4 1.3 Ala-L-boroPro Ac-Arg-peg-D- 7.7 ND — Ala-DL(25:75%)-boroPro Ac-Arg-peg-D- 9.5 11170 1176 Ala-DL(50:50%)- boroProAc-Arg-peg-D- 18.3 ND — Ala-DL(75:25%)- boroPro Ac-Arg-peg-D- 1377 71295.2 23.9 0.02 Asp-L-boroPro Ac-Arg-peg-Ser- 2.7 861 319 2.9 1.1Gly-L-boroPro Ac-Arg-peg- 1.8 440 244 2.1 1.2 Gly-L-boroPro Ac-Arg-Gly-17.2 322 18.7 1.6 0.1 Gly-L-boroProData represent the best-fit value±the standard error, inhibition of APCEactivity.

REFERENCES

The following references, to the extent that they provide exemplaryprocedural or other details supplementary to those set forth herein, arespecifically incorporated herein by reference in their entireties.

-   1. Garin-Chesa P, Old U, Rettig W J (1990) Cell surface glycoprotein    of reactive stromal fibroblasts as a potential antibody target in    human epithelial cancers. Proc Natl Acad Sci USA 87:7235-7239.-   2. Park J E, Lenter M C, Zimmermann R N, Garin-Chesa P, Old U,    Rettig W J (1999) Fibroblast activation protein, a dual specificity    serine protease expressed in reactive human tumor stromal    fibroblasts. J Biol Chem 274:36505-36512.-   3. Rettig W J, Garin-Chesa P, Beresford H R, Oettgen H F, Melamed M    R, Old U (1988) Cell-surface glycoproteins of human sarcomas:    differential expression in normal and malignant tissues and cultured    cells. Proc Natl Acad Sci USA 85:3110-3114.-   4. Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E,    Bamberger U, Rettig W J, Schnapp A (2001) Expression of the    fibroblast activation protein during mouse embryo development. Int J    Dev Biol 45:445-447.-   5. Rettig W J, Garin-Chesa P, Healey J H, Su S L, Ozer H L, Schwab    M, Albino A P, Old U (1993) Regulation and heteromeric structure of    the fibroblast activation protein in normal and transformed cells of    mesenchymal and neuroectodermal origin. Cancer Res 53:3327-3335.-   6. Acharya P S, Zukas A, Chandan V, Katzenstein A L, Pure E (2006)    Fibroblast activation protein: a serine protease expressed at the    remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol    37:352-360.-   7. Wang X M, Yao T W, Nadvi N A, Osborne B, McCaughan G W, Gorrell M    D (2008) Fibroblast activation protein and chronic liver disease.    Front Biosci 13:3168-3180.-   8. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Jr., Yaccoby    S (2006) Fibroblast activation protein (FAP) is upregulated in    myelomatous bone and supports myeloma cell survival. Br J Haematol    133:83-92.-   9. Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, ltoi E,    Kokubun S (2009) Histogenesis-specific expression of fibroblast    activation protein and dipeptidylpeptidase-IV in human bone and soft    tissue tumours. Histopathology 55:432-440.-   10. Bauer S, Jendro M C, Wadle A, Kleber S, Stenner F, Dinser R,    Reich A, Faccin E, Godde S, Dinges H, Muller-Ladner U, Renner    C (2006) Fibroblast activation protein is expressed by rheumatoid    myofibroblast-like synoviocytes. Arthritis Res Ther 8:R171.-   11. Iwasa S, Okada K, Chen W T, Jin X, Yamane T, Ooi A, Mitsumata    M (2005) ‘Increased expression of seprase, a membrane-type serine    protease, is associated with lymph node metastasis in human    colorectal cancer’. Cancer Lett 227:229-236.-   12. Lee K N, Jackson K W, Christiansen V J, Lee C S, Chun J G, McKee    P A (2006) Antiplasmin-cleaving enzyme is a soluble form of    fibroblast activation protein. Blood 107:1397-1404.-   13. Aggarwal S, Brennen W N, Kole T P, Schneider E, Topaloglu O,    Yates M, Cotter R J, Denmeade S R (2008) Fibroblast activation    protein peptide substrates identified from human collagen I derived    gelatin cleavage sites. Biochemistry 47:1076-1086.-   14. Niedermeyer J, Scanlan M J, Garin-Chesa P, Daiber C, Fiebig H H,    Old U, Rettig W J, Schnapp A (1997) Mouse fibroblast activation    protein: molecular cloning, alternative splicing and expression in    the reactive stroma of epithelial cancers. Int J Cancer 71:383-389.-   15. Christiansen V J, Jackson K W, Lee K N, McKee P A (2007) Effect    of fibroblast activation protein and alpha2-antiplasmin cleaving    enzyme on collagen types I, Ill, and IV. Arch Biochem Biophys    457:177-186.-   16. Huang Y, Wang S, Kelly T (2004) Seprase promotes rapid tumor    growth and increased microvessel density in a mouse model of human    breast cancer. Cancer Res 64:2712-2716.-   17. Cheng J D, Weiner L M (2003) Tumors and their microenvironments:    tilling the soil. Commentary re: A. M. Scott et al., A Phase I    dose-escalation study of sibrotuzumab in patients with advanced or    metastatic fibroblast activation protein-positive cancer. Clin.    Cancer Res., 9: 1639-1647, 2003. Clin Cancer Res 9:1590-1595.-   18. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev    Cancer 6:392-401.-   19. Pure E (2009) The road to integrative cancer therapies:    emergence of a tumor-associated fibroblast protease as a potential    therapeutic target in cancer. Expert Opin Ther Targets 13:967-973.-   20. Hayward S W (2010) Preclinical assessment of fibroblast    activation protein as a target for antitumor therapy. Future Oncol    6:347-349.-   21. Santos A M, Jung J, Aziz N, Kissil J L, Puré E (2009) Targeting    fibroblast activation protein inhibits tumor stromagenesis and    growth in mice. J Clin Invest 119:3613-3625.-   22. Kelly T, Adams J, Bachovchin W, Barton R, Campbell S, Courts S,    Kennedy C, Snow R (1993)

Immunosuppressive boronic acid dipeptides: correlation betweenconformation and activity. J Am Chem Soc 115:12637-12638.

-   23. Rosenblum J S, Kozarich J W (2003) Prolyl peptidases: a serine    protease subfamily with high potential for drug discovery. Curr Opin    Chem Biol 7:496-504.-   24. Narra K, Mullins S R, Lee H O, Strzemkowski-Brun B, Magalong K,    Christiansen V J, McKee P A, Egleston B, Cohen S J, Weiner L M,    Meropol N J, Cheng J D (2007) Phase II trial of single agent    Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in    patients with metastatic colorectal cancer. Cancer Biol Ther    6:1691-1699.-   25. Goossens F, De M, I, Vanhoof G, Scharpe S (1996) Distribution of    prolyl oligopeptidase in human peripheral tissues and body fluids.    Eur J Clin Chem Clin Biochem 34:17-22.-   26. Liu J M, Kusinski M, Hie V, Bignon J, Hajem N, Komorowski J,    Kuzdak K, Stepien H, Wdzieczak-Bakala J (2008) Overexpression of the    angiogenic tetrapeptide AcSDKP in human malignant tumors. Anticancer    Res 28:2813-2817.-   27. Lee K N, Jackson K W, Christiansen V J, Dolence E K, McKee P    A (2011) Enhancement of fibrinolysis by inhibiting enzymatic    cleavage of precursor alpha2-antiplasmin. J Thromb Haemost    9:987-996.-   28. Lee K N, Jackson K W, Christiansen V J, Chung K H, McKee P    A (2004) A novel plasma proteinase potentiates alpha2-antiplasmin    inhibition of fibrin digestion. Blood 103:3783-3788.-   29. Lee K N, Jackson K W, Terzyan S, Christiansen V J, McKee P    A (2009) Using substrate specificity of antiplasmin-cleaving enzyme    for fibroblast activation protein inhibitor design. Biochemistry    48:5149-5158.-   30. Gorrao S S, Hemerly J P, Lima A R, Melo R L, Szeltner Z, Polgar    L, Juliano M A, Juliano L (2007)

Fluorescence resonance energy transfer (FRET) peptides andcycloretro-inverso peptides derived from bradykinin as substrates andinhibitors of prolyl oligopeptidase. Peptides 28:2146-2154.

-   31. Szeltner Z, Polgar L (2008) Structure, function and biological    relevance of prolyl oligopeptidase. Curr Protein Pept Sci 9:96-107.-   32. Scanlan M J, Raj B K, Calvo B, Garin-Chesa P, Sanz-Moncasi M P,    Healey J H, Old U, Rettig W J (1994) Molecular cloning of fibroblast    activation protein alpha, a member of the serine protease family    selectively expressed in stromal fibroblasts of epithelial cancers.    Proc Natl Acad Sci USA 91:5657-5661.-   33. Larrinaga G, Perez I, Blanco L, Lopez J I, Andres L, Etxezarraga    C, Santaolalla F, Zabala A, Varona A, lrazusta J (2010) Increased    prolyl endopeptidase activity in human neoplasia. Regul Pept    163:102-106.-   34. Busek P, Stremenova J, Sedo A (2008) Dipeptidyl peptidase-IV    enzymatic activity bearing molecules in human brain tumors—good or    evil? Front Biosci 13:2319-2326.-   35. Liu J M, Garcia-Alvarez M C, Bignon J, Kusinski M, Kuzdak K,    Riches A, Wdzieczak-Bakala J (2010) Overexpression of the natural    tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in    neoplastic diseases. Ann N Y Acad Sci 1194:53-59.-   36. Myohanen T T, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R,    Moreno-Baylach M J, Garcia-Horsman J A, Mannisto P T (2011) Prolyl    oligopeptidase induces angiogenesis both in vitro and in vivo in a    novel regulatory manner. Br J Pharmacol 163:1666-1678.-   37. Wang T, Shi W (2009) Expression of fibroblast activation    proteins in corneal stromal neovascularization. Curr Eye Res    34:112-117.-   38. Aimes R T, Zijlstra A, Hooper J D, Ogbourne S M, Sit M L, Fuchs    S, Gotley D C, Quigley J P, Antalis T M (2003) Endothelial cell    serine proteases expressed during vascular morphogenesis and    angiogenesis. Thromb Haemost 89:561-572.-   39. Okada K, Chen W T, Iwasa S, Jin X, Yamane T, Ooi A, Mitsumata    M (2003) Seprase, a membrane-type serine protease, has different    expression patterns in intestinal- and diffuse-type gastric cancer.    Oncology 65:363-370.-   40. Karnoub A E, Dash A B, Vo A P, Sullivan A, Brooks M W, Bell G W,    Richardson A L, Polyak K, Tubo R, Weinberg R A (2007) Mesenchymal    stem cells within tumour stroma promote breast cancer metastasis.    Nature 449:557-563.-   41. Coghlin C, Murray G I (2010) Current and emerging concepts in    tumour metastasis. J Pathol 222:1-15.-   42. Bae S, Park C W, Son H K, Ju H K, Paik D, Jeon C J, Koh G Y, Kim    J, Kim H (2008) Fibroblast activation protein alpha identifies    mesenchymal stromal cells from human bone marrow. Br J Haematol    142:827-830.-   43. Emura M, Ochiai A, Horino M, Arndt W, Kamino K, Hirohashi    S (2000) Development of myofibroblasts from human bone marrow    mesenchymal stem cells cocultured with human colon carcinoma cells    and TGF beta 1. In Vitro Cell Dev Biol Anim 36:77-80.-   44. Kraman M, Bambrough P J, Arnold J N, Roberts E W, Magiera L,    Jones J O, Gopinathan A, Tuveson D A, Fearon D T (2010) Suppression    of antitumor immunity by stromal cells expressing fibroblast    activation protein-alpha. Science 330:827-830.-   45. Huang Y, Simms A E, Mazur A, Wang S, Leon N R, Jones B, Aziz N,    Kelly T (2011) Fibroblast activation protein-alpha promotes tumor    growth and invasion of breast cancer cells through non-enzymatic    functions. Clin Exp Metastasis 6:567-579.-   46. Christiansen V J, Jackson K W, Lee K N, McKee P A (2007) The    effect of a single nucleotide polymorphism on human alpha    2-antiplasmin activity. Blood 109:5286-5292.-   47. Duke-Cohan J S, Morimoto C, Rocker J A, Schlossman S F (1995) A    novel form of dipeptidylpeptidase IV found in human serum.    Isolation, characterization, and comparison with T lymphocyte    membrane dipeptidylpeptidase IV (CD26). J Biol Chem 270:14107-14114.-   48. Garcia-Horsman J A, Mannisto P T, Venalainen J I (2007) On the    role of prolyl oligopeptidase in health and disease. Neuropeptides    41:1-24.-   49. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane B    F (2009) Live-cell imaging demonstrates extracellular matrix    degradation in association with active cathepsin B in caveolae of    endothelial cells during tube formation. Exp Cell Res 315:1234-1246.-   50. Bhati R, Patterson C, Livasy C A, Fan C, Ketelsen D, Hu Z,    Reynolds E, Tanner C, Moore D T, Gabrielli F, Perou C M,    Klauber-DeMore N (2008) Molecular characterization of human breast    tumor vascular cells. Am J Pathol 172:1381-1390.-   51. Myohanen H, Virtanen I, Vaheri A (2001) Elimination of    hydrocortisone from the medium enables tissue plasminogen activator    gene expression by normal and immortalized nonmalignant human    epithelial cells. Biol Chem 382:1563-1573.-   52. Mishra P J, Mishra P J, Humeniuk R, Medina D J, Alexe G, Mesirov    J P, Ganesan S, Glod J W, Banerjee D (2008) Carcinoma-associated    fibroblast-like differentiation of human mesenchymal stem cells.    Cancer Res 68:4331-4339.-   53. Thiery J P, Acloque H, Huang R Y, Nieto M A (2009)    Epithelial-mesenchymal transitions in development and disease. Cell    139:871-890.-   54. Baguley B C (2006) Tumor stem cell niches: a new functional    framework for the action of anticancer drugs. Recent Pat Anticancer    Drug Discov 1:121-127.-   55. Momeni N, Nordstrom B M, Horstmann V, Avarseji H, Sivberg B    V (2005) Alterations of prolyl endopeptidase activity in the plasma    of children with autistic spectrum disorders. Bio Med Central    Psychiatry 5:27.-   56. Myohanen T T, Garcia-Horsman J A, Tenorio-Larang J, and Mannisto    P T (2009) Issues about the Physiological Functions of Prolyl    Oligopeptidase Based on Its Discordant Spatial Association with    Substrates and Inconsistencies Among mRNA, Protein Levels, and    Enzymatic Activity. J. Histochem and Cytochem 57(9):831-848.-   57. Maes M, Goossnes F, Scharpe S, Calabrese J, Desnyder R, and    Meltzer H Y (1995) Alterations in plasma prolyl endopeptidase    activity in depression, mania, and schizophrenia: effects of    antidepressants, mood stabilizers, and antipsychotic drugs.    Psychiatry Res. 58:217-225.-   58. Mannisto P T, Venalainen J, Jalkanen A, and Garcia-Horsman J    A (2007) Prolyl oligopeptidaes: a potential target for the treatment    of cognitive disorders. Drug News Perspect (Abstract) 20(5).

1. A compound having the formula:B-Xaa_(1a)-Sp-Xaa_(2a)-Cyc  (Formula II), wherein: B is at least one ofaminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z),τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc),Pyroglutamate (Pyr), Pyrazine, Phenylalanine, and Succinyl (Suc);Xaa_(1a) is a positively-charged or negatively-charged amino-acid; Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm;Xaa_(2a) is a positively-charged amino acid; and Cyc is a boronylproline, proline carbonitrile, nitrile pyrrolidone, or cyanopyrrolidine.2. The compound of claim 1, wherein Xaa_(1a) is α,β-diaminopropionicacid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine,β-homoarginine, homoarginine, lysine, homolysine, β-homolysine,histidine, aspartic acid or glutamic acid.
 3. The compound of claim 2,wherein Xaa_(1a) comprises a methylene group in substitution for thecarbonyl group adjacent Sp.
 4. The compound of claim 1, wherein Xaa_(2a)is α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine,β-homoornithine, arginine, β-homoarginine, homoarginine, lysine,homolysine, β-homolysine, or histidine.
 5. The compound of claim 1,wherein Sp is selected from the group consisting of γ-aminobutyric acid;E-aminocaproic acid; 8-amino-3,6-dioxaoctanoic acid;11-amino-3,6,9-trioxaundecanoic acid;14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid;5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid;8-aminooctanoic acid; 3-(aminooxy)acetic acid; β-alanine; glycine;alanine; threonine, tryptophan; tyrosine; methionine; leucine;isoleucine; valine; serine; proline; ethylene glycol; PEG_(n) (whereinn=1-6); propylene glycol; PPG_(n) (wherein n=1-6); amino-PEG_(n)-carboxygroup (wherein n=1-6); amino-PPG_(n)-carboxy (wherein n=1-6); andcombinations thereof.
 6. The compound of claim 5, wherein Sp is selectedfrom the group consisting of ethylene glycol, PEG_(n) (wherein n=1-6),propylene glycol, 8-amino-3,6-dioxaoctanoic acid, PPG_(n) (whereinn=1-6)), amino-PEG_(n)-carboxy group (wherein n=1-6), anamino-PPG_(n)-carboxy group (wherein n=1-6), and combinations thereof.7. The compound of claim 5, wherein Sp is leucine, isoleucine, valine,or alanine.
 8. The compound of claim 1, wherein Sp has a length in arange of 0.6 nm to 1.75 nm. 9-13. (canceled)
 14. The compound of claim1, comprising an isostere bond between Xaa_(1a) and Sp.
 15. The compoundof claim 1, further comprising a 1-10mer peptide or oligopeptideextending from Cyc in the C-terminal direction.
 16. The compound ofclaim 1, further defined as capable of binding to the active site of POPat a K_(i)<100 nM and capable of binding to DPPIV at a K_(i)>500 nM,and/or as having a K_(i) (DPPIV):K_(i) (POP) ratio>500.
 17. (canceled)18. The compound of claim 1, wherein B is an acetyl, pyroglutamate, orsuccinyl; Xaa_(1a) is lysine; Sp is at least one of Sp is leucine,isoleucine, valine, or alanine, Xaa_(2a) is arginine; and Cyc is aboronyl proline or cyanopyrrolidine.
 19. A pharmaceutical compositioncomprising the compound of claim 1 disposed within apharmaceutically-acceptable carrier or vehicle.
 20. A method ofinhibiting activity of prolyl oligopeptidase (POP) in a cell or tissuewhich expresses POP, comprising: administering to the POP-expressingcell or tissue a compound having the formula:B-Xaa_(1a)-Xaa_(2a)-Cyc  (Formula II), wherein: B is at least one ofaminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z),τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc),Pyroglutamate (Pyr), Pyrazine, Phenylalanine, and Succinyl (Suc);Xaa_(1a) is a positively-charged or negatively-charged amino-acid; Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm;Xaa_(2a) is a positively-charged amino acid; and Cyc is a boronylproline, proline carbonitrile, nitrile pyrrolidone, or cyanopyrrolidine,and wherein activity of the POP in the POP-expressing cell or tissue isinhibited.
 21. The method of claim 20, wherein the POP-expressing cellsor tissues are cancer cells and/or activated fibroblast cells.
 22. Amethod of inhibiting angiogenesis and/or treating cancer in a subject inneed of such therapy, comprising: administering apharmaceutically-acceptable amount of a compound having the formula:B-Xaa₁-Sp-Xaa₂-Cyc, wherein: B is at least one of aminobenzoyl (Abz),acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z), T-Butyloxycarbonyl(Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate(Pyr), Pyrazine, Phenylalanine, and Succinyl (Suc); Xaa₁ is apositively-charged amino acid or negatively-charged amino-acid; Sp is aspacer molecule having a length in the range of 0.3 nm to 2.5 nm; Xaa₂is a positively-charged amino acid, or Xaa₂ is glycine, D-alanine,D-serine, or D-threonine, with the provisio that when Xaa₂ is glycine,D-alanine, D-serine, or D-threonine, Xaa₁ is a positively-charged aminoacid; and Cyc is a boronyl proline, proline carbonitrile, nitrilepyrrolidone, or cyanopyrrolidine. 23-25. (canceled)
 26. A compound,wherein at least a portion of the compound has the formula:B-Xaa_(1a)-Sp-Xaa_(2a)  (Formula IIb), wherein: B is at least one ofaminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z),τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc),Pyroglutamate (Pyr), Pyrazine, Phenylalanine, and Succinyl (Suc);Xaa_(1a) is a positively-charged or negatively-charged amino-acid; Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm; andXaa_(2a) is a positively-charged amino acid.
 27. A method of inhibitingactivity of prolyl oligopeptidase (POP) in a subject suffering from adisorder for which inhibition of POP provides atherapeutically-effective benefit, comprising: administering to asubject in need of such therapy a compound having the formula:B-Xaa_(1a)-Sp-Xaa_(2a)-Cyc  (Formula II) wherein: B is at least one ofaminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z),τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc),Pyroglutamate (Pyr), Pyrazine, Phenylalanine, and Succinyl (Suc);Xaa_(1a) is a positively-charged or negatively-charged amino-acid; Sp isa spacer molecule having a length in the range of 0.3 nm to 2.5 nm;Xaa_(2a) is a positively-charged amino acid; and Cyc is a boronylproline, proline carbonitrile, nitrile pyrrolidone, or cyanopyrrolidine.